



Jeevan Scientific Technology Limited

21st Annual Report 2018 - 2019





UHPLC & LC-MS/MS



Processing Area



Deep Freezers



Centrifuge



QA Team



Clinic

Twenty First Annual Report 2018-2019

CORPORATE INFORMATION

BOARD OF DIRECTORS

Mr. S. S. R. Koteswara Rao	–	Chairman - Independent Director	(DIN: 00964290)
Mr. K. Krishna Kishore	–	Vice Chairman & Managing Director	(DIN: 00876539)
Mr. M. Rajendra Prasad	–	Whole-Time Director & CEO	(DIN: 06781058)
Mrs. K. Vanaja	–	Non- Executive Director	(DIN: 01030437)
Mr. T. Ravi Babu	–	Non-Executive Director	(DIN: 01274099)
Mr. G. Bhanu Prakash	–	Independent Director	(DIN: 00375298)
Mr. K. Rama Krishna Prasad	–	Independent Director	(DIN: 00754823)

CHIEF FINANCIAL OFFICER

Mr. K. Krishna Kishore

REGISTERED OFFICE

Plot No. 1 & 2,
Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Goloconda Post,
Hyderabad, Telangana -500008.
Ph No 040-67364700, Fax: 040-67364707

PHARMACOLOGY UNIT

B-17, TIE, Phase II, Balanagar,
Hyderabad, Telangana - 500037.
Ph No : 040-23721008

STATUTORY AUDITORS

M/s. Pavuluri & Co
Chartered Accountants
Plot No. 48, Flat No. 301,
Sucasa, Phase - I,
Kavuri Hills,
Hyderabad - 500 033.

INTERNAL AUDITORS

M/s. K P & Associates
Chartered Accountants
Hyderabad

BANKERS

Karur Vysya Bank Ltd.
Oriental Bank of Commerce.
Andhra Bank.
State Bank of India.

SECRETARIAL AUDITORS

M/s. S. S. Reddy & Associates
Practicing Company Secretaries
Plot No.8-2-603/23/3 & 8-2-603/23, 15
2nd Floor, HSR Summit, Banjara Hills,
Road No. 10,
Beside No. 1 News Channel Office,
Hyderabad-500034

AUDIT COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S.S.R. Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. G. Bhanu Prakash	-	Member

Jeevan Scientific Technology Limited

NOMINATION & REMUNERATION COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S. S. R. Koteswara Rao	-	Member
Mrs. K. Vanaja	-	Member
Mr. T. Ravi Babu	-	Member

STAKEHOLDERS RELATIONSHIP COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S S R Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. G. Bhanu Prakash	-	Member

INDEPENDENT DIRECTORS COMMITTEE

Mr. S. S. R Koteswara Rao	-	Chairman
Mr. K. Rama Krishna Prasad	-	Member
Mr. G. Bhanu Prakash	-	Member

RISK MANAGEMENT COMMITTEE

Mr. K. Rama Krishna Prasad	-	Chairman
Mr. S S R Koteswara Rao	-	Member
Mr. K. Krishna Kishore	-	Member
Mr. T. Ravi Babu	-	Member

ANTI – SEXUAL HARRASSMENT COMMITTEE

Mrs. Nalini Rama. Y	-	Chairman
Mrs. Lakshmi I	-	Member
Mrs. Krishnaveni N	-	Member
Dr. K. Rajani	-	Outside Member

REGISTRAR & SHARE TRANSFER AGENTS

M/s. CIL Securities Limited,
214, Raghavaratna Towers,
Chiragali Lane, Hyderabad -500001
Phone Number: 040-23202465 / 66612093
Fax: 040-23203028

CORPORATE IDENTITY NUMBER

L72200TG1999PLC031016

LISTED AT: BSE Limited.

ISIN : INE237B01018

WEBSITE: www.jeevanscientific.com

INVESTOR E-MAIL ID: shareholders@jeevanscientific.com

Twenty First Annual Report 2018-2019

NOTICE

Notice is hereby given that the 21st Annual General Meeting of the Shareholders of Jeevan Scientific Technology Limited will be held on Saturday 28th day of September, 2019 at 9.30 A.M at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad-500001 to transact the following business:

ORDINARY BUSINESS:

1. To consider and adopt the Audited Stand alone and consolidated Balance Sheet as at 31st March 2019, Statement of Profit & Loss for the year ended 31st March 2019 , statement of Cash Flows for the year ended 31st March 2019 and together with the Report of the Board of directors and the Auditors Report thereon.
2. To appoint a director in place of Mr. T. Ravi Babu (DIN: 01274099) who retires by rotation and being eligible, offers himself for re-appointment.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 13.08.2019

Jeevan Scientific Technology Limited

NOTES:

1. **A MEMBER ENTITLED TO ATTEND AND VOTE IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE INSTEAD OF HIMSELF/HERSELF AND A PROXY NEED NOT BE A MEMBER OF THE COMPANY.** The instrument of Proxy in order to be effective shall be deposited at the Registered Office of the Company by not less than 48 hours before the commencement of the Meeting.
Pursuant to the provisions of Section 105 of the Companies Act, 2013, a person can act as a proxy on behalf of not more than fifty (50) members and holding in aggregate not more than 10% of the total share capital of the Company carrying voting rights. A member holding more than 10% of the total share capital of the Company carrying voting rights may appoint a single person as proxy, who shall not act as a proxy for any other person or shareholder. The appointment of proxy shall be in the Form No. MGT.11 annexed herewith.
2. Attendance slip, proxy form and the route map giving directions to reach the venue of the 21st Annual General Meeting is given at the end of the Notice.
3. Corporate members intending to send their authorised representative(s) to attend the Meeting are requested to send to the Company/ Registrar and Share Transfer Agent, a certified true copy of the relevant Board Resolution together with the specimen signature(s) of the representative(s) authorised under the said Board Resolution to attend and vote on their behalf at the Meeting.
4. The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is done away with vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the Annual General Meeting held on September 27, 2017.
5. The Register of Members and Share Transfer Books of the Company will remain closed from 21st September, 2019 to 28th September, 2019 (Both days inclusive) for the purpose of AGM.
6. Members holding shares in the electronic form are requested to inform any changes in address/bank mandate directly to their respective Depository Participants.
7. Members/ Proxies/ Authorised Representatives are requested to hand over the enclosed Attendance Slip, duly signed in accordance with their specimen signature(s) registered with the Company for admission to the meeting hall. Members who hold shares in dematerialised form are requested to bring their Client ID and DP ID Numbers for identification.
8. In case of joint holders attending the Meeting, only such joint holders who are higher in the order of names will be entitled to vote.
9. The Company or its Registrar and Share Transfer Agent cannot act on any request received directly from the members holding shares in electronic form for any change of bank particulars or bank mandates. Such changes are to be advised only to the Depository Participant of the members.
10. The Securities and Exchange Board of India has mandated submission of Permanent Account Number (PAN) by every participant in securities market. Members holding shares in demat form are, therefore, requested to submit PAN details to the Depository Participants

Twenty First Annual Report 2018-2019

with whom they have demat accounts. Members holding shares in physical form can submit their PAN details to the Company/ Registrar and Share Transfer Agents (M/s. CIL Securities Limited.)

11. As a measure of austerity, copies of the annual report will not be distributed at the Annual General Meeting. Members are therefore, requested to bring their copies of the Annual Report to the Meeting.
12. Members holding shares in the same name under different ledger folios are requested to apply for Consolidation of such folios and send the relevant share certificates to **M/s. CIL Securities Limited**, Share Transfer Agents of the Company for their doing the needful.
13. Members are requested to send their queries at least 10 days before the date of meeting so that information can be made available at the meeting.
14. In respect of shares held in physical mode, all shareholders are requested to intimate changes, if any, in their registered address immediately to the registrar and share transfer agent of the company and correspond with them directly regarding share transfer/ transmission /transposition, Demat / Remat, change of address, issue of duplicate shares certificates, ECS and nomination facility.
15. SEBI has decided that securities of the listed companies can be transferred only in dematerialized form w.e.f cut off date being 05.12.2018. In view of the above and to avail various benefits of dematerialization, members are advised to dematerialize shares held by them in physical form.
16. In terms of Section 72 of the Companies Act, 2013, a member of the company may nominate a person on whom the shares held by him/her shall vest in the event of his/her death. Members desirous of availing this facility may submit nomination in prescribed Form-SH-13 to the company/RTA in case shares are held in physical form, and to their respective depository participant, if held in electronic form.
17. Electronic copy of the Annual Report for 2018-2019 is being sent to all the members whose email IDs are registered with the Company/Depository Participants(s) for communication purposes unless any member has requested for a hard copy of the same. For members who have not registered their email address, physical copies of the Annual Report for 2018-2019 is being sent in the permitted mode.
18. Members may also note that the Notice of the 21st Annual General Meeting and the Annual Report for 2018-2019 will also be available on the Company's website www.jeevanscientific.com for their download. The physical copies of the aforesaid documents will also be available at the Company's Registered Office for inspection during normal business hours on working days. Even after registering for e-communication, members are entitled to receive such communication in physical form, upon making a request for the same, by post free of cost. For any communication, the shareholders may also send requests to the Company's investor email id: shareholders@jeevanscientific.com.
19. Voting through electronic means
Pursuant to Section 108 of the Companies Act, 2013, a read with the relevant Rules of the Act and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 the Company is pleased to provide the facility to Members to exercise

Jeevan Scientific Technology Limited

their right to vote by electronic means. The Members, whose names appear in the Register of Members / list of Beneficial Owners as on 20th September, 2019, i.e. the dates prior to the commencement of book closure date are entitled to vote on the Resolutions set forth in this Notice. The remote e-voting period will commence at 9.00 a.m. on 25th September, 2019 and will end at 5.00 p.m. on 27th September, 2019. The Company has appointed Mrs. D. Renuka (C.P. No. 3460), Practicing Company Secretary, to act as the Scrutinizer, to scrutinize remote e-voting and physical voting process in a fair and transparent manner. The Members desiring to vote through remote e-voting refer to the detailed procedure given hereinafter.

(I) Procedure for remote e-voting

- i. The voting period begins at 9.00 a.m. on 25th September, 2019 and will end at 5.00 p.m. on 27th September, 2019. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date (20th September, 2019) may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- ii. The shareholders should log on to the e-voting website www.evotingindia.com.
- iii. Click on Shareholders.
- iv. Now Enter your User ID
 - a) For CDSL: 16 digits beneficiary ID,
- b) For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
- c) Members holding shares in Physical Form should enter Folio Number registered with the Company.
- v. Next enter the Image Verification as displayed and Click on Login.
- vi. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier voting of any company, then your existing password is to be used.
- vii. If you are a first time user follow the steps given below:

	For Members holding shares in Demat Form and Physical Form
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders)- Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field. In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.
DOB	Enter the Date of Birth as recorded in your demat account or in the company records for the said demat account or folio in dd/mm/yyyy format.
Dividend Bank Details	Enter the Dividend Bank Details as recorded in your demat account or in the company records for the said demat account or folio. <ul style="list-style-type: none"> • Please enter the DOB or Dividend Bank Details in order to login. If the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (iv).

Twenty First Annual Report 2018-2019

- viii. After entering these details appropriately, click on "SUBMIT" tab.
- ix. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- x. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- xi. Click on the EVSN Jeevan Scientific Technology Limited.
- xii. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xiii. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.
- xiv. After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
- xv. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
- xvi. You can also take out print of the voting done by you by clicking on "Click here to print" option on the Voting page.
- xvii. If Demat account holder has forgotten the same password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.

(II) In case of members receiving the Physical copy of Notice of AGM [for members whose e-mail IDs are not registered with the company/ depository participant(s) or requesting physical copy]:

- A. Please follow all steps from sl. no. (ii) to sl. no. (xvii) above, to cast vote.
- Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to www.evotingindia.com and register themselves as Corporate.
 - A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
 - After receiving the login details a compliance user should be created using the admin login and password. The Compliance user would be able to link the account(s) for which they wish to vote on.
 - The list of accounts should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.
 - A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.

Jeevan Scientific Technology Limited

B. The voting period begins at 9.00 a.m. on 25th September, 2019 and will end at 5.00 p.m. on 27th September, 2019. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on 20th September, 2019 may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter. Once the vote on a resolution is cast by the shareholder, the shareholder shall not be allowed to change it subsequently.

In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at www.evotingindia.com under help section or write an email to helpdesk.evoting@cdslindia.com.

20. The voting rights of shareholders shall be in proportion to their shares of the paid up equity share capital of the Company as on the cut-off date (record date) of 20th September, 2019.
21. Shareholders can also cast their vote using CDSL's mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. iPhone and Windows phone users can download the app from the App Store and the Windows Phone Store respectively . Please follow the instructions as prompted by the mobile app while voting on your mobile.
22. Mrs. D. Renuka, Practicing Company Secretary, bearing C.P. Number 3460 has been appointed as the Scrutinizer to scrutinize the e-voting process.
23. The Scrutinizer shall within a period not exceeding three (3) days from the conclusion of the e-voting period unblock the votes in the presence of at least two (2) witnesses not in the employment of the Company and make a Scrutinizer's Report of the votes cast in favour or against, if any, forthwith to the Chairman of the Company.
24. The Results shall be declared on or after the AGM of the Company. The Results declared along with the Scrutinizer's Report shall be placed on the Company's website www.jeevanscientific.com and on the website of CDSL immediately after declaration of result by chairman and communicated to the BSE Limited.
25. The Ministry of Corporate Affairs (vide circular nos. 17/2011 and 18/2011 dated April 21 and April 29, 2011 respectively), has undertaken a 'Green Initiative in Corporate Governance' and allowed companies to share documents with its shareholders through an electronic mode. Members are requested to support this green initiative by registering/uploading their email addresses, in respect of shares held in dematerialized form with their respective Depository Participant and in respect of shares held in physical form with the Company's Registrar and Share Transfer Agents.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 13.08.2019

Twenty First Annual Report 2018-2019

Information in accordance with Schedule V of Companies Act, 2013

I. GENERAL INFORMATION

1. Nature of Industry : Clinical Research
2. Date or expected date of commencement of commercial: The Company started its commercial operations in the year 02.02.1999
3. In case of new companies, expected date of commencement of business activities as per project approved by financial institutions appearing in the prospects: Not Applicable
4. Financial performance based on given indications

Particulars	2018-19 (Rs. in lakhs)	2017-18 (Rs. in lakhs)
Turnover	2,640.13	2,016.91
Net profit after Tax	137.35	30.54

5. Foreign investments or collaborations, if any: Not Applicable

ADDITIONAL INFORMATION

(As per Regulation 36(3) of SEBI (LODR) Regulation 2015)

As required under the Listing Regulations, the particulars of Directors who seek appointment/re-appointment are given below:

Name of the Director	Mr. T Ravi Babu
Age	51 years
DIN	01274099
Date of Appointment	28/02/2000
Qualification	MBA
Brief resume and expertise in	More than 18 years of experience in freelancing, specific functional areas advertising and consulting computer graphics and also worked as Director of Cinematography in Indian Broadcasting Company at New York for 4 years..
Relationship between Directors inter se [(As per Section 2(77) of the Companies Act, 2013 and Rule 4 of Companies (Specification of Definition Rules, 2014)]	Promoter of the company
Directorship in other Companies	NIL
Chairmanship/membership of Committees of other Companies	NIL
Shareholding in the Company	2500
Last remuneration drawn	NIL
No. Of board meetings attended during the year	5

Jeevan Scientific Technology Limited

DIRECTOR'S REPORT

To the Members,

The Directors have pleasure in presenting before you the 21st Director's Report of the Company together with the Audited Statements of Accounts for the year ended 31st March, 2019.

FINANCIAL SUMMARY/HIGHLIGHTS, OPERATIONS, STATE OF AFFAIRS:

The performance during the period ended 31st March, 2019 has been as under:

(Rs. In Lakhs)

Particulars	Standalone		Consolidated	
	2018-2019	2017-2018	2018-2019	2017-2018
Total Income	2,640.13	2,016.91	2,713.17	2,132.04
Total Expenditure	2,478.15	1,968.42	2,576.62	2,095.84
Profit Before Tax	161.98	48.49	136.55	36.20
Provision for Tax	26.03	23.79	25.15	25.02
Profit before Other Comprehensive Income	135.95	24.70	111.40	11.18
Other Comprehensive Income	1.40	5.84	1.40	5.84
Profit after Tax	137.35	30.54	112.80	17.02

REVIEW OF OPERATIONS:

During the year under review, your company recorded a turnover of Rs. 2,640.13 Lakhs as against Rs. 2,016.91 Lakhs in the previous financial year. The turnover includes revenue from the Clinical Research services.

MATERIAL CHANGES AND COMMITMENTS:

There were no material changes and commitments affecting financial position of the company between 31st March 2019 and the date of Board's Report. (i.e. 13.08.2019)

CHANGE IN THE NATURE OF BUSINESS, IF ANY:

During the period under review and the date of Board's Report there was no change in the nature of Business.

TRANSFER TO RESERVES:

During the year under review, 38,42,000 warrants were converted into equity shares on 12-06-2018, and an amount of Rs. 7,78,00,500 received towards share premium amount (@ Rs. 20.25 premium per share) was transferred to reserves.

FAMILIARISATION PROGRAMMES:

The Company familiarises its Independent Directors on their appointment as such on the Board with the Company, their roles, rights, responsibilities in the Company, nature of the industry in which the Company operates, etc. through familiarisation programme. The Company also conducts orientation programme upon induction of new Directors, as well as other initiatives to update the Directors on a continuing basis. The familiarisation programme for Independent

Twenty First Annual Report 2018-2019

Directors is disclosed on the Company's website www.bnrsecurities.com

CORPORATE GOVERNANCE:

A separate section titled "Report on Corporate Governance" along with the Auditors' Certificate on Corporate Governance as stipulated under Regulation 34 read with Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.

REVISION OF FINANCIAL STATEMENTS:

There was no revision of the financial statements for the year under review.

EXTRACT OF ANNUAL RETURN:

Extract of Annual Return is Annexed as Annexure no.II of this Annual Report.

SHARE CAPITAL:

The authorised capital of the company is Rs. 21,00,00,000/- consisting of 2,10,00,000 equity shares of Rs. 10/- each and the paid up share capital of the Company is Rs. 15,30,14,650/- consisting of 1,53,01,465 equity shares of Rs. 10/- each.

In the Board Meeting held on 12.06.2018, 38,42,000 warrants were converted into 38,42,000 equity shares of Rs. 10/- each at an issue price of Rs. 30.25 per share.

As a result, the paid up capital of the company increased from Rs. 11,45,94,650./- consisting of 1,14,59,465 equity shares of Rs. 10/- each to Rs. 15,30,14,650./- consisting of 1,53,01,465 equity shares of Rs. 10/- each .

DIVIDEND:

As the profits are inadequate, the Directors do not propose any dividend for the year under review.

BOARD MEETINGS:

The Board of Directors duly met 6 (Six) times on 26.05.2018, 12.06.2018, 14.08.2018, 12.11.2018, 14.02.2019 and 06.03.2019 and in respect of which meetings, proper notices are given and the proceedings are properly recorded and signed in the Minutes Book maintained for the purpose.

DIRECTORS AND KEY MANAGERIAL PERSONNEL: The following Directors/ KMPs are appointed or resigned during the year 2018-19 and upto the date of Board's Report as on 13.08.2019:

- i. Mr. K. Krishna Kishore was appointed as CFO of the Company w.e.f 11th October, 2018 and as compliance officer w.e.f 7th June 2019.
- ii. Mr. G. Ravi Kumar resigned as CFO of the Company w.e.f 10th October, 2018
- iii. Mr. Chandra Sekhar, Company Secretary cum Compliance officer resigned w.e.f 06th June, 2019

As required under regulation 36 (3) of the SEBI (LODR), Regulations, 2015, brief particulars of the Directors or Key Managerial Personnels who are appointed during the year and upto the date of Board's Report or seeking appointment/re-appointment are given as under:-

Jeevan Scientific Technology Limited

Name of the Director	Mr. T Ravi Babu
Age	51 years
DIN	01274099
Date of Appointment	28/02/2000
Qualification	MBA
Brief resume and expertise in specific functional areas	More than 18 years of experience in freelancing, advertising and consulting computer graphics and also worked as Director of Cinematography in Indian Broadcasting Company at New York for 4 years.
Relationship between Directors inter se [(As per Section 2(77) of the Companies Act, 2013 and Rule 4 of Companies (Specification of Definition Rules, 2014)]	Promoter of the company
Directorship in other Companies	NIL
Chairmanship/membership of Committees of other Companies	NIL
Shareholding in the Company	2500
Last remuneration drawn	NIL
No. Of board meetings attended during the year	5

DIRECTOR'S RESPONSIBILITY STATEMENT:

In pursuance of section 134 (5) of the Companies Act, 2013, the Directors hereby confirm that:

- (a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) The Directors had prepared the annual accounts on a going concern basis; and
- (e) The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Twenty First Annual Report 2018-2019

DECLARATION FROM INDEPENDENT DIRECTORS ON ANNUAL BASIS:

The Company has received a declarations from Independent directors of the company, Mr. G. Bhanu Prakash, Mr. S.S.R Koteswara Rao and Mr. K. Rama Krishna Prasad, to the effect that they are meeting the criteria of independence as provided in Sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 25 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

STATUTORY COMPLIANCE:

The Company has complied with the required provisions relating to statutory compliance with regard to the affairs of the Company in all respects.

INFORMATION ABOUT THE FINANCIAL PERFORMANCE / FINANCIAL POSITION OF THE SUBSIDIARIES / ASSOCIATES / JOINT VENTURES:

In accordance with Section 129(3) of the Companies Act, 2013, a statement containing salient features of the financial statements of the subsidiary companies in Form AOC 1 is as an attachment herewith forming part of the Annual Report. In accordance with third provision to Section 136(1) of the Companies Act, 2013, the Annual Report of your Company, containing therein its audited standalone and the consolidated financial statements has been placed on the website of the Company at www.jeevanscientific.com. Further, audited financial statements together with related information and other reports of each of the subsidiary companies, have also been placed on the website of the Company at www.jeevanscientific.com.

THE NAMES OF COMPANIES WHICH HAVE BECOME OR CEASED TO BE ITS SUBSIDIARIES, JOINT VENTURES OR ASSOCIATE COMPANIES DURING THE YEAR.

No companies have become or ceased to be the subsidiaries, joint ventures or associate companies of the company.

DETAILS IN RESPECT OF FRAUDS REPORTED BY AUDITORS UNDER SUB-SECTION (12) OF SECTION 143 OTHER THAN THOSE WHICH ARE REPORTABLE TO CENTRAL GOVERNMENT.

There were no frauds reported by the auditors as per section 143 (12).

AUDITORS:

STATUTORY AUDITORS:

M/s. Pavuluri & Co, were appointed as Statutory Auditors for a period of 5 years in an earlier Annual General Meeting held on 27th September, 2017.

The requirement to place the matter relating to appointment of Auditors for ratification by members at every Annual General Meeting is done away with vide notification dated May 7, 2018 issued by the Ministry of Corporate Affairs, New Delhi. Accordingly, no resolution is proposed for ratification of appointment of Auditors, who were appointed in the Annual General Meeting held on September 27, 2017.

INTERNAL AUDITORS:

M/s. K P & Associates, Chartered Accountants, Hyderabad are the internal Auditors of the Company for the financial year 2018-19

SECRETARIAL AUDITORS:

Pursuant to the provisions of Section 134(3)(f) & Section 204 of the Companies Act, 2013, Secretarial audit report as provided by M/s. S.S. Reddy & Associates., Practicing Company

Jeevan Scientific Technology Limited

Secretaries is annexed to this Report as Annexure - III.

INDIAN ACCOUNTING STANDARDS

The implementation of Indian Accounting Standards (IAS) was a major change process which the company has implemented with effect from 01st April, 2017 onwards.

QUALIFICATIONS IN AUDIT REPORTS:

(a) **Statutory Auditors Report:**

The Board has duly reviewed the Statutory Auditor's Report on the Accounts for the year ended March 31, 2019 and has noted that the same does not have any reservation, qualification or adverse remarks. However, the Board decided to further strengthen the existing system and procedures to meet all kinds of challenges and growth in the market expected in view of the robust growth in the industry.

(b) **Secretarial Audit Report:**

The Board has duly reviewed the Secretarial Audit Report on the Compliances according to the provisions of section 204 of the Companies Act 2013 and has noted that the same does not have any reservations qualifications, or adverse remarks. The Secretarial Audit Report in Form MR-3 is annexed to the Annual Report as Annexure - III.

CONSOLIDATED FINANCIAL STATEMENTS:

In compliance with the provisions of the Companies Act, 2013 and the Accounting Standards AS-21 and AS-27 on consolidated financial statements, the Directors have provided the consolidated financial statements for the financial year ended March 31, 2019 which forms part of the Annual Report.

CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:

The required information as per Sec.134(3)(m) of the Companies Act 2013 is provided hereunder:

A. Conservation of Energy:

The Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using energy efficient computers and purchase of energy efficient equipment.

B. Technology Absorption:

i. Research and Development (R&D): The company has started a Bioanalytical Lab in the new premises. Bioanalytical research laboratory is designed with state of the art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS labs, which can accommodate up to 12 LCMS/ MS. Jeevan Scientific offers a unique combination of highly trained workforce enabled with well-equipped bio analytical research and development (R&D) laboratory.

ii. Technology absorption, adoption and innovation: There was considerable technology absorption, adoption and innovation with the addition of the above equipment in the new facility the results of which can be seen in the years to come.

Twenty First Annual Report 2018-2019

- C. Foreign Exchange Earnings and Out-Go:** The foreign exchange earned in terms of actual inflows during the year and the foreign exchange outgo during the year in terms of actual outflow: Please refer to note no.1(xiv) of notes to accounts.

DETAILS RELATING TO DEPOSITS, COVERING THE FOLLOWING:

The Company has not accepted any deposits falling within the meaning of Sec.73, 74 & 76 of the Companies Act, 2013 read with the Rule 8(v) of Companies (Accounts) Rules 2014, during the financial year under review.

DETAILS OF ADEQUACY OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls with reference to financial statements as designed and implemented by the Company are adequate. During the year under review, no material or serious observation has been received from the Internal Auditors of the Company for inefficiency or inadequacy of such controls. The Company maintains appropriate system of internal control, including monitoring procedures, to ensure that all assets are safeguarded against loss from unauthorized use or disposition. Company policies, guidelines and procedures provide for adequate checks and balances, and are meant to ensure that all transactions are authorized, recorded and reported correctly.

DISCLOSURE OF ORDERS PASSED BY REGULATORS OR COURTS OR TRIBUNAL

No orders have been passed by any Regulator or Court or Tribunal which can have impact on the going concern status and the Company's operations in future.

INSURANCE:

The properties and assets of your Company are adequately insured.

PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:

The company has not given any Loans, Guarantees or Investments during the year under review.

CREDIT & GUARANTEE FACILITIES:

The Company has been availing facilities of Credit and Guarantee as and when required, for the business of the Company, from The Karur Vysya Bank Ltd. and Personal Guarantees were given by Mr. K. Krishna Kishore, Vice Chairman & Managing Director, Smt. K. Vanaja, Director & Shri. M. Rajendra Prasad Whole Time Director & CEO without any consideration for obtaining Bank Guarantees.

RISK MANAGEMENT POLICY:

The Company follows a comprehensive system of Risk Management. The Company has adopted a procedure for assessment and minimization of probable risks. It ensures that all the risks are timely defined and mitigated in accordance with the well structured risk management process.

CORPORATE SOCIAL RESPONSIBILITY POLICY:

Since the Company does not have net worth of Rs. 500 Crore or more, or turnover of Rs. 1000 Crore or more, or a net profit of Rs. 5 Crore or more during the financial year, section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is not applicable and hence the Company need not adopt any Corporate Social Responsibility Policy.

Jeevan Scientific Technology Limited

RELATED PARTY TRANSACTIONS:

All contracts/arrangements/transactions entered into by the Company during the financial year with related parties were in the ordinary course of business and on arm's length basis. During the year, the Company had not entered into any contract/arrangement/transaction with related parties which could be considered material in accordance with the policy of the company on materiality of related party transactions.

The Policy on materiality of related party transactions and dealing with related party transactions as approved by the Board may be accessed on the Company's website at www.jeevanscientific.com.

The Directors draw attention of the members to Note no.31 in notes to accounts which sets out related party disclosures.

DISCLOSURE ABOUT COST AUDIT:

Cost Audit is not applicable to the Company.

STATEMENT SHOWING THE NAMES OF THE TOP TEN EMPLOYEES IN TERMS OF REMUNERATION DRAWN AND THE NAME OF EVERY EMPLOYEE:

A statement showing the names of the top ten employees in terms of remuneration drawn and the name of every employee is annexed to this Annual report as Annexure A

RATIO OF REMUNERATION TO EACH DIRECTOR:

Under section 197(12) of the Companies Act, 2013, and Rule 5(1)(2) & (3) of the Companies(Appointment & Remuneration) Rules, 2014 read with Schedule V of the Companies Act, 2013 a remuneration to Mr. K. Krishna Kishore, Vice-Chairman and Managing Director of the Company is 25:1 and to Mr. Rajendra Prasad, Whole-Time director and CEO of the Company is 25:1.

NON-EXECUTIVE DIRECTORS' COMPENSATION AND DISCLOSURES

None of the Independent / Non-Executive Directors has any pecuniary relationship or transactions with the Company which in the Judgment of the Board may affect the independence of the Directors.

CEO/ CFO Certification

The Managing Director and CEO/ CFO certification of the financial statements for the year 2018-19 is provided elsewhere in this Annual Report.

BOARD EVALUATION:

Pursuant to the applicable provisions of the Companies Act, 2013 and SEBI Listing Regulations, the Board has carried out an Annual Evaluation of its own performance, performance of the Directors and the working of its Committees. The Board's functioning was evaluated on various aspects, including inter alia degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning.

Evaluation of the Committees performance was based on the criteria like composition, its terms of the reference and effectiveness of committee meetings, etc., Individual Director's performance evaluation is based on their preparedness on the issues to be discussed, meaningful and constructive discussions and their contribution to the Board and Committee meetings. The Chairperson was evaluated mainly on key aspects of his role. These performance

Twenty First Annual Report 2018-2019

exercises were conducted seeking inputs from all the Directors / Committee Members wherever applicable.

The evaluation procedure followed by the company is as mentioned below:

- i) Feedback is sought from each Director about their views on the performance of the Board, covering various criteria such as degree of fulfilment of key responsibilities, Board structure and composition, establishment and delineation of responsibilities to various Committees, effectiveness of Board processes, information and functioning, Board culture and dynamics, quality of relationship between the Board and the Management and efficacy of communication with external stakeholders. Feedback was also taken from every Director on his assessment of the performance of each of the other Directors.
- ii) The Nomination and Remuneration Committee (NRC) then discusses the above feedback received from all the Directors.
- iii) Based on the inputs received, the Chairman of the NRC also makes a presentation to the Independent Directors at their meeting, summarising the inputs received from the Directors as regards Board performance as a whole and of the Chairman. The performance of the Non-Independent Non-Executive Directors and Board Chairman is also reviewed by them.
- iv) Post the meeting of the Independent Directors, their collective feedback on the performance of the Board (as a whole) is discussed by the Chairman of the NRC with the Chairman of the Board. It is also presented to the Board and a plan for improvement is agreed upon and is pursued.
- v) Every statutorily mandated Committee of the Board conducts a self-assessment of its performance and these assessments are presented to the Board for consideration. Areas on which the Committees of the Board are assessed include degree of fulfilment of key responsibilities, adequacy of Committee composition and effectiveness of meetings.
- vi) Feedback is provided to the Directors, as appropriate. Significant highlights, learning and action points arising out of the evaluation are presented to the Board and action plans are drawn up. During the year under report, the recommendations made in the previous year were satisfactorily implemented.

The peer rating on certain parameters, positive attributes and improvement areas for each Board member are also provided to them in a confidential manner. The feedback obtained from the interventions is discussed in detail and, where required, independent and collective action points for improvement are put in place.

LISTING WITH STOCK EXCHANGES:

The Company confirms that it has paid the Annual Listing Fees for the year 2018-2019 to Bombay Stock Exchange where the Company's Shares are listed.

MANAGEMENT DISCUSSION AND ANALYSIS:

Management discussion and analysis report for the year under review as stipulated under Regulation 4(3) read with schedule V , Part B of SEBI(Listing Obligations and Disclosure Requirements), Regulations 2015 with the stock exchange in India is presented in a separate section forming part of the annual report.

Jeevan Scientific Technology Limited

INDUSTRY BASED DISCLOSURES AS MANDATED BY THE RESPECTIVE LAWS GOVERNING THE COMPANY

The Company is not a NBFC, Housing Companies etc., and hence Industry based disclosures is not required.

SECRETARIAL STANDARDS

The company is in compliance with Secretarial Standards issued by The Institute of Company Secretaries of India on Meetings of the Board of Directors and General Meetings.

EVENT BASED DISCLOSURES

During the year under review, the Company has not taken up any of the following activities:

- 1. Issue of sweat equity share:** The Company has not issued any sweat equity shares during the year under review and hence no information as per provisions of Section 54(1)(d) of the Act read with Rule 8(13) of the Companies (Share Capital and Debenture) Rules, 2014.
- 2. Issue of shares with differential rights:** The Company has not issued any shares with differential rights and hence no information as per provisions of Section 43(a)(ii) of the Act read with Rule 4(4) of the Companies (Share Capital and Debenture) Rules, 2014.
- 3. Issue of shares under employee's stock option scheme:** The Company has not issued any equity shares under Employees Stock Option Scheme during the year under review and hence no information as per provisions of Section 62(1)(b) of the Act read with Rule 12(9) of the Companies (Share Capital and Debenture) Rules, 2014
- 4. Non- Exercising of voting rights :** During the year under review, there were no instances of non-exercising of voting rights in respect of shares purchased directly by employees under a scheme pursuant to Section 67(3) of the Act read with Rule 16(4) of Companies (Share Capital and Debentures) Rules, 2014.
- 5. Disclosure on purchase by company or giving of loans by it for purchase of its shares:** The company did not purchase or give any loans for purchase of its shares.
- 6. Buy back shares:** The company did not buy-back any shares during the period under review.
- 7. Disclosure about revision:** Since the company did not undergo any revision, this clause is Not Applicable to the company for the period under review.
- 8. Preferential Allotment of Shares:** 38,42,000 warrants were converted into 38,42,000. equity shares of Rs.10/- each at an issue price of Rs. 30.25 per share on preferential basis on 12-06-2018

The proceeds of the preferential issues was spent/ utilized towards intended objects and as mentioned in the explanatory statement of the notice of the AGM dated 30th Day of August, 2016.

EMPLOYEE RELATIONS:

The Directors are pleased to record their sincere appreciation of the contribution by the staff at all levels in the improved performance of the Company.

None of the employees is drawing Rs. 8,50,000 and above per month or Rs, 1,02,00,000/- and above in aggregate per annum, the limits prescribed under Section 197(12) of Companies

Twenty First Annual Report 2018-2019

Act 2013 read with Rule 5 of Companies(Appointment & Remuneration Of Managerial Personnel) Rules, 2014.

DISCLOSURE UNDER THE SEXUAL HARASSMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION AND REDRESSAL) ACT, 2013

The Company has in place an Anti Sexual Harassment Policy in line with the requirements of The Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. Internal Complaint Committee (ICC) has been set up to redress complaints received regarding sexual harassment. All employees are covered under this policy.

The following is the summary of sexual harassment complaints received and disposed during the calendar year.

- No. of complaints received: Nil
- No. of complaints disposed off: Nil

The directors further state that during the year under review, there were no cases filed pursuant to the sexual harassment of women at work place. (Prevention, prohibition and Redressal act, 2013)

PUBLIC DEPOSITS:

During the year under review, the Company has neither accepted nor renewed any deposit within the meaning of Section 73 and 76of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014.

ACKNOWLEDGEMENTS:

The Directors wish to place on record their appreciation of the contribution made by the employees at all levels, to the continued growth and prosperity of your Company.

The Directors also wish to place on record their appreciation of business constituents, banks and other financial institutions and shareholders of the Company like SEBI, BSE, NSE, MCX, NSDL, CDSL, The Karur Vysya Bank, Oriental Bank of Commerce, Andhra Bank and State Bank of India etc. for their continued support for the growth of the Company.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Place : Hyderabad
Date : 13.08.2019

Sd/-
K. Krishna Kishore
Vice Chairman &
Managing Director
(DIN : 00876539)

Sd/-
M. Rajendra Prasad
Whole-Time Director
and CEO
(DIN : 02376561)

Jeevan Scientific Technology Limited

CODE OF CONDUCT

DECLARATION BY DIRECTOR OF AFFIRMATION BY DIRECTORS AND SENIOR MANAGEMENT PERSONNEL OF COMPLIANCE WITH THE CODE OF CONDUCT:

The shareholders

M/s. Jeevan Scientific Technology Limited

Pursuant to Reg. 17(5) read with Reg. 34(3), Schedule V, part D of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 I, K. Krishna Kishore, Managing Director of the Company do hereby declare that the directors and senior management of the Company have exercised their authority and powers and discharged their duties and functions in accordance with the requirements of the code of conduct as prescribed by the company and have adhered to the provisions of the same.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 13.08.2019

Twenty First Annual Report 2018-2019

CERTIFICATE BY THE MANAGING DIRECTOR OF THE COMPANY

To
The Board of Directors
Jeevan Scientific Technology Limited

Dear Sirs,

As required under Regulation 17(8) read with Part B, Schedule II of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we state that:

1. We have reviewed the financial statements and the cash flow statement for the year ended 31st March 2019 and to the best of our knowledge and belief;
 - a) These statements do not contain any materially untrue statement nor omit any material fact nor contain statements that might be misleading, and
 - b) These statements present a true and fair view of the company's affairs and are in compliance with the existing accounting standards, applicable laws and regulations.
2. There are, to the best of my knowledge and belief, no transactions entered into by the company during the year, which are fraudulent, illegal or violative of the company's code of conduct.
3. We accept responsibility for establishing and maintaining internal controls, I have evaluated the effectiveness of the internal control systems of the company and I have disclosed to the auditors and the audit committee, deficiencies in the design or the operation of internal controls, if any, of which I was aware and the steps that I have taken or propose to take and rectify the identified deficiencies and,
4. That we have informed the auditors and the audit committee of:
 - a) Significant changes in the internal control during the year;
 - b) Significant changes in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and
 - c) Instances of significant fraud of which we have become aware and the involvement of any employee having a significant role in the company's internal control system.

For and on behalf of the Board
Jeevan Scientific Technology Limited

Sd/-

K. Krishna Kishore

Vice Chairman & Managing Director
(DIN : 00876539)

Place : Hyderabad
Date : 13.08.2019

Jeevan Scientific Technology Limited

MANAGEMENT DISCUSSIONS & ANALYSIS REPORT

This report contains financial review, opportunities, challenge, outlook etc.

i) **FINANCIAL REVIEW:**

Income earned to the extent of **Rs. 2,640.13** lakhs as against Rs. **2,016.91** lakhs of previous year and earned a profit of **Rs. 137.35 lakhs** as against Rs. **30.54** lakhs compared to last year.

ii) **PERFORMANCE:**

During the year under review your company recorded a turnover of Rs. **2,640.13** Lakhs as against Rs. **2,016.91** Lakhs for the previous financial year. The turnover is mainly from the core Clinical Research Services. The Business plan is to ensure at least two fold growth in business in the coming year(s) with the stable business. During the Financial Year under report, **Clinical Research Services** division has expanded into offering the complete portfolio of services as explained below:

Jeevan has the advantage of fully integrated scientific expertise team in Clinical research functions. Jeevan started offering a varied range of clinical research services like Bioavailability/Bioequivalence studies and Phase I to Phase IV services to pharmaceutical and biotechnology industries. The technical team at Jeevan has immense experience in handling various projects in diverse therapeutic areas for different regulatory authorities. The leadership team at Jeevan has over 200 years of cumulative experience in this arena, which comprises successful execution of more than 2500 clinical research projects for several pharmaceutical clients across the globe.

a. **Bioanalytical Research:**

Bioanalytical research laboratory is designed with state of the art facility equipped with advanced analytical instrumentation having 2 processing labs and 4 LC-MS/MS labs, which can accommodate up to 12 LC-MS/MS. During this financial year, your company acquired a total of 10 LC-MS/MS systems and these were added over the period to accommodate maximum possible work. Jeevan Scientific offers a unique combination of highly trained workforce enabled with well-equipped bioanalytical research and development (R&D) laboratory. Your bioanalytical laboratory located at Hyderabad is performing well and faced several successful regulatory and client audits.

b. **Clinical Operations:**

Being BA/BE studies are prime focused JSTL offering services, JSTL built a facility for executing the clinical phase of the BA/BE studies. In this regard, Jeevan established its clinical pharmacology centre in Hyderabad at B-17, TIE, Phase II, Balanagar, , Hyderabad, Telangana – 500037. This facility is spread over 20,000 sft and distributed in the 2nd, 3rd and 4th floors of the building. This facility accommodate a total of 132 beds distributed in to 4 clinical pharmacology units with bed capacity of 42(Clinic 1), 24(Clinic 2), 42(Clinic 3) and 24(Clinic 4). This facility also consists of special care areas (3+3 beds), emergency lift, tie-up with tertiary care hospital and a dedicated ambulance to handle emergencies. This facility is capable of carrying out approximately 200 studies per year at a peak capacity. During this financial year, your company completed a total of 110 studies, which was an optimal growth for a

Twenty First Annual Report 2018-2019

facility with an age limit of 2 years. Experienced, trained medical and para-medical staff conducts all these studies at this facility as per GCP and applicable regulations. The facility is in compliance with all the statutory requirements and also the applicable regulatory requirements like Drug Control General of India (DCGI). This facility being used to carry out the BA/BE studies for pharmaceutical companies who are developing molecules for global market.

c. Clinical Trials and Trial Management:

Jeevan's Clinical operation team has a vast experience in executing clinical projects of different therapeutic areas across the globe. Jeevan has rich pool of clinical investigators experienced in handling various phases of clinical projects including Pharmacokinetic and Pharmacodynamic studies. The Project management team oversee the technical and administrative aspects of the study. The team is committed to ensure timely update of project status, and meeting the client requirements in agreed timelines.

d. Regulatory Services:

Jeevan's Scientific Medical Writing team is structured with a team of competent writers, with diverse portfolios. The team is currently supporting major pharma clients across the globe, to achieve their objectives in Regulatory & technical documents writing. Jeevan provide expert services for the management of concerns with regulatory authorities and fulfill client expectations in a realistic and transparent manner.

e. Clinical Data Management and Statistical Analysis Services:

The Data Management team has hands on experience in handling clinical data, and the team ensures efficient and reliable management of the data in compliance with industry standards and regulatory requirements.

f. Pharmacovigilance Services:

Jeevan scientific offers a wide range of comprehensive pharmacovigilance and safety monitoring services. Jeevan's aim at a rapid pace growth, and retains an experienced vigilance team, thus being able to provide a wide range Pharmacovigilance services for different regulatory bodies. Currently your company is woring with a about eight clients in this area. During this financial year, your company could able to take advantage of the experience of this pharmacovigilance services and initiated a good number of contracts with small and medium pharmaceutical companies across USA and India.

A. AN IMPORTANT MILESTONE:

World Health Organization (WHO) auditors conducted an audit of our clinical pharmacology Centre and Bioanalytical facilities. The purpose of this audit was to review the BA/BE studies conducted and submitted by our sponsor to USFDA, WHO and MOH, South Africa. The auditors audited the facilities for a total of 4 days. We are please to inform that the auditors were satisfied with our procedures and processes which resulted with Nil Critical Observations.

USFDA auditors conducted an audit of our clinical pharmacology centre. The purpose of this audit was to review the BA/BE studies conducted and submitted by our sponsor to USFDA. The auditors audited our facilities for a total of 8 days. We are pleased to

Jeevan Scientific Technology Limited

inform you that the auditors were satisfied with our procedures and processes which resulted with Nil 483 Observations. The earlier USFDA audited resulted with one 483 was also closed with verification of documents submitted to USFDA, the product got approved and an Establishment Inspection Report (EIR) also submitted.

With the above inspections completed, your facilities are audited by USFDA (3 times), CDSCO (4 times) and WHO (1 time) and there were no outstanding observations/matters with the respective regulatory authorities.

B. OPPORTUNITIES:

Your Company could visualize increasing opportunities in exploring new avenues in Clinical Research Services. The marketing efforts of the company received an encouraging response. Today there is an ample business for Clinical Research Services in India and abroad. The quality based infrastructure and manpower are not easily available in the market. Due to these strengths with Jeevan we are able to see lot of opportunities coming to Jeevan. Further your company successfully completed stringent regulatory inspections like USFDA, WHO and CDSCO and we are expecting to have more and more opportunities in the area of clinical research services.

C. CHALLENGES:

Your Company faces normal market competition in all its business from domestic and overseas companies. However, our business strategies and global competitive cost position have enabling us to retain the market position and maintain operating margin and enhance long term, even under difficult operating conditions for the IT industry, Pharmaceutical Sector is going to play a vital role in increasing the revenues of the organization. We endeavor to enhance its competitive advantage through a process of continuous improvements and by implementing appropriate business strategies.

D. Advantages of CROs in India

None of the following advents of India changed drastically to have a competitive edge over other organizations located outside India and India is considered as the hub for the clinical trial industry and where in we provide the Clinical Research Services.

- India offers a set of advantages that are so unique and strong vis-a-vis other regions of the world that no major drug research company can afford to ignore India in their medium to long term.
- Ability to conduct a trial faster than most of the major locations in the world in most of the significant therapeutic segments. In this industry, time is money in true sense. In a study by Ernst & Young, it was concluded that in most cases there is a 20%-30% time advantage of carrying out a Phase III study in India compared to undertaking it in North America or in Western Europe.
- India has a huge pool of subjects/ patients (many of them are treatment- naïve) with wide spectrum of diseases that are willing to participate in clinical studies. The past experience has shown that in most of the multi country trials, patient enrolment is rapid in India, thereby speeding up the drug development process. The 20-year clock on drug patent starts ticking when a new compound is discovered, not when it is approved. An early completion of drug testing results in the reduction in cost incurred on its development and provides more time for selling it as a monopoly product enabling better recovery of costs incurred as well as earning good profits.

Twenty First Annual Report 2018-2019

- English is the main language of communications in the hospitals in all major cities.
- Carrying out a study in India in strict accordance with global guidelines results in cost saving of between 25-40% when compared to the regions mentioned above.
- India has a talented pool of Clinical Research Professionals (highly trained medical professionals) and infrastructure, which includes all super specialties of Medicine.
- Importing clinical supplies has become easier. An import license is granted with the clinical trial permission.
- Apart from cost advantage, the more promising and long-standing advantage is the speed of recruitment/completion of trial that enables the drug developer to have longer time in the market before expiry of the patent to fetch the obvious benefits.
- IT enabled infrastructure at a lower cost.
- In the recent past, the efficient regulatory system in the country, enabling to attract more business from abroad in the area of clinical research.

D. OUTLOOK:

The outlook for margins in current scenario will depend upon global demand and supply trends in the pharmaceutical industry. We intend to extend our client base and explore the new avenues and opportunities by entering in to tie-up arrangements with more national and International pharmaceutical companies.

E. ADEQUACY OF INTERNAL CONTROL:

Your company has internal auditors to ensure that internal control systems are in place and all assets are safeguarded and protected against loss. An extensive program of Internal Audit and reviews supplement the internal control systems by management & documented policy guidelines and procedures. The internal control systems are designed to ensure that the financial records are available for preparing financial statements and other data and maintaining accountability of assets.

F. QUALITY:

The QA team is focused on continual improvement of Quality Management System and reports directly to management. QA auditors are armed with knowledge on national, international regulations and guidelines. The QA team audits quality systems and studies, carried out by Jeevan, in accordance with set procedures and applicable regulatory guidelines, to ensure fulfillment of quality requirements. Our Motto is to ensure total Customer Satisfaction. Proactive efforts are directed towards determining customers' requirements and achieving all round customer satisfaction. This is primarily achieved through automated systems, high attention to complaint resolution online communication and information exchange, quality circles and adoption of programs.

G. HUMAN RESOURCES DEVELOPMENT (HRD):

Yours is a young Company, with human resources of an average age of 30 years for its employees as on March 31, 2019. Right from the beginning the company got good HR policies for retaining manpower. Your company employs a total of 200 people with good qualifications and high technical background and experienced in the area of work where they are in.

H. LEARNING & TRAINING:

Training programs have been devised to develop cross-functional skills and is a continuous process across functions and throughout the organization.

ENHOPS:

Enhops Solutions Pvt. Ltd. in India and Enhops, Inc., USA are fully owned subsidiary companies of Jeevan Scientific Technology Limited, Hyderabad. Enhops has clients across the globe – USA, UAE, Saudi Arabia, UK & India and clientele includes organizations from start-ups to Fortune 500 companies. The analysts forecast the global software testing services market to grow at a CAGR of 15.1% during the period 2018-2022.

Enhops Service Offerings include Quality Assurance, Quality Engineering, Quality solutions and Test advisory & consulting.

Enhops traditional offerings include, Test Advisory Services: Today's digital business world demands high-quality products and services. Organizations should invest in innovation and quality assurance for their software and applications to stay ahead of their competition. They need a reliable software-testing partner who can assess their testing requirements, refine QA practice and advise on a QA roadmap in line with their business needs.

Test Automation: Traditional software testing approaches, including manual testing, are not enough to rapidly deliver software with impeccable quality. Hence, test automation has gained lot of prominence in the recent times. Also, agile-driven software development and test practices have made test automation as an integral component of continuous integration and testing for continuous delivery.

Performance Testing: Today's hyper-connected world across mobile phones, smart devices, diverse media channels, and business applications demand enterprises to offer seamless end user experience so as to achieve competitive advantage. The slightest application downtime can put the reputation of an enterprise at stake and cause substantial revenue loss. Hence, testing of such business-critical applications/software requires a different perception entirely by putting customer experience at the centre.

Security Testing: Data security is becoming extremely critical with more and more technological innovations happening in the industry. Security breach can happen at network level, system software level, client-side or server-side. Enhops Security Testing Services helps our customer to develop and secure their web or mobile applications as well as meet applicable regulatory and compliance requirements.

Mobile testing: Usage of mobile devices and applications has seen tremendous growth in the recent past. They are considerably enabling businesses and customers to interact in a whole new format. This exponential growth in the mobile market is bringing in new testing challenges with variant platforms, OS versions, screen sizes and networks.

Test Centre of Excellence: Some of the common testing challenges we see in an organization are – ambiguous requirements, aggressive schedules, limited budgets for testing, complex environments, high operations costs and so on. Test Centre of Excellence (TCoE) is a centralized testing function established to address these challenges effectively and meet testing needs of all business units successfully.

Twenty First Annual Report 2018-2019

DevOps: Industry recognizes the need for continuous integration and deployment. Without bringing testing into the mainstream development lifecycle, DevOps is incomplete, leading to quality issues. Organizations are looking to adopt DevOps to reduce Build to Deploy time. DevOps framework integrates development and operations with focus on continuous integration and testing to cut down the cycle time. The framework encompasses testing at various levels such as ambiguity reviews of individual user stories, testing at individual sprint level and complete end-to-end testing at the release level.

Functional Manual Testing: Early testing brings lot of benefits in terms of quality, time and cost. Static and dynamic testing goes hand in hand to make this happen. Involving testing teams in requirement workshops helps in understanding the expectations and build required tests soon.

Process Framework Establishment: Enhops brings its vast experience and expertise to establish a robust test methodology that will offer benefits through unified test governance, standardization and reusability. Our proprietary Global Delivery Methodology is used as basis to establish process framework at our client locations. handled as change requests and are addressed based on the priority assigned.

Our Differentiators:

- CORE: CORE is a homegrown methodology to establish and maintain Test Center of Excellence (TCoE).
- QuesT: QuesT is an online questionnaire management tool, which is used for Test Advisory Services.
- EstiMate: EstiMate tool uses the industry standard PERT three-point estimation and test point analysis technique to understand the complexity and estimate effort.
- KnoRA: Enhops KnoRA tool helps in managing requirements ambiguity analysis and reporting ambiguous requirements.
- OptiTest: OptiTest is Enhops' proprietary tool that supports test data generation for Orthogonal array testing.
- QGuage: QGuage is Enhops' dashboard management tool that helps in generating customized metric reports and dashboards as per the requirement.
- PrediQT: PrediQT is Enhops' statistical prediction model that helps in predicting defects based on historical data.
- CalRol: Enhops Automation ROI analyzer is an effective and simple way to understand the benefits derived automation at defines intervals.

Focus Area's in the Year 2019 - 2020

Enhops has embarked into next generation technologies & testing offerings keeping in mind the latest trends in the QA & QE industry. With the advent of Agile and DevOps development technologies, the software development industry is undergoing major disruptions. This has lead to the evolution of new testing approaches that Enhops has acquired and Enhops is focusing on the following trends to stay ahead in the competition,

1. Digital Transformation with Agile: Businesses are undergoing digital transformation ever since data has become valuable in gaining insights. The latest addition to this trend is the adoption of agile methodology to undergo a digital transformation. As digital transformation is an ongoing process, agile helps to deliver valuable outcomes frequently for the business rather than waiting for a long time.

Jeevan Scientific Technology Limited

2. Machine learning in testing: Machine learning is bringing about revolutionary changes in workflows and processes. In testing, machine learning can be used for Test suite optimization, Predictive analytics, Log analytics, Traceability, Defect analytics
3. Increasing Adoption of DevOps: In DevOps, the testing begins at the beginning of the development cycle. This development approach facilitates Continuous Integration and Continues Delivery. This allows testers to perform Continuous Testing and Continuous Monitoring to validate that the developers have built the right application. The functionality and performance of the application are tested continuously along with development.
4. Big Data Testing: Big Data is the high volume of data generated at a high velocity. In Big Data testing, testers have to verify that terabytes of data are successfully processed using commodity cluster and other supportive components. This type of testing focuses on performance testing and functional testing.
5. IoT Testing: There are more connected devices than ever before as IoT (Internet of Things) technology is gaining traction. IoT testing is conducted to test IoT technology based devices. The various types of testing for IoT systems are Usability Testing, Compatibility Testing, Reliability & Scalability Testing, Data Integrity Testing, Security testing, Performance Testing
6. Performance Engineering: Performance engineering will replace performance testing in the near future. Rather than executing performance test scripts, the focus will be on analyzing how all the elements of the system work together. The various elements of the system include performance, security, usability, hardware, software, configuration, business value and the customer.
7. Test Automation: The test automation helps the testing team to focus their time and efforts on creating test cases rather than managing testing needs. Test automation helps to track and manage all testing needs, the types of testing required along with the test coverage. Test automation helps to ensure high- quality software is delivered.
8. Combining Manual and Automated Testing: More and more quality assurance professionals are using a combination of manual and automated testing approaches to harness the benefits of both as well as to overcome their respective shortcomings.
9. Shortening Delivery Cycle: Rapid changes in technologies, platforms, and devices are putting pressure on software development teams to deliver the finished products faster and more frequently. Testing needs to be integrated with development to facilitate delivery. Software organizations are ready to invest more in improving their development and delivery processes by employing the right set of tools.
10. Integration: With shortening delivery cycles, there is a greater need for integration of various elements of a product development. To facilitate smart testing and analytics, the data is collected from disparate sources such as requirement management systems, change control systems, task management systems, and test environment.

Enhops is one of the few independent testing organizations who is utilizing AI & ML in software testing. ML and AI are undeniably growing to be significant elements in software testing and QA as well. AI will advance accuracy, give enhanced revenue and lower costs for all QA processes. Henceforth, it improves competitive positioning and customer experience. Most importantly, AI helps identify bugs quicker and faster. Enhops is one of the few testing companies who has embarked into this journey.

REPORT ON CORPORATE GOVERNANCE

In accordance with Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the report containing the details of Corporate Governance systems and processes at Jeevan Scientific Technology Limited as follows:

COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:

The Company is in full compliance with the requirements of Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

BOARD DIVERSITY:

The Company recognizes and embraces the importance of a diverse board in its success. We believe that a truly diverse board will leverage differences in thought, perspective, knowledge, skill, regional and industry experience, cultural and geographical background, age, ethnicity, race and gender, which will help us, retain our competitive advantage. The Board has adopted the Board Diversity Policy which sets out the approach to diversity of the Board of Directors. The Board Diversity Policy is available on our website, www.jeevanscientific.com

FAMILIARIZATION PROGRAM FOR INDEPENDENT DIRECTORS:

All new independent directors inducted into the Board attend an orientation program. The details of training and familiarization program are provided in the corporate governance report. Further, at the time of the appointment of an independent director, the Company issues a formal letter of appointment outlining his / her role, function, duties and responsibilities.

COMPANY'S CODE OF CONDUCT FOR THE PREVENTION OF INSIDER TRADING:

The Board of Directors has adopted the Insider Trading Laws in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulation, 2015. The Insider Trading Laws of the Company lays down guidelines and procedures to be followed, and disclosures to be made while dealing with shares of the Company. The policy has been formulated to regulate, monitor and ensure reporting of deals by employees and to maintain the highest ethical standards of dealing in Company securities.

The Insider Trading Laws of the Company covering code of practices and procedures for fair disclosure of unpublished price sensitive information and code of conduct for the prevention of insider trading, is available on our website www.jeevanscientific.com

Jeevan Scientific Technology Limited

During the year under review 6 board meetings were conducted and the Composition of the Board, attendance at board meetings (BM) held during the financial year under review and at the last Annual General Meeting (AGM), number of Directorships and memberships / chairmanships in public companies (including the Company) are given below.

S.No.	Name of the Director	Category	Attendance at Board Meeting	Whether Attended AGM Held on 28-09-2018	No. of Director Ships in Other Public Companies	No. of Other Board Committees in which he is Member	No. of Other Board Committees in which he is a Chairman
1.	Mr. K. Krishna Kishore, Vice Chairman & Managing Director	Executive Promoter	6	Yes	Nil	3	Nil
2.	Ms. K. Vanaja	Non Executive Non-Independent Director	6	Yes	Nil	1	Nil
3.	Mr. T. Ravi Babu	Non-Executive Non-Independent Director	5	No	Nil	2	Nil
4.	Mr. G. Bhanu Prakash	Non-Executive Independent Director	2	No	Nil	3	Nil
5.	Mr. M. Rajendra Prasad, Executive Director	Executive Wholetime Director and CEO	6	Yes	Nil	Nil	Nil
6.	Mr. K. Rama Krishna Prasad	Non-Executive Independent Director	6	Yes	Nil	5	4
7.	Mr. S.S.R Koteswara Rao, Chairman	Non-Executive Independent Director	5	Yes	2	5	1

Alternate Directorships, Directorships in Private Bodies and Membership in governing councils, chambers and other bodies were not considered.

As seen from the above, the Non-Executive Directors constitute more than half of the total number of Directors. The Company has a Non-Executive Chairman and one third of the total strength of the Board comprises of Independent Directors. Managing Director is overseeing the day-to-day operations of the Company.

DISCLOSURE OF RELATIONSHIPS BETWEEN DIRECTORS INTER-SE

Mr. K. Krishna Kishore and Mrs. K. Vanaja are inter-se related as Husband and Wife.

NUMBER OF SHARES AND CONVERTIBLE INSTRUMENTS HELD BY NON-EXECUTIVE DIRECTORS:

None of the non-Executive Directors of the company except as mentioned below hold any shares and Convertible Instruments in their name.

- i. Thammareddy Ravi (2500 equity shares)
- ii. Bhanu prakash Gali (3000 equity shares)
- iii. K Vanaja (15,73,800 equity shares)
- iv. K R K Prasad (3,00,000 equity shares)

COMPOSITION OF AUDIT COMMITTEE:

- I. The Audit Committee of the Company is constituted in line with the provisions of Regulation 18 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section 177 of the Companies Act, 2013.
- II. The terms of reference of the Audit Committee include a review of the following:
 1. Overview of the Company's financial reporting process and disclosure of its financial information to ensure that the financial statements reflect a true and fair position and that sufficient and credible information is disclosed.
 2. Recommending the appointment and removal of external auditors, fixation of audit fee and also approval for payment for any other services.
 3. Discussion with external auditors before the audit commences, of the nature and scope of audit as well as post-audit discussion to ascertain any area of concern.
 4. Reviewing the financial statements and draft audit report including quarterly / half yearly financial information.
 5. Reviewing with management the annual financial statements before submission to the Board, focusing on:
 - a) Any changes in accounting policies and practices;
 - b) Qualification in draft audit report;
 - c) Significant adjustments arising out of audit;
 - d) The going concern concept;
 - e) Compliance with accounting standards;
 - f) Compliance with stock exchange and legal requirements concerning financial statements;
 - g) Any related party transactions
 - h) Reviewing the company's financial and risk management's policies.
 - i) Disclosure of contingent liabilities.
 - j) Reviewing with management, external and internal auditors, the adequacy of internal control systems.

Jeevan Scientific Technology Limited

- k) Reviewing the adequacy of internal audit function, including the audit character, the structure of the internal audit department, approval of the audit plan and its execution, staffing and seniority of the official heading the department, reporting structure, coverage and frequency of internal audit.
- l) Discussion with internal auditors of any significant findings and follow-up thereon.
- m) Reviewing the findings of any internal investigations by the internal auditors into the matters where there is suspected fraud or irregularity or a failure of internal control systems of a material nature and reporting the matter to the Board.
- n) Looking into the reasons for substantial defaults in payments to the depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
- o) Reviewing compliances as regards the Company's Whistle Blower Policy.

III. The previous Annual General Meeting of the Company was held on 28-Sep-2018 and Chairman of the Audit Committee attended previous AGM.

IV. The composition of the Audit Committee and the attendance of each member of the Audit Committee are given below:

The Company has complied with all the requirements of Regulation 18 of SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 relating to the composition of the Audit Committee. During the financial year 2018-2019, (4) four meetings of the Audit Committee were held on the 26.05.2018, 14.08.2018, 12.11.2018 and 14.02.2019

The details of the composition of the Committee and attendance of the members at the meetings are given below:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. K. Rama Krishna Prasad	Chairman	NED(I)	4	4
Mr. K. Krishna Kishore	Member	ED	4	4
Mr. S.S.R Koteswara Rao	Member	NED(I)	4	4
Mr. G. Bhanu Prakash	Member	NED(I)	4	1

NED (I) : Non Executive Independent Director

ED : Executive Director

Twenty First Annual Report 2018-2019

V. NOMINATION & REMUNERATION COMMITTEE

The details of composition of the Committee are given below:

Name	Designation	Category	No of Meetings held	No of Meetings attended
Mr. K. Rama Krishna Prasad	Chairman	NED(I)	3	1
Mr. T. Ravi Babu	Member	NED	3	2
Mrs. K. Vanaja	Member	NED	3	3
Mr. S.S.R Koteswara Rao	Member	NED(I)	3	2

NED (I) : Non Executive Independent Director

NED : Non Executive Director

Terms of reference:

The main term of reference of the Committee is to approve the fixation/revision of remuneration of the Managing Director/Whole Time Director of the Company and while approving:

- To take into account the financial position of the Company, trend in the industry, appointee's qualification, experience, past performance, past remuneration etc.
- To bring out objectivity in determining the remuneration package while striking a balance between the interest of the Company and the Shareholders.

Remuneration Policy:

The objectives of the remuneration policy are to motivate Directors to excel in their performance, recognize their contribution and retain talent in the organization and reward merit.

The remuneration levels are governed by industry pattern, qualifications and experience of the Directors, responsibilities shouldered, individual performance etc.

The details of remuneration paid to the Executive and Non Executive Directors per annum for the financial year 2018-2019 are given below:

Amount in Rs.(p.a)

Name of the Director	Remuneration/Sitting Fees
Mr. K. Krishna Kishore	54,00,000 (Remuneration)
Mr. M. Rajendra Prasad	54,00,000 (Remuneration)
Mrs. K. Vanaja	65,000 (Sitting Fee)
Mr. S.S.R. Koteswara Rao	92,500 (Sitting Fee)
Mr. T. Ravi Babu	52,500 (Sitting Fee)
Mr. G. Bhanu Prakash	30,000 (Sitting Fee)
Mr. K. Rama Krishna Prasad	1,00,000 (Sitting Fee)

None of the Directors is drawing any Commission, Perquisites, Retirement benefits etc.

Jeevan Scientific Technology Limited

PERFORMANCE EVALUATION CRITERIA FOR INDEPENDENT DIRECTORS:

The Performance evaluation criteria for Independent Directors is already mentioned under the head 'Board Evaluation' in Directors' Report.

POLICY FOR SELECTION OF DIRECTORS AND DETERMINING DIRECTORS' INDEPENDENCE

1. Scope:

This policy sets out the guiding principles for the Nomination & Remuneration Committee for identifying persons who are qualified to become Directors and to determine the independence of Directors, in case of their appointment as independent Directors of the Company.

2. Terms and References:

2.1 **"Director"** means a director appointed to the Board of a Company.

2.2 **"Nomination and Remuneration Committee"** means the committee constituted in accordance with the provisions of Section 178 of the Companies Act, 2013 and Reg. 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2.3 **"Independent Director"** means a director referred to in sub-section (6) of Section 149 of the Companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

Qualifications and criteria

3.1.1 The Nomination and Remuneration Committee, and the Board, shall review on annual basis, appropriate skills, knowledge and experience required of the Board as a whole and its individual members. The objective is to have a board with diverse background and experience that are relevant for the Company's operations.

3.1.2 In evaluating the suitability of individual Board member the NR Committee may take into account factors, such as:

- General understanding of the company's business dynamics, global business and social perspective;
- Educational and professional background
- Standing in the profession;
- Personal and professional ethics, integrity and values;
- Willingness to devote sufficient time and energy in carrying out their duties and responsibilities effectively.

3.1.3 The proposed appointee shall also fulfil the following requirements:

- shall possess a Director Identification Number;
- shall not be disqualified under the companies Act, 2013;
- shall Endeavour to attend all Board Meeting and Wherever he is appointed as a Committee Member, the Committee Meeting;
- shall abide by the code of Conduct established by the company for Directors and senior Management personnel;

Twenty First Annual Report 2018-2019

- shall disclose his concern or interest in any company or companies or bodies corporate, firms, or other association of individuals including his shareholding at the first meeting of the Board in every financial year and thereafter whenever there is a change in the disclosures already made;
- Such other requirements as any be prescribed, from time to time, under the companies Act, 2013, SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other relevant laws.

3.1.4 The Nomination & Remuneration Committee shall evaluate each individual with the objective of having a group that best enables the success of the company's business.

3.2 **Criteria of Independence**

3.2.1 The Nomination & Remuneration Committee shall assess the independence of Directors at the time of appointment/ re-appointment and the Board shall assess the same annually. The Board shall re-assess determinations of independence when any new interest or relationships are disclosed by a Director.

3.2.2 The criteria of independence, as laid down in companies Act, 2013 and Regulation 16(b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is as below:

An independent director in relation to a company, means a director other than a managing director or a whole-time director or a nominee director-

- a. Who, in the opinion of the Board, is a person of integrity and possesses relevant expertise and experience;
- b. (i) who is or was not a promoters of the company or its holding, subsidiary or associate company;
(ii) Who is not related to promoters or directors of the company its holding, subsidiary or associate company
- c. Who has or had no pecuniary relationship with the company, its holding, subsidiary or associate company, or their promoters, or director, during the two immediately preceding financial year or during the current financial year;
- d. None of whose relative has or had pecuniary relationship or transaction with the company, its holding, subsidiary or associate company, or their promoters, or directors, amounting to two per cent or more of its gross turnover or total income or fifty lakh rupees or such higher amount as may be prescribed, whichever is lower, during the two immediately preceding financial year or during the current finance year;
- e. Who, neither himself nor any of his relative-
 - (i) Holds or has held the position of a key managerial personnel or is or has been employee of the or associate company in any of the three finance years immediately preceding the finance year in which he is proposed to be appointed;
 - (ii) Is or has been an employee or proprietor or a partner, in any of the three finance year immediately preceding the finance year in which he is proposed to be appointed of-

Jeevan Scientific Technology Limited

- (A) a firm of auditors or company secretaries in practice or cost auditors of the company or its holding, subsidiary or associate company; or
- (B) any legal or a consulting firm that has or had any transaction with the company, its holding subsidiary or associate company amounting to ten per cent or more of the gross turnover of more of the gross turnover of such firm;
 - (iii) holds together with his relatives two per cent or more of the total voting power of the company; or
 - (iv) is a chief Executive or director, by whatever name called, of any non-profit organization that receives twenty-five per cent or more of its receipt from the company any of its promoters , directors or its holding subsidiary or associate company or that holds two per cent or more of the total voting power of the company; or
 - (v) is a material supplier, service provider or customer or a lessor or lessee of the company.
- f. Shall possess appropriate skills experience and knowledge in one or more field of finance , law management, sales, marketing administration, research, corporate governance, technical operations, corporate social responsibility or this disciplines related to the company's business.
- g. Shall possess such other qualifications as may be prescribed from time to time, under the companies Act, 2013.
- h. Who is not less than 21 years of age

3.2.3 The independent Director shall abide by the “code for independent Directors “as specified in Schedule IV to the companies A ct, 2013.

3.3 other directorships/ committee memberships

3.3.1 The Board members are expected to have adequate time and expertise and experience to contribute to effective Board performance Accordingly, members should voluntarily limit their directorships in other listed public limited companies in such a way that it does not interfere with their role as director of the company. The NR Committee shall take into account the nature of, and the time involved in a director service on other Boards, in evaluating the suitability of the individual Director and making its recommendations to the Board.

3.3.2 A Director shall not serve as director in more than 20 companies of which not more than 10 shall be public limited companies.

3.3.3 A Director shall not serve an independent Director in more than 7 listed companies and not more than 3 listed companies in case he is serving as a whole-time Director in any listed company.

3.3.4 A Director shall not be a member in more than 10 committee or act chairman of more than 5 committee across all companies in which he holds directorships.

For the purpose of considering the limit of the committee, Audit committee and stakeholder's relationship committee of all public limited companies, whether listed or not, shall be included and all other companies including private limited companies,

Twenty First Annual Report 2018-2019

foreign companies and companies under section 8 of the companies Act, 2013 shall be excluded.

Remuneration policy for Directors, key managerial personnel and other employees:

1. Scope:

1.1 This policy sets out the guiding principles for the Nomination and Remuneration committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the company.

2. Terms and Reference:

In this policy the following terms shall have the following meanings:

2.1 “**Director**” means directors appointed to the Board of the company.

2.2 “**Key Managerial Personnel**” means

- (i) The Chief Executive Office or the managing director or the manager;
- (ii) The company secretary;
- (iii) The whole-time director;
- (iv) The chief finance Officer; and
- (v) Such other office as may be prescribed under the companies Act, 2013

2.3 “Nomination and Remuneration committee” means the committee constituted by Board in accordance with the provisions of section 178 of the companies Act, 2013 and Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

3. Policy:

3.1 Remuneration to Executive Director and key managerial personnel

3.1.1 The Board on the recommendation of the Nomination and Remuneration (NR) committee shall review and approve the remuneration payable to the Executive Director of the company within the overall approved by the shareholders.

3.1.2 The Board on the recommendation of the NR committee shall also review and approve the remuneration payable to the key managerial personnel of the company.

3.1.3 The remuneration structure to the Executive Director and key managerial personnel shall include the following components:

- (i) Basic pay
- (ii) Perquisites and Allowances
- (iii) Stock Options
- (iv) Commission (Applicable in case of Executive Directors)
- (v) Retrial benefits
- (vi) Annual performance Bonus

3.1.4 The Annual plan and Objectives for Executive committee) shall be reviewed by the NR committee and Annual performance Bonus will be approved by the committee based on the achievement against the Annual plan and Objectives.

3.2 Remuneration to Non – Executive Directors

3.2.1 The Board, on the recommendation of the NR Committee, shall review and approve

Jeevan Scientific Technology Limited

the remuneration payable to the Non – Executive Directors of the Company within the overall limits approved by the shareholders.

3.2.2 Non – Executive Directors shall be entitled to sitting fees attending the meetings of the Board and the Committees thereof. The Non- Executive Directors shall also be entitled to profit related commission in addition to the sitting fees.

3.3. Remuneration to other employees

3.3.1. Employees shall be assigned grades according to their qualifications and work experience, competencies as well as their roles and responsibilities in the organization. Individual remuneration shall be determined within the appropriate grade and shall be based on various factors such as job profile skill sets, seniority, experience and prevailing remuneration levels for equivalent jobs.

VI. STAKEHOLDERS RELATIONSHIP COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category
Mr. K. Rama Krishna Prasad	Chairperson	NED(I)
Mr. K. Krishna Kishore	Member	ED
Mr. S.S.R. Koteswara Rao	Member	NED(I)
Mr. Gali Bhanu Prakash	Member	NED (I)

NED (I) : Non Executive Independent Director

ED : Executive Director

B) Powers:

The Committee has been delegated with the following powers:

- To redress shareholder and investor complaints relating to transfer of shares, Dematerialization of Shares, non-receipt of Annual Reports, non-receipt of declared dividend and other allied complaints.
- To approve, transfer, transmission, and issue of duplicate / fresh share certificate(s)
- Consolidate and sub-division of share certificates etc.
- To redress, approve and dispose off any, other complaints, transactions and requests etc., received from any shareholder of the company and investor in general.

The Board has delegated the power to process the transfer and transmission of shares to the Registrar and Share Transfer Agents, who process share transfers within a week of lodgement in the case of shares held in physical form.

The Company has designated an exclusive e-mail ID called shareholders@jeevanscientific.com

C.) NAME AND DESIGNATION OF COMPLIANCE OFFICER

Mr. T. Chandra Sekha, Company Secretary of the company, is the compliance officer of the Company till 6th June 2019 and Mr. K. Krishna Kishore appointed as Compliance Officer of the company with effect from 7th June 2019.

Twenty First Annual Report 2018-2019

D.) DETAILS OF COMPLAINTS/REQUESTS RECEIVED, RESOLVED AND PENDING DURING THE YEAR 2018-19

INVESTOR COMPLAINTS

Particulars	Year ended 31-Mar-2019
Pending at the beginning of the year	Nil
Received during the year	Nil
Disposed of during the year	Nil
Remaining unresolved at the end of the year	Nil

VII. RISK MANAGEMENT COMMITTEE

A.) Composition:

The Details of composition of the Committee are given below:

Name	Designation	Category
Mr. K.Rama Krishna Prasad	Chairperson	NED(I)
Mr. T. Ravi Babu	Member	NED
Mr. K. Krishna Kishore	Member	ED
Mr. S.S.R. Koteswara Rao	Member	NED(I)

NED (I) : Non Executive Independent Director

ED : Executive Director

NED : Non Executive Director

Role and Responsibilities of the Committee includes the following:

- Framing of Risk Management Plan and Policy
- Overseeing implementation of Risk Management Plan and Policy
- Monitoring of Risk Management Plan and Policy
- Validating the process of risk management
- Validating the procedure for Risk minimisation.
- Periodically reviewing and evaluating the Risk Management Policy and practices with respect to risk assessment and risk management processes.
- Continually obtaining reasonable assurance from management that all known and emerging risks have been identified and mitigated or managed.

Annual General Body Meetings:

Location and time of last three Annual General Meetings are as under:

Year	Location	Date	Time	Spl resolutions.
2018	III Floor, R.R. Towers	28-Sep-2018	09.30 A.M	Yes
2017	III Floor, R.R. Towers	27-Sep-2017	09.30 A.M	No
2016	III Floor, R.R. Towers	30-Sep-2016	09.00 A.M	Yes

Jeevan Scientific Technology Limited

During the year 2018-19 under review following resolutions were put to vote and were passed by Special Resolution :-

1. RE-APPOINTMENT OF MR. S. S. R. KOTESWARA RAO (DIN: 00964290) AS AN INDEPENDENT DIRECTOR OF THE COMPANY

During the last year under review no resolution was put to vote and was passed by Postal Ballot.

A. PECUNIARY RELATIONSHIP OR TRANSACTIONS OF THE NON-EXECUTIVE DIRECTORS VIS-À-VIS THE LISTED COMPANY: The Non- Executive Directors have no pecuniary relationship or transactions.

B. CRITERIA FOR MAKING PAYMENTS TO NON-EXECUTIVE DIRECTORS: As per the remuneration policy of the company.

C. REMUNERATION TO DIRECTORS PAID DURING THE FINANCIAL YEAR 2018-19 AND OTHER DISCLOSURES

Name of the Director	Salary (Rs) (p.a)	Sitting fees (Rs)(p.a)	Number of shares held	Service Contracts	Stock Option Details	Fixed Component	Performance Based Incentive
Mr. K. Krishna Kishore	54,00,000	-	20,01,391	-	-	-	-
Mr. M. Rajendra Prasad	54,00,000	-	8,96,250	-	-	-	-
Mr.S.S.R.Koteswara Rao	-	92,500	-	-	-	-	-
Mrs. K. Vanaja	-	65,000	15,73,800	-	-	-	-
Mr. T. Ravi Babu	-	52,500	2,500	-	-	-	-
Mr. G. Bhanu Prakash	-	30,000	3,000	-	-	-	-
Mr. K. Rama Krishna Prasad	-	1,00,000	3,00,000	-	-	-	-

D. INDEPENDENT DIRECTORS' MEETING:

As per clause 7 of the schedule IV of the Companies Act (Code for Independent Directors), a separate meeting of the Independent Directors of the Company (without the attendance of Non-Independent directors) was held on 06-Mar-2019, and discussed the following:

1. Evaluation of the performance of Non Independent Directors and the Board of Directors as whole;
2. Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

All the Independent Directors of the Company were present at the meeting.

As required under Regulation 34(3) read with Schedule V of SEBI (Listing Obligations

Twenty First Annual Report 2018-2019

and Disclosure Requirements) Regulations 2015, the company regularly familiarizes Independent Directors with the Company, their roles, rights, responsibilities in the company, nature of the industry in which the company operates, business model of the company etc.

FORMAL ANNUAL EVALUATION:

As per section 149 of the Companies Act, 2013 read with clause VII (1) of the schedule IV and rules made there under, the independent directors of the company had a meeting on 06th day of March, 2019 without attendance of non-independent directors and members of management. In the meeting the following issues were taken up:

- (a) Review of the performance of non-independent directors and the Board as a whole;
- (b) Review of the performance of the Chairperson of the company, taking into account the views of executive directors and non-executive directors;
- (c) Assessing the quality, quantity and timeliness of flow of information between the company management and the Board that is necessary for the Board to effectively and reasonably perform their duties.

The meeting also reviewed and evaluated the performance of non-independent directors. The company has 4 (Four) non-independent directors namely: i.) Mr. K. Krishna Kishore – Vice chairman & Managing Director ii) Mr. M. Rajendra Prasad - Whole time director & CEO iii.) Mrs. K. Vanaja – Non Executive Director and iv) Mr. T. Ravi Babu - Non Executive Director. The meeting recognized the significant contribution made by non-independent directors in the shaping up of the company and putting the company on accelerated growth path. They devoted more time and attention to bring up the company to the present level.

The meeting also reviewed and evaluated the performance of the Board as whole in terms of the following aspects:

- Preparedness for Board/Committee meetings
- Attendance at the Board/Committee meetings
- Guidance on corporate strategy, risk policy, corporate performance and overseeing acquisitions and disinvestments.
- Monitoring the effectiveness of the company's governance practices
- Ensuring a transparent board nomination process with the diversity of experience, knowledge, perspective in the Board.
- Ensuring the integrity of the company's accounting and financial reporting systems, including the independent audit, and that appropriate systems of control are in place, in particular, systems for financial and operational control and compliance with the law and relevant standards.

It was noted that the Board Meetings have been conducted with the issuance of proper notice and circulation of the agenda of the meeting with the relevant notes thereon.

VIII. OTHER DISCLOSURES

A. MATERIALLY SIGNIFICANT RELATED PARTY TRANSACTIONS

During the year under review, the Company had not entered in to any materially significant transaction with any related party. Remuneration paid to directors is well within the limits of Section 197 read with Schedule V of Companies Act, 2013. During the year, the Company had not entered into any other contract/arrangement/transaction with related parties which

Jeevan Scientific Technology Limited

could be considered material in accordance with the policy of the company on materiality of related party transactions that may have potential conflict with the interests of the Company at large. All the related party transactions during the year are in the ordinary course of business and on arm's length basis.

B. COMPLIANCES:

There are no penalties imposed on the Company by the Stock Exchanges or SEBI or any other statutory authority on any matter related to capital markets, during the last three years.

C. WHISTLE BLOWER POLICY

With a view to adopt the highest ethical standards in the course of business, the Company has a whistle blower policy in place for reporting the instances of conduct, which are not in conformity with the policy. Directors, employees, vendors or any person having dealings with the Company may report non-compliance to the Chairman of the Audit Committee, who reviews the report. Confidentiality is maintained of such reporting and it is ensured that the whistle blowers are not subjected to any discrimination. No person was denied access to the Audit Committee.

D. COMPLIANCE WITH THE MANDATORY REQUIREMENTS AND ADOPTION OF THE NON-MANDATORY REQUIREMENTS OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015.

All mandatory requirements of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 have been appropriately complied with and the status of non-mandatory requirements is given below:

The Board & Separate posts of Chairman and CEO: The positions of the Chairman and the CEO are separate of the company. All other requirements of the Board during the year have been complied with.

- Shareholders' rights: The quarterly results are uploaded on the website of the Company www.jeevanscientific.com. The soft copy of the quarterly results is also sent to the shareholders who have registered their e-mail addresses.
- Audit qualifications: Company's financial statements are unqualified.
- Reporting of Internal Auditor: The Internal Auditor of the Company directly reports to the Audit Committee on functional matters.
- Modified opinion in Audit Report: The audit report does not contain any qualification.

E. WEBLINK FOR POLICIES ADOPTED BY THE COMPANY :

Different policies adopted by the company are available for reference at http://www.jeevanscientific.com/policies_documents.html

ACCOUNTING STANDARDS AND TREATMENT:

The Accounting Treatment, as prescribed in the Accounting Standards has been followed in the preparation of financial statements.

Twenty First Annual Report 2018-2019

MEANS OF COMMUNICATION:

The Quarterly, Half-Yearly and Annual Accounts are normally published by the Company in the newspapers in English version circulating in the whole of India in Business Standard and in Newspapers in the language of Region in Andhra Prabha. Official news items are sent to the Bombay Stock Exchange, where shares of the Company are listed.

DISCLOSURE OF ACCOUNTING TREATMENT

The Company has complied with the appropriate accounting policies and has ensured that they have been applied consistently. There have been no deviations from the treatment prescribed in the Accounting Standards notified under Section 129 of the Companies Act, 2013.

SHARE HOLDERS INFORMATION:

Annual General Meeting:

Day, Date & Time : 28TH day, September, 2019 9.30 A.M
Venue : III Floor, R.R. Towers, C.A. Lane, Abids, Hyderabad 500001.

FINANCIAL CALENDAR:

Un-Audited results for Quarter ending Jun 30 2019 - on or before 14-Aug-2019

Un-Audited results for Quarter ending Sep 30 2019 - on or before 14-Nov-2019

Un-Audited results for Quarter ending Dec 31 2019 - on or before 14-Feb-2020

Audited results for Quarter & Year ending Mar 31 2020 - on or before 30-May-2020

Book closure Dates: 21-Sep-2019 to 28-Sep-2019 (Both days inclusive)

Listing of Equity Shares : Bombay Stock Exchange.

Code : 538837

ISIN : INE237B01018

Address : Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001

LISTING ON STOCK EXCHANGES:

The equity shares of the Company are listed on BSE Ltd. The Company has paid the listing fees for the year 2019-20 to BSE limited.

A) ELECTRONIC CONNECTIVITY:

Demat ISIN Number: INE237B01018

B) NATIONAL SECURITIES DEPOSITORY LIMITED

Trade World, Kamala Mills Compound

Senapati Bapat Marg, Lower Parel

Mumbai – 400 013.

C) CENTRAL DEPOSITORY SERVICES (INDIA) LIMITED

PhirozeJeejeebhoy Towers, 28th Floor

Dalal Street, Mumbai – 400 023.

Jeevan Scientific Technology Limited

REGISTRAR AND TRANSFER AGENTS:

Physical & Demat
CIL Securities Ltd
214, R.R. Towers, C.A. Lane
Abids, Hyderabad –500001.
Vide SEBI Regn. No. INR 000002276

LOCATION & ADDRESS FOR CORRESPONDENCE:

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad 500008 .

MARKET DATA:

Month	High	Low
April'18	45.45	38.50
May'18	45.95	33.10
June'18	39.00	31.40
July'18	35.60	28.15
Aug'18	35.80	25.00
Sept'18	36.25	27.55
Oct'18	36.60	24.30
Nov'18	43.75	24.15
Dec'18	39.65	31.30
Jan'19	39.70	28.05
Feb'19	36.90	25.55
Mar'19	36.60	26.00

Disclosure:

- a) Materially significant related party transactions of the Company of material nature with its promoters, the directors or the Management their subsidiaries or relatives if that may have potential conflict with the interests of the Company at large:

The transactions with the related parties were mentioned in Notes on Accounts as accounting standard 18 (note no. 24) in the schedules forming part of the balance sheet.

- b) Details of Non Compliance by the Company, penalties imposed on the Company by Stock Exchanges, SEBI or any other statutory authority on any matter related to capital markets during the last three years:

The Company has complied with all the requirements of regulatory authorities on capital markets and no penalties have been imposed against it.

Twenty First Annual Report 2018-2019

SHARE TRANSFER SYSTEM:

Securities lodged for transfer at the Registrar's address are normally processed within 15 days from the date of lodgment, if the documents are clear in all respects. All requests for dematerialization of shares are processed and the confirmation is given to the depositories within 15 days. Senior executives of the Company are empowered to approve transfer of shares. Grievances received from investors and other miscellaneous correspondence on change of address etc., are processed by the Registrars within 30 days. The Company extends the facility of simultaneous transfer and dematerialization of shares to the shareholders.

Pursuant to clause 47(c) of the listing agreement and Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the Stock Exchanges, certificates on half yearly basis have been issued by a Company secretary in practice for due compliance of share transfer formalities by the Company. Pursuant to SEBI (depositories and participants) regulations, 1966, certificates have also been received from a Company secretary in practice for timely dematerialization of the shares of the Company and for conducting a Secretarial Audit on a quarterly basis for reconciliation of the Share Capital of the Company.

DEMATERIALIZATION & LIQUIDITY:

The paid share capital of the Company consists of 1,53,01,465 equity shares of Rs. 10/- each and out of the same physical share holding consists of 5,56,233 (3.63%) equity shares , through National Securities Depository Limited (NSDL) 73,04,512 (47.74%) equity shares and through Central Depository Services (India) Limited (CDSL) 74,40,720 (48.63%) equity shares as on 31st March 2019.

DISTRIBUTION OF SHAREHOLDING-AS ON: 31-Mar-2019.

No. of Shares		No. of Share Holders	% of Total	No. of Shares	% of Total
(1)		(2)	(3)	(4)	(5)
Upto	- 500	1913	69.46	4,09,635	2.68
501	- 1,000	312	11.33	2,67,176	1.75
1,001	- 2,000	193	7.01	3,01,162	1.97
2,001	- 3,000	105	3.81	2,68,814	1.76
3,001	- 4,000	35	1.27	1,29,984	0.85
4,001	- 5,000	45	1.63	2,14,023	1.40
5,001	- 10,000	60	2.18	4,76,018	3.11
10,001 and above		91	3.31	1,32,34,653	86.48
TOTAL		2,754	100.00	1,53,01,465	100.00

Jeevan Scientific Technology Limited

SHAREHOLDING PATTERN AS ON 31ST MARCH,2019:

S. No	Category	No. of shares held	Percentage of shareholding
A Shareholding of Promoter and Promoter group			
1.	Indian Individual	58,25,891	38.07
2.	Foreign Individual	-	-
	Sub-Total A	58,25,891	38.07
B Public Shareholding			
1.	Institutions	-	-
2.	Non Institutions	94,75,574	61.93
	Sub Total B	94,75,574	61.93
	Grand Total (A+B)	1,53,01,465	100.00

Pursuant to first provision to sub-section (3) of section 129 of Companies Act, 2013, read with rule 5 of Companies (Accounts) Rules, 2014 - AOC-1, the Company is presenting summarised financial information about individual subsidiaries as at March 31, 2019.

Information relating to Subsidiaries as at March 31, 2019.

Sl. No.	Name of the Subsidiary	Reporting Currency	Exchange rate as on 31-Mar-2019	Share Capital	Reserves and Surpluses	Total Assets	Investments	% of holding	Sales and Other Income	Profit before taxation	Provision for Taxation	Profit after taxation	Proposed Dividend
1.	Enhops Solutions Private Limited	INR	—	1,00,00,000				99.99%					
2.	Enhops, Inc.(U.S.A)	INR	—	2,69,070				100%	—				

Notes: The following information shall be furnished at the end of the statement:

- Names of subsidiaries which are yet to commence operations- None
- Names of subsidiaries which have been liquidated or sold during the year- None

STATEMENT SHOWING THE NAMES OF TOP TEN EMPLOYEES PURSUANT TO SEC. 197 READ WITH RULE 5 (1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

Rule 5 (1) Of The Companies (Appointment And Remuneration Of Managerial Personnel) Rules, 2014

- 1 The ratio of remuneration to each director to the median remuneration of the employees of the company for the financial year.

Director	Total Remuneration	Ratio to median remuneration
K. Krishna Kishore	54,00,000	25:01
M. Rajendra Prasad	54,00,000	25:01

- 2 The percentage increase in remuneration of each director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year

Name	Designation	Remuneration		Increase/ (Decrease)%
		FY 2018-19	FY 2017-18	
K. Krishna Kishore	Vice Chairman & Managing Director	54,00,000	36,00,000	50.00%
M. Rajendra Prasad	Executive Director & CEO	54,00,000	30,99,996	74.19%
G. Krishna Sowjanya	Company Secretary	13,500	1,80,000	-
G. Ravi Kumar	Chief Executive Officer	7,88,710	-	-
T. Chandra Sekhar	Company Secretary	4,16,849	-	-

- 3 The percentage increase in the median remuneration of employees in the financial year

Particulars	Remuneration		Increase/ (Decrease)%
	FY 2018-19	FY 2017-18	
Median Remuneration of all the employees per annum*	2,16,000	2,65,259	(18.57%)

*Employees who have served for whole of the respective financial years have been considered.

Jeevan Scientific Technology Limited

4	Particulars	Number
	The number of employees on the rolls of the company as on March 31, 2019	213

- 5 Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and details if there are any exceptional circumstances for increase in the managerial remuneration**

Particulars		Increase/ (Decrease)%
Average percentage increase in the remuneration of all Employees* (Other than Key Managerial Personnel)		16.00%
Average Percentage increase in the Remuneration of Key Managerial Personnel		
K. Krishna Kishore	Vice Chairman & Managing Director	50.00%
M. Rajendra Prasad	Executive Director & CEO	74.19%

**Employees who have served for whole of the respective financial years have been considered.*

- 6 Affirmation that the remuneration is as per the remuneration policy of the company.**

The Company is in compliance with its remuneration policy.

AUDITOR'S CERTIFICATE ON CORPORATE GOVERNANCE

To
The Members of
Jeevan Scientific Technology Limited

We have examined the Compliance with conditions of Corporate Governance of M/s. Jeevan Scientific Technology Limited for the year ended 31st March, 2019 as stipulated in Regulation 34(3) read with Para E Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The Compliance with the conditions of Corporate Governance is the responsibility of the Management. Our examination has been limited to review the procedures and implementations thereof adopted by the Company for ensuring the compliance with the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statement of the Company.

In our opinion and to the best of our information and according to the explanations given to us and representations made by the Directors and the Management's, we certify that the company has complied with conditions of the Corporate Governance as stipulated in Regulation 34 (3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

As required by the guidance note issued by the institute of Chartered Accountants of India, we have to state that no grievances of investors are pending for a period exceeding one month against the Company as per the records maintained by the Company.

We further state that such compliance is neither an assurance as to future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the company.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad
Date : 30.05.2019

Jeevan Scientific Technology Limited

CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS

(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,
The Members of
Jeevan Scientific Technology Limited

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of M/s. Jeevan Scientific Technology Limited with CIN: L72200TG1999PLC031016. and having its registered office at Plot No. 1&2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad - 500008 (hereinafter referred to as 'the Company'), and produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C clause 10 (i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to me by the Company and its officers, I hereby certify as on date that, none of the Directors on the Board of the Company as stated below, have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs or any such other Statutory Authorities.

S. No	Name of the Director	DIN	Date of appointment in the Company
1	Mr. S. S. R. Koteswara Rao	00964290	10 th August 2015
2	Mr. K. Krishna Kishore	00876539	2 nd February 1999
3	Mr. M. Rajendra Prasad	06781058	1 st April 2014
4	Mrs. K. Vanaja	01030437	2 nd February 1999
5	Mr. T. Ravi Babu	01274099	28 th February 2000
6	Mr. G. Bhanu Prakash	00375298	31 st January 2009
7	Mr. K. Rama Krishna Prasad	00754823	12 th February 2016

Ensuring the eligibility for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. My responsibility is to express an opinion on the basis of my verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

Sd/-

D. Renuka

Practicing Company Secretary

Membership No. : 11963

C.P. No. : 3460

Place : Hyderabad

Date : 30.05.2019

Twenty First Annual Report 2018-2019

UN PAID / UN CLAIMED DIVIDEND:

DISCLOSURE WITH RESPECT TO DEMAT SUSPENSE ACCOUNT/ UNCLAIMED SUSPENSE ACCOUNT

As per Regulation 34(3) read with Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company hereby discloses the details of unpaid/unclaimed dividend and the respective share thereof as follows:

**

Aggregate No. of Shareholders and the outstanding shares in the suspense account at the beginning of the year	No. of shareholders who approached the company for transfer of shares from suspense account during the year	No. of shareholders to whom shares were transferred from suspense account during the year	Aggregate No. of Shareholders and the outstanding shares in the suspense account at the end of the year
NIL	NIL	NIL	NIL

**** Voting Right on these shares shall remain frozen till the rightful owner of such shares claims the shares.**

In terms of the provisions of the Companies Act, the Company is obliged to transfer dividends, which remain unpaid or unclaimed for a period of seven years from the declaration to the credit of the Investor education and Protection Fund established by the Central Government. The Company has not declared any dividend since its inception and hence the transfer of any unpaid /unclaimed dividend to the credit of the Investor education and Protection Fund does not arise.

Jeevan Scientific Technology Limited

Annexure II

MGT 9

Extract of Annual Return

As on the Financial Year 31-Mar-2019

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:	
i. CIN	L72200TG1999PLC031016
ii. Registration Date	02/02/1999
iii. Name of the Company	Jeevan Scientific Technology Limited
iv. Category / Sub-Category of the Company	Company limited by shares / Non-Government Company
v. Address of the Registered office and contact details	Plot No. 1&2, Sai Krupa Enclave, contact details Manikonda, Near Lanco Hills, Golconda Post, Hyderabad- 500008, Telangana, India. Phone No: +91-40-67364700 Fax No: +91-40-67364707
vi. Whether listed company Yes / No	Yes
vii. Name, Address and Contact details of Registrar and Transfer Agent, if any	M/s. CIL Securities Limited, 214, Raghava Ratna Towers, Chairag Ali Lane, Abids, Hyderabad- 500001 Ph: +91-40-23203155, Fax: +91-40-23203028

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

Sl. No.	Name and Description of main products /services	NIC Code of the Product / service	% to total turnover of the company
1	Research and experimental development services in medical sciences	99811301	96.50

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:-

Sl. No.	Name and Address of the Company	CIN/GIN	Holding/ Subsidiary/ Associate	%of Shares held	Applicable Section
1	Enhops Solutions Pvt. Ltd.	U72300TG2015PTC100314	Subsidiary	100%	2(87)(ii)
2	Enhops, Inc. (U.S.A)	n/a	Subsidiary	100%	2(87)(ii)

Twenty First Annual Report 2018-2019

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)

i) Category-wise Share Holding;-

Category of Share holders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
A. Promoters									
(1) Indian									
Individual/ HUF	33,04,691	—	33,04,691	28.84	44,97,691	—	44,97,691	29.39	0.55
Central Govt	—	—	—	—	—	—	—	—	—
State Govt (s)	—	—	—	—	—	—	—	—	—
Bodies Corp.	85,200	—	85,200	0.74	85,200	—	85,200	0.56	0.18
Banks / FI	—	—	—	—	—	—	—	—	—
Any Other....	9,43,000	—	9,43,000	8.23	12,43,000	—	12,43,000	8.12	0.11
Sub-total(A) (1) :-	43,32,891	—	43,32,891	37.81	58,25,891	—	58,25,891	38.07	0.26
(2) Foreign									
a) NRIs -Individuals	—	—	—	—	—	—	—	—	—
b) Other-Individuals	—	—	—	—	—	—	—	—	—
c) Bodies Corp.	—	—	—	—	—	—	—	—	—
d) Banks / FI	—	—	—	—	—	—	—	—	—
e) AnyOther....	—	—	—	—	—	—	—	—	—
Sub-total(A) (2):-	—	—	—	—	—	—	—	—	—
Totalshareholding of Promoter (A) = (A)(1)+(A)(2)	43,32,891	—	43,32,891	37.81	58,25,891	—	58,25,891	38.07	0.26
B. Public Shareholding									
1.Institutions									
a) Mutual Funds	—	—	—	—	—	—	—	—	—
b) Banks / FI	—	—	—	—	—	—	—	—	—
c) Central Govt	—	—	—	—	—	—	—	—	—
d) State Govt(s)	—	—	—	—	—	—	—	—	—
e) Venture Capital Funds	—	—	—	—	—	—	—	—	—
f) Insurance Companies	—	—	—	—	—	—	—	—	—
g) FIs	—	—	—	—	—	—	—	—	—
h) ForeignVenture Capital Fund	—	—	—	—	—	—	—	—	—
i) Others(specify)	—	—	—	—	—	—	—	—	—

Jeevan Scientific Technology Limited

Category of Share holders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
2. Non Institutions									
a) Bodies Corp.	1,33,102	—	1,33,102	1.16	1,33,922	—	1,33,922	0.88	0.28
i) Indian	1,33,102	—	1,33,102	1.16	1,33,922	—	1,33,922	0.88	0.28
ii) Overseas	—	—	—	—	—	—	—	—	—
b) Individuals	43,48,961	10,80,933	54,29,894	47.38	68,79,301	4,21,233	73,00,534	47.71	0.33
i) Individual share holders holding nominal share capital up to Rs. 2 lakh	18,58,910	4,32,933	22,91,843	20.00	28,75,565	4,21,233	32,96,798	21.54	1.54
ii) Individual shareholders holding nominal share capital in excess of Rs 2lakh	24,90,051	6,48,000	31,38,051	27.38	40,03,736	-	40,03,736	26.17	1.21
c) Others (specify)									
1. NRI	9,22,600	6,35,000	15,57,600	13.59	19,00,960	1,35,000	20,35,960	13.31	0.28
2. Clearing Members	5,978	—	5,978	0.05	5,158	—	5,158	0.03	0.02
Sub-total (B)(2):- Total Public Shareholding(B)= (B)(1)+(B)(2)	54,10,641	17,15,933	71,26,574	62.19	89,19,341	5,56,233	94,75,574	61.93	0.26
C. Shares held by Custodian for GDRs & ADRs	—	—	—	—	—	—	—	—	—
Grand Total (A+B+C)	97,43,532	17,15,933	1,14,59,465	100.00	1,47,45,232	5,56,233	1,53,01,465	100.00	—

Twenty First Annual Report 2018-2019

(ii) Shareholding of Promoters

Share Holder's Name	No. of Shares held at the beginning of the year			No. of Shares held at the end of the year			% Change during the year
	No. of Shares	% of Total Shares	% of Shares pledged/ encumbered to total Shares	No. of Shares	% of Total Shares	% of Shares pledged/ encumbered to total Shares	
1. K. Krishna Kishore(HUF)	2,00,000	1.75	—	2,00,000	1.31	—	0.44
2. T. ChalapathiRao	3,84,700	3.36	—	3,84,700	2.51	—	0.85
3. K. Vanaja	12,57,800	10.98	—	15,73,800	10.29	—	0.69
4. K. Gopi Krishna	2,70,000	2.36	—	7,20,000	4.71	—	2.35
5. Jeevan Krishna Kuchipudi	4,24,300	3.70	—	7,24,300	4.73	—	1.03
6. T. Sridevi	1,34,000	1.17	—	1,34,000	0.88	—	0.29
7. Jeevana Mitra Chit Fund Private Limited	85,200	0.74	—	85,200	0.56	—	0.18
8. T. Ravi	2,500	0.02	—	2,500	0.02	—	0.00
9. Krishna Kishore Kuchipudi	15,74,391	13.74	—	20,01,391	13.08	—	0.66

(iii) Change in Promoters' Shareholding (please specify, if there is no change):

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	K. Vanaja				
	At the beginning of the year	12,57,800	10.98	15,73,800	10.29
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 3,16,000 convertible warrants into 3,16,000 equity shares on 12.06.2018.			
	At the End of the year	15,73,800	10.29	15,73,800	10.29

Jeevan Scientific Technology Limited

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
2.	K. Gopi Krishna				
	At the beginning of the year	2,70,000	2.36	7,20,000	4.71
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 4,50,000 convertible warrants into 4,50,000 equity shares on 12.06.2018			
	At the End of the year	7,20,000	4.71	7,20,000	4.71

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
3.	Jeevan Krishna Kuchipudi				
	At the beginning of the year	4,24,300	3.70	7,24,300	4.73
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 3,00,000 convertible warrants into 3,00,000 equity shares on 12.06.2018			
	At the End of the year	7,24,300	4.73	7,24,300	4.73

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
4.	K. Krishna Kishore				
	At the beginning of the year	15,74,391	13.74	20,01,391	13.08
	Date wise Increase/ Decrease in Promoters Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer / bonus/sweat equity etc)	Conversion of 4,19,000 convertible warrants into 4,19,000 equity shares on 12.06.2018 and Purchas of 8,000 Equity Shares from open market			
	At the End of the year	20,01,391	13.08	20,01,391	13.08

Twenty First Annual Report 2018-2019

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	Durisala Desaiiah				
	At the beginning of the year	8,30,000	7.24	8,30,000	5.42
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2018-19			
	At the End of the year	8,30,000	5.42	8,30,000	5.42

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
2.	N. Gopala Krishna Reddy				
	At the beginning of the year	0	0	5,00,000	3.27
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 5,00,000 convertible warrants into 5,00,000 equity shares on 12.06.2018			
	At the End of the year	5,00,000	3.27	5,00,000	3.27

Jeevan Scientific Technology Limited

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
3.	Radhika Rampa				
	At the beginning of the year	5,00,000	4.36	5,00,000	3.27
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2018-19			
	At the End of the year	5,00,000	3.27	5,00,000	3.27

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
4.	N. Mani Kanta				
	At the beginning of the year	1,00,000	0.88	3,20,000	2.09
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 2,20,000 convertible warrants into 2,20,000 equity shares on 12.06.2018			
	At the End of the year	3,20,000	2.09	3,20,000	2.09

Twenty First Annual Report 2018-2019

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
5.	K. Rama Krishna Prasad				
	At the beginning of the year	3,00,000	2.62	3,00,000	1.96
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2018-19			
	At the End of the year	3,00,000	1.96	3,00,000	1.96

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
6.	Vidyullatha Kodali				
	At the beginning of the year	0	0	3,00,000	1.96
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 3,00,000 convertible warrants into 3,00,000 equity shares on 12.06.2018			
	At the End of the year	3,00,000	1.96	3,00,000	1.96

Jeevan Scientific Technology Limited

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
7.	Nutakki Sridevi				
	At the beginning of the year	2,30,000	2.01	2,30,000	1.50
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2018-19			
	At the End of the year	2,30,000	1.50	2,30,000	1.50

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
8.	T.Vimala				
	At the beginning of the year	27,500	0.24	2,27,500	1.49
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 2,00,000 convertible warrants into 2,00,000 equity shares on 12.06.2018			
	At the End of the year	2,27,500	1.49	2,27,500	1.49

Twenty First Annual Report 2018-2019

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
9.	Nara Kiran Kumar				
	At the beginning of the year	0	0	2,00,000	1.31
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 2,00,000 convertible warrants into 2,00,000 equity shares on 12.06.2018			
	At the End of the year	2,00,000	1.31	2,00,000	1.31

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
10.	Akhila Kakarala				
	At the beginning of the year	2,00,000	2.16	1,99,986	1.31
	Date wise Increase // Decrease in other than Directors, Promoters and Holders of GDRs and ADRs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	There was no change in the shareholding during the Financial Year 2018-19			
	At the End of the year	1,99,986	1.31	1,99,986	1.31

Jeevan Scientific Technology Limited

(v) Shareholding Pattern of Directors and Key Managerial Personnel

Sl. No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company	No. of shares	% of total shares of the company
1.	M. Rajendra Prasad				
	At the beginning of the year	3,34,250	2.92	8,96,250	5.86
	Date wise Increase / Decrease in Directors, and KMPs Share holding during the year specifying the reasons for increase/ decrease (e.g.allotment / transfer /bonus/sweat equity etc)	Conversion of 5,62,000 convertible warrants into 5,62,000 equity shares on 12.06.2018			
	At the End of the year	8,96,250	5.86	8,96,250	5.86

V. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL

A. Remuneration to Managing Director, Whole-time Directors and/or Manager:

Sl.No.	Particulars of Remuneration	Name of MD/WTD/ Manager:		Total Amount
1.	Gross salary (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961	Remuneration to managing Director Mr. K. Krishna Kishore Rs.54,00,000/- Per Annum.	Remuneration to Whole time Director(s): Mr. M. Rajender Prasad = Rs. 54,00,000/- Per Annum.	---
2.	Stock Option	—	—	—
3.	Sweat Equity	—	—	—
4.	Commission - as % of profit - Others, specify...	—	—	—
5.	Others, please specify	—	—	—
6.	Total (A)	54,00,000	54,00,000	1,08,00,000
7.	Ceiling as per the Act	—	—	—

Twenty First Annual Report 2018-2019

B. Remuneration to other directors:

Particulars of Remuneration	Name of Director			Amount
Independent Directors - Fee for attending board / committee meetings - Commission - Others, please specify	Mr. SSR Koteswara Rao	Mr. K. Rama Krishna Prasad	Mr. G. Bhanu Prakash	---
Total (1)	92,500	1,00,000	30,000	2,25,000
Other Directors - Fee for attending board / committee meetings - commission - Others, please specify	Ms. K. Vanaja	Mr. T. Ravi Babu		—
Total (2)	65,000	52,500		1,17,500
Total (B)=(1+2)	1,57,500	1,52,500	30,000	3,40,000
Total Managerial Remuneration				1,11,40,000
Overall Ceiling as per the Act				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD

Particulars of Remuneration	Key Managerial Personnel		Total
	Company Secretary	Chief Financial Officer	
1. Gross salary(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 (b) Value of perquisites u/s17(2) Income-tax Act, 1961 (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961	G. Krishna Sowjanya Rs.13,500 T. Chandra Sekhar Rs. 4,16,849	G. Ravi Kumar Rs.7,88,710	Rs.12,19,059
2. Stock Option	—	—	
3. Sweat Equity	—	—	
4. Commission- as % of profit- others, specify...	—	—	
5. Others, pleaseSpecify	—	—	
6. Total	Rs. 4.30,349/-	Rs. 7,88,710/-	Rs. 12,19,059

Jeevan Scientific Technology Limited

VI. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority[RD / NCLT/ COURT]	Appeal made, if any(give Details)
A. COMPANY					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—
B. DIRECTORS					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—
C. OTHER OFFICERS IN DEFAULT					
Penalty	—	—	—	—	—
Punishment	—	—	—	—	—
Compounding	—	—	—	—	—

Twenty First Annual Report 2018-2019

FORM MR-3 SECRETARIAL AUDIT REPORT

(Pursuant to section 204(1) of the Companies Act, 2013 and
Rule 9 of the Companies (Appointment and Remuneration Personnel) Rules, 2014

FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2019

To
The Members of
M/s. Jeevan Scientific Technology Limited

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Jeevan Scientific Technology Limited (hereinafter called "the Company"). Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's Books, Papers, Minute Books, Forms and Returns filed and other Records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the company has, during the financial year commencing from 1st April, 2018 and ended 31st March, 2019, complied with the statutory provisions listed hereunder and also that the Company has proper Board process and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. We have examined the books, papers, minute books, forms and returns filed and other records maintained by M/s. Jeevan Scientific Technology Limited ("The Company") for the financial year ended on 31st March, 2019, according to the provisions of:
 - i. The Companies Act, 2013 (the Act) and the rules made there under for specified sections notified and came in to effect from 12th September, 2013 and sections and Rules notified and came in to effect from 1st April, 2014;
 - ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made there under;
 - iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
 - iv. Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of Foreign Direct Investment (FDI) and Overseas Direct Investment and External Commercial Borrowings;
 - v. The Securities and Exchange Board of India Act, 1992 ('SEBI Act');
2. Provisions of the following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (SEBI Act) were not applicable to the Company under the financial year 2018-19.
 - i. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011; Complied with yearly and event-based disclosures.

Jeevan Scientific Technology Limited

- ii. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **During the year under review 38,42,000 warrants were converted to 38,42,000 equity shares of Rs. 10/- each.**
- iii. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **Not Applicable as the company has not delisted/ proposed to delist its equity shares during the year under review.**
- iv. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **Not Applicable as the Company has not bought back/ proposed to buy-back any of its securities during the year under review.**
- v. The Securities and Exchange Board of India (Registrars to an issue and Share Transfer Agents) Regulations, 1993, regarding the Companies Act and dealing with client; **Not Applicable as the Company is not registered as Registrar to an Issue and Share Transfer Agent during the year under review.**
- vi. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008. **Not Applicable as the Company has not issued any debt securities during the year under review.**
- vii. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **Not Applicable as the Company has not issued any Employee Stock Options during the year under review.**
- viii. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015; **The Company has framed code of conduct for regulating & reporting trading by insiders and for fair disclosure and displayed the same on the Company's website i.e. www.jeevanscientific.com.**
- ix. Other applicable laws include the following:
 - The Payment of Gratuity Act, 1972
 - Employees Provident Fund and Miscellaneous Provisions Act, 1952
 - Employees State Insurance Act, 1948
 - Income Tax Act, 1961
 - Indian Stamp Act, 1899
 - Minimum Wages Act, 1948
 - Payment of Bonus Act, 1965
 - Payment of Wages Act, 1936
 - Shops and Establishments Act, 1948

We have also examined compliance with the applicable clauses of the following:

- i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 were complied with to the extent applicable except delay in filing of the following disclosure :
 - Mrs. G Krishna Sowjanya resigned as Company Secretary of the company on 28.04.2018. Mr. T. Chandrasekhar was appointed as Company Secretary and Compliance Officer with effect from 12.11.2018. Further, the company has paid the penalty levied by BSE vide notice

Twenty First Annual Report 2018-2019

LIST/COMP/538837/Reg. 6(1)-Dec18/1113/2018-191 dated 12.02.2019 on 19.02.2019 for delay in appointment of company secretary.

ii.) Secretarial Standards issued by The Institute of Company Secretaries of India.

During the period under review the Company has complied with the provisions of the Companies Act, 2013, Rules, Regulations, Guidelines, Standards, etc. mentioned above including the following:

a) During the year the Company has conducted 6 meetings of the Board, 4 meetings of the Audit Committee, 7 meetings of the Stakeholder Relationship Committee, 3 meetings of the Nomination and Remuneration Committee and 1 meeting of the Independent Directors. We have also examined compliance with the applicable clauses of the Secretarial Standards issued by the Institute of Company secretaries of India.

b) During the year the company has conducted an Extra Ordinary General Meeting on 30.03.2019 for continuation of current term of Sri. S.S.R. Koteswara Rao , Independent Director of the company who attained the age of 75 years by passing a special resolution.

c) As per the information and explanations provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we report that

(i) The provisions of the Foreign Exchange Management Act, 1999 and the Rules and Regulations made there under to the extent of:

- External Commercial Borrowings were not attracted to the Company under the financial year under report;
- Foreign Direct Investment (FDI) was not attracted the company under the financial year under report;
- Overseas Direct Investment by Residents in Joint Venture/Wholly Owned Subsidiary abroad was not attracted to the company under the financial year under report.

(ii) As per the information and explanations provided by the company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we report that the Company has not made any GDRs/ADRs or any Commercial Instrument under the financial year under report.

We further report that:

i.) The Company has a Managing Director namely Mr. K. Krishna Kishore.

ii.) The Company has Chief Executive Officer namely Mr. M. Rajendra Prasad.

iii.) The Company has M/s. K.P. & Associates, Chartered Accountants as internal auditors.

iv.) The Company had also disclosed to the Stock Exchange in terms of following amendments and circulars issued by the SEBI during the financial year 2018-19:

- SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 – Fund raising by issuance of Debt Securities by Large Entities.
- SEBI circular — CIR/CFD/CMD1/27/2019 – Annual Secretarial Compliance report.
- Regulation 23(9) of SEBI (LODR) Regulations 2015 – Related Party Disclosure - *Delay in Intimation of Related Party Disclosure to BSE by twelve (12) days.*

Jeevan Scientific Technology Limited

- v.) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- vi.) Adequate notice of board meeting is given to all the directors along with agenda and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and meaningful participation at the meeting.
- vii) As per the minutes of the meeting duly recorded and signed by the Chairman, the decisions of the Board were unanimous and no dissenting views have been recorded.
- viii) We, further report that there are adequate systems and processes in the company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- ix) We further report that during the year under report, the Company has not undertaken event/action having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards etc.
- x) The compliance by the Company of applicable financial laws like Direct and Indirect tax laws has not been reviewed thoroughly in this audit since the same have been subject to review by statutory financial audit and other designated professionals.

**For S.S. Reddy & Associates
Practicing Company Secretaries**

Sd/-

**S. Sarveswar Reddy
Proprietor
C.P.No: 7478**

Place: Hyderabad

Date : 13.08.2019

To
The Members of
M/s. Jeevan Scientific Technology Limited

Our report of even date is to be read along with this letter.

1. Maintenance of secretarial record is the responsibility of the management of the company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have relied on the reports given by the concerned professionals in verifying the correctness and appropriateness of financial records and books of accounts of the company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The secretarial Audit report is neither an assurance as to future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

**For S.S. Reddy & Associates
Practicing Company Secretaries**

Sd/-

**S. Sarveswar Reddy
Proprietor
C.P.No: 7478**

**Place: Hyderabad
Date : 13.08.2019**

Jeevan Scientific Technology Limited

INDEPENDENT AUDITOR'S REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,

Report on the Standalone Audit of Financial Statements:

Opinion

We have audited the accompanying standalone financial statements of M/s. **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Company"), which comprise the Balance Sheet as on 31st March, 2019, and the Statement of Profit and Loss (including other Comprehensive Income), statement of changes in equity and statement of cash flows for the year ended 31st March, 2019 and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("IndAS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2019, and the loss and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as key audit matters to be communicated in our report.

Twenty First Annual Report 2018-2019

Sr No	Key Audit Matter	Auditor's Response
1	<p>Revenue Recognition</p> <p>Revenue is recognized to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at fair value consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognizes revenue when it satisfies its performance obligation by transferring the goods to the customers.</p> <p>Revenue is key driver of the business and judgment is involved in determining when contractual obligations have been performed and to the extent that the right to consideration has been earned.</p> <p>The management of the Company focuses on revenue as a key performance measure which could create an incentive for revenue to be recognized before the risks and rewards have been transferred. We therefore identified.</p> <p>Revenue Recognition as a significant risk and key audit matter.</p>	<p>Our audit work included, but was not restricted to:</p> <ul style="list-style-type: none"> • We understood business revenue recognition policy and how they are applied, including the relevant controls, and tested controls over revenue recognition; • Analytical review of the revenue recognized over the year- Agreeing on a sample basis amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of goods, where relevant. • We performed cut-off testing for a sample of revenue transactions around the period end date, to check that they were recognized in the appropriate period; • We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements. • The Company's accounting policy on Revenue recognition is shown in note 2.5 to the financial statements and related disclosures are included in notes. • Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognized for the year ended 31st March 2019 in the standalone financial statements.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Financial Performance Highlights, Directors' Report including Annexures to Directors' Report, but does not include the standalone financial statements and our auditor's report thereon.

The other information as stated above not made available to us as of the date of signing of this report is expected to be made available to us after the date of this statutory auditor's report.

Jeevan Scientific Technology Limited

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information when made available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

When we read the other information, if we conclude that there is material misstatement therein, we are required to communicate the matter to those charged with governance.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance, in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

Twenty First Annual Report 2018-2019

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3

Jeevan Scientific Technology Limited

and 4 of the Order, to the extent applicable.

2. As required by Section 143(3) of the Act, we report that:
- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
 - c) The Balance Sheet, the Statement of Profit and Loss (including other comprehensive income), Statement of changes in equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164(2) of the Act.
 - f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company has no pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - (iii) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad
Date : 30.05.2019

Twenty First Annual Report 2018-2019

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & Regulatory Requirement’ of our report of even date to the Standalone financial statements of the Company for the year ended March 31, 2019:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
(b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, a portion of the fixed asset has been physically verified by the management during the year and no material discrepancies between the books records and the physical fixed assets have been noticed.
(c) The title deeds of immovable properties are held in the name of the company.
- 2) (a) The management has conducted the physical verification of inventory at reasonable intervals.
(b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- 3) The Company has not granted any loans, secured or unsecured to companies, firms, Limited Liability partnerships or other parties covered in the Register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.
- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales tax, Service Tax, Duty of Customs, Duty of Excise, Value added Tax, Cess and any other statutory dues with the appropriate authorities though there has been slight delay in few cases.
(b) According to the information and explanations given to us, no undisputed amounts payable in respect of the above were in arrears as at March 31, 2019 for a period of more than six months from the date on when they become payable.

Jeevan Scientific Technology Limited

- 8) In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks.
- 9) Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised moneys by way of initial public offer or further public offer including debt instruments and term Loans. Accordingly, the provisions of clause 3 (ix) of the Order are not applicable to the Company and hence not commented upon.
- 10) Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the year.
- 11) Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;
- 12) In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii) of the Order are not applicable to the Company.
- 13) All transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 in so far as our examination of the proceedings of the meetings of the Audit Committee and Board of Directors are concerned. The details of related party transactions have been disclosed in the Standalone Ind AS Financial Statements as required by the applicable Accounting Standard.
- 14) The Company has made preferential allotment of shares during the year under review. The requirement specified under section 42 of the companies act 2013 has been complied.
- 15) Based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company and hence not commented upon.

In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad
Date : 30.05.2019

“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of

Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2019 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Jeevan Scientific Technology Limited

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of Standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the Standalone financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that

Twenty First Annual Report 2018-2019

the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad
Date : 30.05.2019

Jeevan Scientific Technology Limited

Stand Alone Balance Sheet as at 31st March, 2019

(In Rupees)

Particulars	Note No.	As at 31.03.2019	As at 31.03.2018
Assets			
(1) Non-current Assets			
a) Property, Plant and Equipment	2	195,677,264	179,976,619
b) Other Intangible Assets	2	7,319,381	6,749,558
c) Intangible Assets Process Knowhow	2	63,080,259	51,203,910
d) Financial Assets			
i) Investments	3	10,269,070	10,269,070
ii) Loans	4	47,627,198	35,226,109
iii) Advances	5	38,274,468	5,137,909
c) Deferred tax asset (net)	6	0	0
(2) Current Assets			
a) Inventories	7	2,304,039	989,587
b) Financial Assets			
i) Trade receivables	8	145,061,584	161,238,640
ii) Cash and cash equivalents	9	35,995,406	6,712,313
iii) Bank balances other than (ii) above	10	563,173	7,016,821
iv) Loans & Advances (current)	11	4,118,092	4,236,158
v) Other Financial Assets	12	11,003,442	2,702,750
c) Current Tax Assets (Net)	13	43,906,341	19,879,838
d) Other Current Assets	14	2,970,386	1,607,918
Total		<u>608,170,103</u>	<u>492,947,200</u>
Equity and Liabilities			
Equity			
a) Equity Share Capital	A	153,014,650	114,594,650
b) Other Equity	B	174,672,946	112,446,768
Liabilities			
(1) Non-current Liabilities			
a) Financial liabilities Borrowings	15	74,654,990	98,372,835
b) Provisions	16	1,809,705	968,587
c) Deferred tax Liability (net)	6	3,815,718	1,158,997
(2) Current Liabilities			
a) Financial Liabilities			
i) Borrowings	17	72,576,400	70,414,014
ii) Trade Payables	18	24,366,173	20,562,838
iii) Other Financial liabilities	19	39,828,508	25,839,766
iv) Other Financial Creditors	20	19,394,295	25,545,192
b) Other current liabilities	21	39,106,747	22,818,054
c) Provisions	22	4,929,971	225,498
Total		<u>608,170,103</u>	<u>492,947,200</u>
Summary of significant accounting policies and notes	1		

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:223169
Place : Hyderabad
Date : 30.05.2019

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Twenty First Annual Report 2018-2019

Stand Alone Statement of Profit and Loss for the Period ended 31st March, 2019

(In Rupees)

Particulars	Note No.	For the Year 2018-2019	For the Year 2017-2018
Continuing Operations			
Income			
I. Revenue from operations	23	254,316,324	192,643,389
II. Other Income	24	9,696,829	9,047,831
III. Total revenue(I+II)		<u>264,013,153</u>	<u>201,691,220</u>
IV. Expenses			
Cost of Material consumed	25	16,417,939	12,987,432
Employee benefits expenses	26	79,160,557	49,851,992
Finance costs	27	17,569,435	16,631,043
Depreciation	2	22,850,756	16,588,890
Amortisation on Process Knowhow	2	7,894,676	4,058,837
Other expenses	28	103,922,092	96,723,499
Total expenses		<u>247,815,455</u>	<u>196,841,693</u>
V. Profit/ (Loss) before tax (III)-(IV)		<u>16,197,698</u>	<u>4,849,527</u>
Tax expenses			
Current Tax		3,334,588	924,077
Less: Mat Credit (Entitlement) / utilization		(3,388,452)	(985,600)
Deferred Tax		2,656,721	2,440,861
Total tax expenses		<u>2,602,857</u>	<u>2,379,338</u>
Profit / (Loss) for the period from continuing operations		<u>13,594,841</u>	<u>2,470,189</u>
Profit / (Loss) from discontinuing operations		-	-
Tax expense from discontinuing operations		-	-
Profit / (Loss) from discontinuing operations (After tax)		-	-
Profit / (loss) for the Period		<u>13,594,841</u>	<u>2,470,189</u>
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss (Re-measurements of post-employment benefit obligations)		193,616	645,160
(ii) Income tax relating to items that will not be reclassified to profit and loss		53,864	61,523
B (i) Items that will be reclassified to profit and loss		-	-
(ii) Income tax relating to items that will be reclassified to profit and loss		-	-
Total Comprehensive Income		<u>13,734,593</u>	<u>3,053,826</u>
Earning per equity share			
(Face value of Rs.10/- each)			
Basic		0.90	0.27
Diluted		0.94	0.32

Per our report of even Date

for PAVULURI & Co.

Chartered Accountants

Firm Regn No: 012194S

Sd/-

CA N. Rajesh

Partner

Membership No:223169

Place : Hyderabad

Date : 30.05.2019

for and on behalf of the Board of Directors

Jeevan Scientific Technology Limited

Sd/-

K.Krishna Kishore

Vice Chairman & Managing Director

DIN: 00876539

Sd/-

M. Rajendra Prasad

Executive Director & CEO

DIN: 06781058

Sd/-

T. Chandra Sekhar

Company Secretary

M.No. 48005

Jeevan Scientific Technology Limited

Stand Alone Cash Flow statement for the year ended 31st March, 2019

(In Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
A. Cash flow from operating activities		
Net Profit before tax and extraordinary items	16,197,698	4,849,527
Adjustments for:		
Depreciation	33,895,133	24,711,388
Loss on Sale of Assets	0	3,995
Interest	17,114,413	15,274,436
Operating profit before working capital changes	67,207,244	44,839,346
Adjustments for:		
Inventories	-1,314,453	3,752,091
Trade and other receivables	-62,932,188	-76,752,171
Trade and other Paybles	-38,294,572	-80,771,063
Cash generated from operations	41,255,175	52,610,328
Taxes Provision	0	0
Interest paid	17,114,413	15,274,436
Net cash from operating activity	24,140,762	37,335,892
B. Cash flow from investing activities		
Purchase of fixed assets	62,041,952	124,353,827
Investments	0	0
Sale/ Transfer of fixed assets	0	9,000
Net cash used in investing activity	-62,041,952	-124,344,827
C. Cash flow from financing activity		
Proceeds from loans	-23,717,845	50,897,670
Increase in Capital	38,420,000	21,800,000
Increase in Other Equity	46,028,480	26,071,503
Net cash generated in financing activity	60,730,635	98,769,173
Net increase in cash and cash equivalents (A+B+C)	22,829,445	11,760,239
Cash and cash equivalents as at 31.03.2018	13,729,134	1,968,895
Cash and cash equivalents as at 31.03.2019	36,558,579	13,729,134

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:223169
Place : Hyderabad
Date : 30.05.2019

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research services.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The standalone financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

b) Basis of measurement

The standalone financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The standalone financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the entity operates. All financial information presented in Indian rupees.

d) Use of estimates and judgment

The preparation of standalone financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the "functional currency"). The standalone financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

Jeevan Scientific Technology Limited

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) Non-derivative financial assets

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are

Twenty First Annual Report 2018-2019

measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) Non-derivative financial liabilities

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. Property plant and equipment:

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the standalone financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

Jeevan Scientific Technology Limited

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA / BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Investment in development method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalised as intangible asset. Each method will be of useful for a minimum period of 10-12 years. It is also decided by the Board that the amortisation of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

- a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.
- b) The basis of determining the cost is

Twenty First Annual Report 2018-2019

Raw materials	:	Weighted average cost
Stores and Consumables	:	Weighted average cost
Work in process and finished goods	:	valued at lower of cost and net realizable value

- c) In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

- i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12 month ECL.

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognised during the period is

Jeevan Scientific Technology Limited

recognised as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

b) The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.

c) Accrued Leave Salary:

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. Provisions

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. Revenue recognition:

Ind AS 115 recognises revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

The said revision has nil impact on the financials of the company as the company was recognising and accounting revenue in line with the Ind AS 115.

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in

Jeevan Scientific Technology Limited

equity or in other comprehensive income.

a) **Current income tax**

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) **MAT credit**

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) **Deferred income tax**

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax asset are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. **Foreign currency transaction**

i. **Initial recognition**

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

Twenty First Annual Report 2018-2019

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

iv. Foreign currency Transactions. (in lakhs)

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	711.16	497.08
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Ind AS issued and not yet effective:

Ind AS 116 Leases :

Ministry of Corporate Affairs has notified 'The Companies (Indian Accounting Standards) Amendment Rules, 2019 dated March 30, 2019 which inter alia includes the new standard on Leases Ind AS 116 replacing the existing standard Ind AS 17, to be effective from the 1st April 2019. The impact of the same is yet to be assessed. The Company is proposing to use the Modified Retrospective Approach for transitioning to Ind AS 116.

Jeevan Scientific Technology Limited

xviii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

Twenty First Annual Report 2018-2019

10. Property, Plant and Equipment
I. Tangible Assets

(in Rupees)

S. No.	Description	GROSS BLOCK				DEPRECIATION				NET BLOCK							
		As at 01.04.2017	Additions	Deletions	As at 31.03.2018	As at 31.03.2017	Additions	Deletions	As at 31.03.2018	As at 31.03.2017	Additions	Deletions	As at 31.03.2019	As at 31.03.2018	As at 31.03.2017		
1	LEASE HOLD BUILDINGS	8,165,864	0	0	8,165,864	0	0	8,165,864	0	0	0	8,165,864	0	0	806,948		
2	PLANT & MACHINERY	8,165,864	0	0	8,165,864	0	0	8,165,864	0	0	0	8,165,864	0	0	806,948		
	a. Electrical Installations	17,868,587	121,757	0	18,145,878	2,643,877	0	1,619,085	4,262,962	0	1,626,059	5,889,021	12,256,857	13,727,382	15,224,710		
	b. Airconditioners	1,194,942	0	0	1,194,942	867,082	0	56,760	923,842	0	56,760	890,602	214,340	271,100	327,860		
	c. U.P.S. Systems	1,048,582	0	0	1,048,582	832,610	0	49,808	882,418	0	49,808	932,226	116,356	166,164	215,972		
	d. Inverter	275,203	0	0	275,203	175,626	0	13,072	188,698	0	13,072	201,770	73,433	86,505	99,577		
		20,387,314	121,757	0	20,664,605	4,519,195	0	1,738,725	6,257,920	0	1,745,699	8,003,619	12,660,986	14,251,151	15,868,119		
3	COMPUTERS	16,042,822	2,075,779	0	18,118,601	1,793,699	0	2,280,334	11,674,617	0	2,587,175	14,261,792	5,650,508	6,443,984	6,648,539		
	a. Computers	16,042,822	2,075,779	0	18,118,601	1,793,699	0	2,280,334	11,674,617	0	2,587,175	14,261,792	5,650,508	6,443,984	6,648,539		
4	VEHICLES	6,571,475	4,202,964	0	10,774,439	5,574,019	0	843,903	3,223,983	0	1,390,651	4,614,634	11,733,824	7,550,456	4,191,395		
	a. Motor Car	131,086	0	49,170	81,916	143,994	0	225,910	105,638	36,175	12,453	81,916	135,468	0	25,448		
	b. Scooter	6,702,561	4,202,964	49,170	10,856,355	5,718,013	0	16,574,568	2,485,718	36,175	856,356	3,305,899	11,869,292	7,550,456	4,276,843		
5	FURNITURE & FIXTURES	28,547,276	1,037,682	0	29,584,958	72,376	0	29,657,334	7,499,042	0	2,576,984	10,076,026	12,496,632	17,160,702	19,508,932	21,048,234	
	a. Furniture	988,151	0	0	988,151	0	0	988,151	0	0	988,151	0	0	0	0		
	b. Fixtures	29,535,427	1,037,682	0	30,573,109	72,376	0	30,645,485	8,487,193	0	2,576,984	11,064,177	2,420,606	17,160,702	19,508,932	21,048,234	
6	OFFICE & LABORATORY EQUIPMENT	1,315,859	366,360	0	1,682,219	380,470	0	2,062,689	418,483	0	206,112	624,595	862,045	1,200,644	897,376		
	a. Office Equipments	63,413,019	85,879,213	0	149,292,232	31,494,979	0	180,787,211	7,843,319	0	10,431,520	18,274,839	15,498,088	33,772,927	147,014,284	131,017,393	55,569,700
	b. Laboratory Equipments	460,323	0	0	460,323	296,659	0	21,865	318,524	0	21,865	340,389	119,934	141,799	163,664		
	c. E.P.A.B.X & Telephones	15,100	0	0	15,100	12,752	0	717	13,469	0	717	14,186	914	1,631	2,348		
	d. Fax Machine	366,841	0	0	366,841	366,841	0	366,841	366,841	0	366,841	366,841	366,841	366,841	366,841		
	e. Projector with LCD Panel	65,571,142	86,245,573	0	151,816,715	31,875,449	0	183,692,164	8,938,054	0	10,660,214	19,598,268	15,758,120	35,356,388	148,335,776	132,218,447	56,633,088
7	LIBRARY:	89,983	0	0	89,983	82,060	0	4,274	86,334	0	3,649	89,983	0	3,649	7,923		
	a. Books	89,983	0	0	89,983	82,060	0	4,274	86,334	0	3,649	89,983	0	3,649	7,923		
	Total:	146,495,113	93,683,755	49,170,240	129,698,391	39,615,071	0	279,744,769	60,153,079	36,175	18,923,835	84,067,505	195,677,264	179,976,619	105,229,694		

II. Intangible Assets

		GROSS BLOCK						DEPRECIATION						NET BLOCK							
		As at 01.04.2017		As at 31.03.2018		As at 31.03.2019		Up to 01.04.2017		For the year 31.03.2018		Up to 31.03.2018		Deletions For the year 31.03.2019		Up to 31.03.2019		As at 31.03.2018		As at 31.03.2017	
S. No.	Description	Additions	Deletions	As at 31.03.2018	Additions	Deletions	As at 31.03.2019	Up to 01.04.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	Deletions 31.03.2019	For the year 31.03.2019	Up to 31.03.2019	As at 31.03.2019	As at 31.03.2018	As at 31.03.2017				
1	COMPUTERS Software	3,819,184	0	10,724,848	2,655,856		13,380,704	2,278,024	0	1,697,266	3,975,290	0	2,086,033	6,061,323	7,319,381	6,749,558	4,627,640				
2	COPYRIGHTS	0	0	1,204,000	0		1,204,000	1,172,550	0	31,450	1,204,000	0	0	1,204,000	0	0	31,450				
	Total:	3,819,184	0	11,928,848	2,655,856	0	14,584,704	3,450,574	0	1,728,716	5,179,290	0	2,086,033	7,265,323	7,319,381	6,749,558	4,659,090				

III. Intangible Assets Process Knowhow

		GROSS BLOCK						DEPRECIATION						NET BLOCK							
		As at 01.04.2017		As at 31.03.2018		As at 31.03.2019		Up to 01.04.2017		For the year 31.03.2018		Up to 31.03.2018		Deletions For the year 31.03.2019		Up to 31.03.2019		As at 31.03.2018		As at 31.03.2017	
S. No.	Description	Additions	Deletions	As at 31.03.2018	Additions	Deletions	As at 31.03.2019	Up to 01.04.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	Deletions 31.03.2019	For the year 31.03.2019	Up to 31.03.2019	As at 31.03.2019	As at 31.03.2018	As at 31.03.2017				
1	Process Knowhow	26,850,888	0	55,262,747	19,771,025		75,033,772	0	0	4,058,837	4,058,837	0	7,894,676	11,953,513	63,080,259	51,203,910	28,411,859				
	Total:	26,850,888	0	55,262,747	19,771,025	0	75,033,772	0	0	4,058,837	4,058,837	0	7,894,676	11,953,513	63,080,259	51,203,910	28,411,859				

Notes: An amount of Rs. 31,49,703/- has been transferred from depreciation to Process Knowhow since the assets are used to create process knowhow

Twenty First Annual Report 2018-2019

Notes to financial statements for the year ended 31st March, 2019

3. Non Current Investments

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Enhops Solutions Inc.	269,070	269,070
Enhops Solutions Pvt Ltd	10,000,000	10,000,000
Total	10,269,070	10,269,070

4. Long Term Loans

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
i) Loans to Subsidiaries	47,627,198	35,226,109
Total	47,627,198	35,226,109

5. Advances

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
i) Capital Advances	32,500,000	-
ii) Security Deposit	5,670,869	5,034,310
iii) Other Advances	103,599	103,599
Total	38,274,468	5,137,909

6. Deferred Tax (Net)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Deferred Tax Asset / (Liability) Opening	-1,158,997	1,281,864
Add/Less: Deferred Tax liability	-2,656,721	-2,440,861
Total	-3,815,718	-1,158,997

7. Inventories

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Work in progress point of sale boxes	210,240	210,240
Consumables - R & D	2,093,799	779,346
Total	2,304,039	989,586

Jeevan Scientific Technology Limited

8. Trade receivables (Unsecured)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Debtors outstanding for more than Six months Considered good	76,707,791	79,539,482
Doubtful debts	889,815	1,164,207
Other debts for less than six months Considered good	68,353,793	81,699,158
	145,951,399	162,402,847
Less: Bad Debts Written off	889,815	1,164,207
Total	145,061,584	161,238,640

9. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Cash and cash equivalents Balances with Banks in current accounts	90,372	337,273
cash on hand	35,905,034	6,375,040
Total	35,995,406	6,712,313

10. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Bank balances other than in fixed deposits more than 12 months	563,173	524,806
in fixed deposits Less than 12 months	0	6,492,015
Total	563,173	7,016,821

11. Loans and Advances (Current)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Advances Given	4,118,092	4,236,158
Total	4,118,092	4,236,158

Twenty First Annual Report 2018-2019

12. Other Financial Assets

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Interest Receivable	8,411,442	2,702,750
Rent Receivable	2,592,000	-
Total	11,003,442	2,702,750

13. Current Tax Assets (Net)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Tax deducted at source	33,642,777	12,950,862
MAT Credit	10,263,564	6,928,976
Total	43,906,341	19,879,838

14. Other Current Assets

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Prepaid Expenses	2,502,863	1,373,014
Hero Finance corporation	467,523	234,904
Total	2,970,386	1,607,918

Jeevan Scientific Technology Limited

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited

Statement of changes in Equity for the Period ended 31st March 2019

(in Rupees)

A. Equity Share Capital	As at 31.03.2019	As at 31.03.2018
Authorised 2,10,00,000 equity Shares of Rs.10/- each	210,000,000	210,000,000
Issued, subscribed and paid- up 1,53,01,465 (31st March 2019:1,53,01,465) equity Shares of Rs. 10/- each fully paid-up	153,014,650	114,594,650

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Issued, subscribed and paid- up		
Opening Balance	114,594,650	92,794,650
Add : issue of shares during the year	38,420,000	21,800,000
Total	153,014,650	114,594,650

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share Holder	As at 31.03.2019		As at 31.03.2018	
	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding
Sri K. Krishna Kishore	2,201,391	14.39%	1,774,391	15.48%
Smt. K. Vanaja	1,573,800	10.29%	1,257,800	10.98%
Dr. Desaiiah Durisala	830,000	5.42%	830,000	7.24%
Sri M. Rajendra Prasad	896,250	5.86%	-	-

Twenty First Annual Report 2018-2019

B. Other Equity

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus			Debt Instruments through other comprehensive income	Equity Instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves								
Balance at the beginning of the reporting period i.e. 1st April 2017	-	-	-	65,566,766	-	(31,645,530)	-	-	-	-	-	47,604,502	81,525,738
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	65,566,766	-	(31,645,530)	-	-	-	-	-	47,604,502	81,525,738
Total comprehensive Income for the year	-	-	-	-	-	3,053,826	-	-	-	-	-	-	3,053,826
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued during the Year	-	-	-	44,145,000	-	-	-	-	-	-	-	(16,277,796)	27,867,204
Balance at the end of the reporting period i.e. 31st March, 2018	-	-	-	109,711,766	-	(28,591,704)	-	-	-	-	-	31,326,706	112,446,768

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt Instruments through other comprehensive income	Equity Instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Shares forfeited reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e. 1st April 2018	-	-	-	109,711,766	-	(28,591,704)	-	-	-	-	-	-	31,326,706	112,446,768
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the reporting period	-	-	-	109,711,766	-	(28,591,704)	-	-	-	-	-	-	31,326,706	112,446,768
Total comprehensive Income for the year	-	-	-	-	-	13,734,593	-	-	-	-	-	-	-	13,734,593
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issued during the Year	-	-	-	77,800,500	2,016,541	-	-	-	-	-	-	-	(31,326,456)	48,491,585
Balance at the end of the reporting period i.e. 31st March, 2019	-	-	-	187,512,266	2,016,541	(14,857,111)	-	-	-	-	-	1,250	174,672,946	

Jeevan Scientific Technology Limited

15. Long Term Borrowings

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2018
Term Loan- secured				
A) From Banks				
i) Car Loans- Hypothecation against the Cars	3,909,516	2,748,553	3,394,554	1,497,467
ii) Machinery loans	70,245,474	71,699,117	30,860,016	17,568,540
B) Intercorporate Loans	-	9,000,000	-	-
C) Loans and advances from related parties	500,000	14,925,165	-	-
Total	74,654,990	98,372,835	34,254,570	19,066,007

16. Long Term Provisions

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Gratuity Payable	1,809,705	968,587
Total	1,809,705	968,587

17. Short Term Borrowings

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Loan repayable on Demand		
i) Loan From Banks (Guaranteed by Director)	72,576,400	70,414,014
Total	72,576,400	70,414,014

18. Trade Payables

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Trade payables (for services received)	24,366,173	20,562,838
Total	24,366,173	20,562,838

Twenty First Annual Report 2018-2019

19. Other Financial Liabilities

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Current maturities of Long term borrowings	34,254,570	19,066,007
Interest Payable	3,427,880	2,605,961
Rent Payable	2,146,058	4,167,798
Total	39,828,508	25,839,766

20. Other Financial Creditors

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Creditors for Capital Assets	19,394,295	25,545,192
Total	19,394,295	25,545,192

21. Other Current Liabilities

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
TDS Payable	2,228,215	3,780,619
Professional tax payable	20,450	16,550
GST Payable	24,923,072	8,875,848
Provident Fund payable	375,372	261,746
ESI payable	107,440	87,025
Salaries payable	5,091,552	4,051,351
Directors Remuneration Payable	668,235	643,402
Provision for expenses	265,831	1,340,872
Advance received from Customers	5,373,227	3,731,250
Other Payables	53,353	29,391
Total	39,106,747	22,818,054

Jeevan Scientific Technology Limited

22. Short Term Provisions

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Leave Encashment Payable	98,260	93,318
Bonus Payable	1,466,951	116,975
Gratuity Payable	30,172	15,205
Provision for tax	3,334,588	-
Total	4,929,971	225,498

23. Revenue from Operations

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Clinical Research Services- Domestic	183,200,242	123,017,832
Clinical Research Services- Export	71,116,082	49,707,896
Data Management service charges	-	19,917,661
Total	254,316,324	192,643,389

24. Other Non Operating Income

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Interest on Income Tax Refund	109,317	166,222
Interest Received from Others	6,342,991	5,010,019
Interest Received from Banks	158,452	63,188
Miscellaneous Income	686,069	208,402
Rent Received	2,400,000	3,600,000
Total	9,696,829	9,047,831

Twenty First Annual Report 2018-2019

25. Cost of Material Consumed

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Hardware		
Opening Stock	210,240	210,240
Purchases: Components & Software	-	-
	210,240	210,240
Less: Closing Stock	210,240	210,240
Total (A)	-	-
Consumables - R & D		
Opening Stock	779,346	4,531,437
Purchases: Consumables	20,885,167	13,473,286
	21,664,513	18,004,723
Less: Closing Stock	2,093,799	779,346
Less: Transfer to Process Knowhow	3,152,775	4,237,945
Total (B)	16,417,939	12,987,432
Total (A+B)	16,417,939	12,987,432

26. Employees Benefit Expenses

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Salaries & Allowances	62,154,889	39,358,312
Contribution to Provident Fund & Others	2,868,265	1,785,231
Staff Welfare Expenses	2,451,766	1,889,413
Gratuity	716,382	559,746
Bonus	1,151,965	116,975
Leave encashment	259,290	93,318
Director's Remuneration	9,558,000	6,048,997
Total	79,160,557	49,851,992

27. Fiance Cost

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Bank charges	200,142	151,677
Loan Processing Charges	254,880	1,120,090
FLC Charges	-	84,840
Interest expense		
on Vehicle Loans	442,238	166,041
on Bank Overdraft	5,749,177	3,588,051
on Term loan from Bank	10,071,815	7,312,323
on Customduty	-	40,124
on Others	100,873	-
on Unsecured Loans	750,310	4,167,897
Total	17,569,435	16,631,043

Jeevan Scientific Technology Limited

28. Other Expenses

(in Rupees)

Particulars	For the Year 2018-2019	For the Year 2017-2018
Rent	10,536,487	8,961,140
Electricity	6,927,335	4,691,596
Repairs & Maintenance	2,902,776	2,031,716
Insurance	1,577,290	950,218
Licenses & Renewals	1,352,452	1,559,354
Communication Charges	1,167,943	2,144,274
Travelling, Conveyance	2,533,458	1,383,867
Printing & Stationery	2,335,124	1,447,775
Advertisement, Publicity & Business Promotion	915,695	722,611
Professional Charges	4,864,754	11,861,294
Technical Services	5,570,786	-
Audit Fee: As Auditors	60,000	70,000
: For Certification	40,000	68,607
General Expenses	2,227,692	2,611,331
Office Maintenance	2,951,845	5,450,111
Director's Sitting fees	340,000	337,000
Registrar's fee	144,091	169,992
Web Designing Charges	63,192	8,626
Garden Maintenance	76,360	73,385
Conference Fee	-	17,250
BSE Listing Fee	250,000	287,500
ROC Filing Fee	22,100	37,200
Interest on delay Payments for Statutory dues	3,328,861	89,317
Service Tax Paid	-	144,794
Volunteer Expenses	15,865,232	9,824,582
Volunteer Study Payments	36,248,167	21,762,754
Bad Debts Written off	889,815	1,164,207
Deposits Written Off	-	8,400
VAT Input Credit Written Off	-	49,637
Foreign Exchange Variance Loss	610,193	177,474
Water Bill Paid	120,444	152,192
Loss on Sale of Assets	-	3,995
Data Management Service Charges	-	18,461,300
Total	103,922,092	96,723,499

Twenty First Annual Report 2018-2019

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2019.

Accounting Disclosures Statement	GRATUITY	
Period of accounting	1-Apr-18 to 31-Mar-19	
	<i>(all figures in Indian Rupees)</i>	
Valuation Results as at	31-Mar-18	31-Mar-19
I Changes in present value of obligations		
PVO at beginning of period	746,915	983,792
Interest cost	49,969	75,208
Current Service Cost	509,777	641,174
Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	-	(24,231)
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	(322,869)	163,934
PVO at end of period	983,792	1,839,877
II Interest Expenses		
Interest cost	49,969	75,208
III Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-
IV Net Liability		
PVO at beginning of period	746,915	983,792
Fair Value of the Assets at beginning report	-	-
Net Liability	746,915	983,792
V Net Interest		
Interest Expenses	49,969	75,208
Interest Income	-	-
Net Interest	49,969	75,208

Jeevan Scientific Technology Limited

VI	Actual return on plan assets	-	-
	Less Interest income included above	-	-
	Return on plan assets excluding interest income	-	-
VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	(144,417)	18,382
	Due to Experience	(178,452)	145,552
	Total Actuarial (Gain)/Loss	(322,869)	163,934
	*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience		
VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	-	24,231
	Contributions by Employee	-	-
	Benefits Paid	-	(24,231)
	Fair Value of Plan Assets at end	-	-
IX	Past Service Cost Recognised		
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Average remaining future service till vesting of the benefit	-	-
	Recognised Past service Cost- non vested benefits	-	-
	Recognised Past service Cost- vested benefits	-	-
	Unrecognised Past Service Cost- non vested benefits	-	-
X	Amounts to be recognized in the balance sheet and statement of profit & loss account		
	PVO at end of period	983,792	1,839,877
	Fair Value of Plan Assets at end of period	-	-
	Funded Status	(983,792)	(1,839,877)
	Net Asset/(Liability) recognized in the balance sheet	(983,792)	(1,839,877)

Twenty First Annual Report 2018-2019

XI Expense recognized in the statement of P & L A/C		
Current Service Cost	509,777	641,174
Net Interest	49,969	75,208
Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Curtailment Effect	-	-
Settlement Effect	-	-
Unrecognized Past Service Cost- non vested benefits	-	-
Expense recognized in the statement of P & L A/C	559,746	716,382
XII Other Comprehensive Income (OCI)		
Actuarial (Gain)/Loss recognized for the period	(322,869)	163,934
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-
Total Actuarial (Gain)/Loss recognized in (OCI)	(322,869)	163,934
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	746,915	983,792
Adjustment to opening balance	-	-
Expenses as above	559,746	716,382
Contribution paid	-	(24,231)
Other Comprehensive Income(OCI)	(322,869)	163,934
Closing Net Liability	983,792	1,839,877
XIV Schedule III of The Companies Act 2013		
Current Liability	15,205	30,172
Non-Current Liability	968,587	1,809,705
XV Projected Service Cost 31 Mar 2020		
Unrecognised Past Service Cost- non vested benefits		912,281
Average remaining future service till vesting of the benefit		
XVI Asset Information		
	Total Amount	Target Allocation
		%
Cash and Cash Equivalents		
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		

Jeevan Scientific Technology Limited

Property		
Total Itemized Assets	-	0%

	Annexure 'A'	
XVII Assumptions as at	31-Mar-18	31-Mar-19
Mortality	IALM (2006-08) Ult.	IALM (2006-08) Ult.
Interest / Discount Rate	7.74%	7.66%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs	-	-
Future Changes in maximum state healthcare benefits	-	-
Expected average remaining service	16.77	16.94
Employee Attrition Rate(<i>Past Service (PS)</i>)	PS: 0 to 40 : 3%	PS: 0 to 40 : 3%

Note-30: Segment Reporting as per Ind-AS-108

A. Basis for segmentation

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company has two reportable segments, (Previous Year three reportable segments) as described below, which are the company's strategic business units. These business units offer different services, and are managed separately because they require different technology and marketing strategies. For each of the business units, the company's Board reviews internal management reports on a periodic basis.

The following summary describes the operations in each of the Company's reportable segments:

B. Information about reportable segments

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit (before tax), segment revenue and segment capital employed as included in the internal management reports that are reviewed by the board of directors. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

Twenty First Annual Report 2018-2019

Reportable Segments

Segment Reporting as on 31-03-2019

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	2640.13	-	-	-	2640.13
Segment Result	161.98	-	-	-	161.98
Assets	6081.70	-	-	-	6081.70
Liabilities	6081.70	-	-	-	6081.70
Depreciation and Amortization	307.45	-	-	-	307.45
Capital Expenditure during the year	620.42	-	-	-	620.42

Segment Reporting as on 31-03-2018

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	1727.25	199.18	-	90.48	2016.91
Segment Result	104.93	5.66	-	(62.10)	48.49
Assets	4105.22	555.87	-	268.38	4929.47
Liabilities	2588.95	-	-	2340.52	4929.47
Depreciation and Amortization	182.05	-	-	24.42	206.47
Capital Expenditure during the year	1243.54	-	-	-	1243.54

Jeevan Scientific Technology Limited

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Non-Executive Director
G Bhanu Prakash	Independent Director
K R K Prasad	Independent Director
Chandra Sekhar Tumula	Company secretary

b. Name of the related party

Name of the entity	Nature of relationship
Jeevana Mitra Finance Corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
EnhopsInc, USA	Wholly owned subsidiary

c. Particulars of transactions with related party

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
Rent Paid		
a) Jeevana Mitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	5,08,00,000	10,79,08,000
b) K Vanaja	85,25,000	1,80,76,000
c) M Rajendra Prasad	1,27,61,000	4,70,000
d) K R K Prasad	-	45,37,500
Interest paid on short term borrowings		
a) K Krishna Kishore	6,64,116	32,96,330
b) K Vanaja	67,704	3,41,198
c) M Rajendra Prasad	-	7,315
Remuneration Paid		
a) K Krishna Kishore	54,00,000	36,00,000
b) M Rajendra Prasad	54,00,000	30,99,996
Loans and Advances given		
Enhops Solutions Pvt Ltd	6,04,97,763	3,93,07,611

Twenty First Annual Report 2018-2019

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
Long term Borrowings		
a) K Krishna Kishore	-	1,34,74,165
b) K Vanaja	5,00,000	14,51,000

(ii) Due from related parties.

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
Long term advances		
Enhops Solutions Pvt Ltd	4,76,27,198	3,52,26,109

Note No. 32: Earnings per share (IND AS-33): The details are as under:

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
1. Profit after Tax (Rs)	1,37,34,593	30,53,827
2. No of Equity shares	1,53,01,465	1,14,59,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	0.90	0.27
5. Weighted Average No of Equity Shares	1,45,41,509	94,34,753
6. Diluted Earnings per share (Rs.)	0.94	0.32

Note No. 33 Accounting for Deferred Taxes on income (INDAS-12): Necessary details have been disclosed in note no: 6.

Note No. 34 General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.
- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

34.1 Disclosures – Revenue (Ind AS 115)

a) Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contract with customers

Jeevan Scientific Technology Limited

Rupees in Lakhs

Segment	Current Year March 31, 2019	Previous Year March 31, 2018
Types of goods or service		
Sale of Service		
Clinical Research Services	2,640.13	1,727.25
Data Management Services	-	199.18
Others		
Other Operating Revenue	-	90.48

Rupees in Lakhs

Segment	Current Year March 31, 2019	Previous Year March 31, 2018
Total revenue from contracts with customers		
India	1,928.97	1519.83
Outside India	711.16	497.08
Types revenue from contracts with customers	2,640.13	2,016.91
Timing of revenue recognition		
Services transferred over time	2,640.13	2,016.91
Total revenue from contracts with customers	2,640.13	2,016.91

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Place : Hyderabad
Date : 30.05.2019

INDEPENDENT AUDITOR'S REPORT

To the members of,

M/s. JEEVAN SCIENTIFIC TECHNOLOGY LIMITED,

Report on the Consolidated Audit of Financial Statements:

Opinion

We have audited the accompanying consolidated financial statements of M/s. **JEEVAN SCIENTIFIC TECHNOLOGY LIMITED** ("the Holding Company"), and its subsidiaries (collectively referred to as "the Group") which comprise the Consolidated Balance Sheet as on 31st March, 2019, and the Consolidated Statement of Profit and Loss (including other Comprehensive Income), statement of changes in equity and Consolidated statement of cash flows for the year ended 31st March, 2019 and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "the Consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act 2013 (the "Act") in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015, as amended, ("IndAS") and other accounting principles generally accepted in India, of the state of affairs of the group as at March 31, 2019, and the Profit and total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below as key audit matters to be communicated in our report.

Jeevan Scientific Technology Limited

Sr No	Key Audit Matter	Auditor's Response
1	<p>Revenue Recognition</p> <p>Revenue is recognized to the extent that economic benefit will flow to the Company and the revenue can be reliably measured. It is measured at fair value consideration received or receivable, net of returns and allowances, discounts and rebates. The Company recognizes revenue when it satisfies its performance obligation by transferring the goods to the customers.</p> <p>Revenue is key driver of the business and judgment is involved in determining when contractual obligations have been performed and to the extent that the right to consideration has been earned.</p> <p>The management of the Company focuses on revenue as a key performance measure which could create an incentive for revenue to be recognized before the risks and rewards have been transferred. We therefore identified</p> <p>Revenue Recognition as a significant risk and key audit matter.</p>	<p>Our audit work included, but was not restricted to:</p> <ul style="list-style-type: none"> • We understood business revenue recognition policy and how they are applied, including the relevant controls, and tested controls over revenue recognition; • Analytical review of the revenue recognized over the year • Agreeing on a sample basis amounts of revenue to customer contracts and verifying the extent, timing and customer acceptance of goods, where relevant. • We performed cut-off testing for a sample of revenue transactions around the period end date, to check that they were recognized in the appropriate period; • We discussed key contractual arrangements with management and obtained relevant documentation, including in respect of rebate and returns arrangements. • The Company's accounting policy on Revenue recognition is shown in note 2.5 to the financial statements and related disclosures are included in notes. • Based on our audit procedures we did not identify any evidence of material misstatement in the revenue recognized for the year ended 31st March 2019 in the consolidated financial statements.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these financial statements

Twenty First Annual Report 2018-2019

that give a true and fair view of the financial position, financial performance, in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's

Jeevan Scientific Technology Limited

ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We did not audit the financial statements of 2 subsidiaries, Enhops Solutions Inc. and Enhops Solutions Pvt Ltd. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-sections (3) and (11) of Section 143 of the Act, insofar as it relates to the aforesaid subsidiaries is based solely on the reports of the other auditors.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the Annexure a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143(3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books

Twenty First Annual Report 2018-2019

- c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss (including other comprehensive income), Consolidated Statement of changes in equity and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the books of accounts.
- d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on 31st March, 2019 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2019 from being appointed as a director in terms of Section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure A".
- g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - (i) The Company has no pending litigations which would impact its financial position.
 - (ii) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - (iii) There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad

Date : 30.05.2019

Jeevan Scientific Technology Limited

“Annexure A” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of JEEVAN SCIENTIFIC TECHNOLOGY LIMITED (“the Company”) as of March 31, 2019 in conjunction with our audit of the consolidated financial statements of the Company for the year ended on that date.

Management’s Responsibility for Internal Financial Controls

The Company’s management is responsible for establishing and maintaining internal financial controls based on “the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India”. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors’ Responsibility

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31 March 2019, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For PAVULURI&Co.
Chartered Accountants
Firm Reg. No:012194S

Sd/-
(CA. N. RAJESH)
PARTNER
M.No : 223169

Place : Hyderabad

Date : 30.05.2019

Jeevan Scientific Technology Limited

Consolidated Balance Sheet as at 31st March, 2019

(In Rupees)

Particulars	Note No.	As at 31.03.2019	As at 31.03.2018
Assets			
(1) Non-current Assets			
a) Property, Plant and Equipment	2	195,758,103	180,522,171
b) Other Intangible Assets	2	7,609,304	7,145,709
c) Intangible Assets Process Knowhow	2	122,569,974	94,025,878
d) Financial Assets			
i) Investments	3	-	-
ii) Loans	4		-
iii) Advances	5	38,274,468	5,137,909
c) Deferred tax asset (net)	6	-	-
(2) Current Assets			
a) Inventories	7	2,304,039	989,587
b) Financial Assets			
i) Trade receivables	8	146,936,186	163,018,038
ii) Cash and cash equivalents	9	36,137,895	7,208,246
iii) Bank balances other than (ii) above	10	563,173	7,016,821
iv) Loans	11	4,118,092	4,236,158
v) Other Financial Assets	12	11,003,442	2,702,750
c) Current Tax Assets (Net)	13	44,367,595	20,152,255
d) Other Current Assets	14	3,369,025	1,613,597
Total		<u>613,011,296</u>	<u>493,769,119</u>
Equity and Liabilities			
Equity			
a) Equity Share Capital	A	153,014,650	114,594,650
b) Other Equity	B	165,317,110	105,545,822
Liabilities			
(1) Non-current Liabilities			
a) Financial liabilities			
Borrowings	15	74,654,990	98,372,835
b) Provisions	16	1,809,705	968,587
c) Deferred tax Liability (net)	6	3,961,526	1,393,060
(2) Current Liabilities			
a) Financial Liabilities			
i) Borrowings	17	72,576,400	70,414,014
ii) Trade Payables	18	24,366,173	20,562,838
iii) Other Financial liabilities	19	50,831,950	28,542,516
iv) Other Financial Creditors	20	19,394,295	25,545,192
b) Other current liabilities	21	42,154,525	27,604,107
c) Provisions	22	4,929,972	225,498
Total		<u>613,011,296</u>	<u>493,769,119</u>
Summary of significant accounting policies and notes	1		

Per our report of even Date

for **PAVULURI & Co.**

Chartered Accountants

Firm Regn No: 012194S

for and on behalf of the Board of Directors

Jeevan Scientific Technology Limited

Sd/-

CA N. Rajesh

Partner

Membership No:223169

Place : Hyderabad

Date : 30.05.2019

Sd/-

K.Krishna Kishore

Vice Chairman & Managing Director

DIN: 00876539

Sd/-

M. Rajendra Prasad

Executive Director & CEO

DIN: 06781058

Sd/-

T. Chandra Sekhar

Company Secretary

M.No. 48005

Twenty First Annual Report 2018-2019

Consolidated Statement of Profit and Loss for the Period ended 31st March, 2019

(In Rupees)

Particulars	Note No.	For the Year 2018-2019	For the Year 2017-2018
Continuing Operations			
Income			
I. Revenue from operations	23	261,276,972	203,984,736
II. Other Income	24	10,039,979	9,220,243
III. Total revenue(I+II)		271,316,951	213,204,979
IV. Expenses			
Cost of Material consumed	25	16,417,939	12,987,432
Employee benefits expenses	26	83,555,387	56,801,315
Finance costs	27	19,682,325	18,556,909
Depreciation	2	23,421,697	17,156,115
Amortisation on Process Knowhow	2	7,894,676	4,058,837
Other expenses	28	106,690,374	100,024,197
Total expenses		257,662,398	209,584,805
V. Profit/ (Loss) before tax (III)-(IV)		13,654,553	3,620,174
Tax expenses			
Current Tax		3,334,588	924,077
Less: Mat Credit Entitlement/ utilization		(3,388,452)	(985,600)
Deferred Tax		2,568,466	2,563,932
Total tax expenses		2,514,602	2,502,409
Profit / (Loss) for the period from continuing operations		11,139,951	1,117,765
Profit / (Loss) from discontinuing operations		-	-
Tax expense from discontinuing operations		-	-
Profit / (Loss) from discontinuing operations (After tax)		-	-
Profit /(loss) for the Period		11,139,951	1,117,765
Other Comprehensive Income			
A (i) Items that will not be reclassified to profit and loss			
Re-measurements of post-employment benefit obligations)		193,616	645,160
(ii) Income tax relating to items that will not be reclassified to profit and loss		53,864	61,523
B (i) Items that will be reclassified to profit and loss		-	-
(ii) Income tax relating to items that will be reclassified to profit and loss		-	-
Total Comprehensive Income		11,279,703	1,701,402
Earning per equity share			
(Face value of Rs.10/- each)			
Basic		0.74	0.15
Diluted		0.78	0.18

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:223169

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Place : Hyderabad
Date : 30.05.2019

Jeevan Scientific Technology Limited

Consolidated Cash Flow statement for the year ended 31st March, 2019

(In Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
A. Cash flow from operating activities		
Net Profit before tax and extraordinary items	13,654,553	3,620,174
Adjustments for:		
Depreciation	34,466,076	25,278,613
Loss on Sale of Assets	-	3,995
Interest	19,007,800	17,120,046
Operating profit before working capital changes	67,128,429	46,022,828
Adjustments for:		
Inventories	-1,314,452	3,752,090
Trade and other receivables	-51,208,101	-59,921,024
Trade and other Paybles	-44,768,733	-83,746,288
Cash generated from operations	59,374,610	73,600,182
Taxes Provision	-	0
Interest paid	19,007,800	17,120,046
Net cash from operating activity	40,366,810	56,480,136
B. Cash flow from investing activities		
Purchase of fixed assets	78,709,699	143,484,004
Investments	-	0
Sale/ Transfer of fixed assets	-	9,000
Net cash used in investing activity	-78,709,699	-143,475,004
C. Cash flow from financing activity		
Proceeds from loans	-23,717,845	50,897,670
Increase in Capital	38,420,000	21,800,000
Increase in Other Equity	46,116,735	25,948,432
Net cash generated in financing activity	60,818,890	98,646,102
Net increase in cash and cash equivalents (A+B+C)	22,476,001	11,651,234
Cash and cash equivalents as at 31.03.2018	14,225,067	2,573,833
Cash and cash equivalents as at 31.03.2019	36,701,068	14,225,067

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:223169

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Place : Hyderabad
Date : 30.05.2019

Significant Accounting Policies and Notes on Accounts

Company Information

The Company was incorporated on 2nd February, 1999 to carry on the business Clinical research, Data management and Information Technology services.

1. Significant Accounting Policies

1.1 Basis of Preparation

a) Statement of Compliance

The consolidated financial statements have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016 and other relevant provisions of the Act.

b) Basis of measurement

The consolidated financial statements have been prepared on a historical cost convention and on an accrual basis, except for the following material items that have been measured at fair value as required by relevant Ind AS:

- i. Certain financial assets and liabilities measured at fair value (refer accounting policy on financial instruments);
- ii. Defined benefit and other long-term employee benefits.

c) Functional and presentation currency

The Consolidated financial statements are presented in Indian rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the entity operates. All financial information presented in Indian rupees.

d) Use of estimates and judgment

The preparation of consolidated financial statements in conformity with Ind AS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on a periodic basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

1.2 Summary of significant accounting policies

i. Functional and presentation currency

Items included in the financial statements of the Company are measured using the currency of the primary economic environment in which these entities operate (i.e. the "functional currency"). The Consolidated financial statements are presented in Indian Rupee, the national currency of India, which is the functional currency of the Company.

ii. Foreign currency transactions and balances

Transactions in foreign currency are translated into the respective functional currencies using the exchange rates prevailing at the dates of the respective transactions. Foreign

Jeevan Scientific Technology Limited

exchange gains and losses resulting from the settlement of such transactions and from the translation at the exchange rates prevailing at reporting date of monetary assets and liabilities denominated in foreign currencies are recognized in the statement of profit and loss and reported within foreign exchange gains / (losses).

Non-monetary assets and liabilities denominated in a foreign currency and measured at historical cost are translated at the exchange rate prevalent at the date of transaction.

iii. Investment in subsidiaries

Investment in subsidiaries is measured at cost. Dividend income from subsidiaries is recognized when its right to receive the dividend is established.

iv. Financial instruments

All financial instruments are recognized initially at fair value. Transaction costs that are attributable to the acquisition of the financial asset (other than financial assets recorded at fair value through profit or loss) are included in the fair value of the financial assets. Purchase or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (regular way trade) are recognized on trade date. While, loans and borrowings and payable are recognized net of directly attributable transactions costs.

For the purpose of subsequent measurement, financial instruments of the Company are classified in the following categories: non-derivative financial assets comprising amortized cost; non derivative financial liabilities at amortized cost.

The classification of financial instruments depends on the objective of the business model for which it is held. Management determines the classification of its financial instruments at initial recognition.

Financial instrument is derecognized only when the Company has transferred its right to receive/ extinguish its obligation to pay cash flow from such financial instruments.

a) Non-derivative financial assets

Financial assets at amortized cost

A financial asset shall be measured at amortized cost if both of the following conditions are met:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

They are presented as current assets, except for those maturing later than 12 months after the reporting date which are presented as non-current assets. Financial assets are measured initially at fair value plus transaction costs and subsequently carried at amortized cost using the effective interest method, less any impairment loss.

Amortized cost is represented by security deposits, cash and cash equivalents, employee and other advances and eligible current and non-current assets.

Cash and cash equivalents comprise cash on hand and in banks and demand deposits

with banks which can be withdrawn at any time without prior notice or penalty on the principal.

For the purposes of the cash flow statement, cash and cash equivalents include cash on hand, in banks and demand deposits with banks, net of outstanding bank overdrafts that are repayable on demand and are considered part of the Company's cash management system.

b) Non-derivative financial liabilities

Financial liabilities at amortized cost

Financial liabilities at amortized cost represented by trade and other payables are initially recognized at fair value, and subsequently carried at amortized cost using the effective interest method.

v. Property plant and equipment:

Recognition and measurement: Normally Property, plant and equipment are measured at cost less accumulated depreciation and impairment losses, if any. Cost includes expenditures directly attributable to the acquisition of the asset. The Company has elected to apply the optional exemption to use this previous GAAP value as deemed cost at 1 April 2015, the date of transition.

Depreciation: Normally the Company depreciates property, plant and equipment over the estimated useful life of the assets as prescribed in Schedule II of the Companies Act 2013 on a straight-line basis from the date the assets are ready for intended use. Wherever the useful life is determined by technical assessment for certain assets, such assets are depreciated as per their assessed life. Assets acquired under finance lease and leasehold improvements are amortized over the lower of estimated useful life and related term. Depreciation methods, useful lives and residual values are reviewed at each reporting date.

When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Subsequent expenditure relating to property, plant and equipment is capitalized only when it is probable that future economic benefits associated with these will flow to the Company and the cost of the item can be measured reliably. Repairs and maintenance costs are recognized in the statement of profit and loss when incurred. The cost and related accumulated depreciation are eliminated from the Consolidated financial statements upon sale or disposition of the asset and the resultant gains or losses are recognized in the statement of profit and loss.

The management estimates the useful lives for the following class of assets, based on internal assessment and independent technical evaluation carried out by external valuers, the management believes that useful lives as given below best represents the period over which the management expects to use these assets. Hence the useful lives for these assets is different from the useful lives as prescribed under Part - C of schedule II of the companies act 2013.

Jeevan Scientific Technology Limited

Plant and machinery	21 years
Electrical Installations	21 years
Computers	6 years
Vehicles- Motor car	10 years
Furniture and Fixtures	15 years
Office Equipment	21 years

Fixed Assets costing Rs.5,000/- or less are fully depreciated in the year of purchase

vi. Intangible assets

Intangible assets are stated at cost less accumulated amortization and impairment. Intangible assets are amortized over their respective estimated useful lives on a straight-line basis, from the date that they are available for use. The estimated useful life of an identifiable intangible asset is based on a number of factors including the effects of obsolescence, demand, competition and other economic factors (such as the stability of the industry and known technological advances) and the level of maintenance expenditures required to obtain the expected future cash flows from the asset.

Policy for accounting of expenses of Research & Development:

Clinical Research is a specified job and the ready availability of newly developed methods for BA/ BE Analysis of drug samples is required to get the business from various Pharmaceutical Clients. JSTL has been in the process of developing process and new methods. Equipment, Machines, Manpower and consumables are used for development of new methods.

Investment in development of a method is calculated on the basis of proportionate of time spent by manpower, machines and also consumable for developing that particular method and the relative expenditure is capitalised as intangible asset. Each method will be of useful for a minimum period of 10-12 years. It is also decided by the Board that the amortisation of the investment in process for developing methods should take place in a period 7 years from the date of the method put to use on quarterly basis in straight line method.

vii. Inventory

- a) Raw materials, Stores and Consumables, work in process and finished products are valued at lower of cost and net realizable value of the respective units.
- b) The basis of determining the cost is
 - Raw materials : Weighted average cost
 - Stores and Consumables : Weighted average cost
 - Work in process and finished goods : valued at lower of cost and net realizable value
- c) In case of identified Obsolete/Surplus/Non-moving items necessary provision is made and charged to revenue.

viii. Impairment

a) Financial assets

In accordance with Ind AS 109, the Company applies expected credit loss (ECL) model for measurement and recognition of impairment loss.

- i. The Company follows 'simplified approach' for recognition of impairment loss allowance on trade receivable.

The application of simplified approach does not require the Company to track changes in credit risk. Rather, it recognises impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition.

For recognition of impairment loss on other financial assets and risk exposure, the Company determines that whether there has been a significant increase in the credit risk since initial recognition. If credit risk has not increased significantly, 12-month ECL is used to provide for impairment loss. However, if credit risk has increased significantly, lifetime ECL is used. If in subsequent period, credit quality of the instrument improves such that there is no longer a significant increase in credit risk since initial recognition, then the entity reverts to recognising impairment loss allowance based on 12 month ECL.

Lifetime ECLs are the expected credit losses resulting from all possible default events over the expected life of a financial instrument. The 12 month ECL is a portion of the lifetime ECL which results from default events that are possible within 12 months after the reporting date.

ECL is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the entity expects to receive (i.e. all shortfalls), discounted at the original EIR. When estimating the cash flows, an entity is required to consider:

- ii. All contractual terms of the financial instrument (including prepayment, extension etc.) over the expected life of the financial instrument. However, in rare cases when the expected life of the financial instrument cannot be estimated reliably, then the entity is required to use the remaining contractual term of the financial instrument.
- iii. Cash flows from the sale of collateral held or other credit enhancements that are integral to the contractual terms.

ECL impairment loss allowance (or reversal) recognised during the period is recognised as income/ expense in the statement of profit and loss. The balance sheet presentation for various financial instruments is described below:

Financial assets measured at amortised cost, contractual revenue receivable: ECL is presented as an allowance, i.e. as an integral part of the measurement of those assets in the balance sheet. The allowance reduces the net carrying amount. Until the asset meets write off criteria, the Company does not reduce impairment allowance from the gross carrying amount.

b) Non-financial assets

The Company assesses at each reporting date whether there is any objective evidence that a non financial asset or a group of non financial assets is impaired. If any such

Jeevan Scientific Technology Limited

indication exists, the Company estimates the amount of impairment loss.

An impairment loss is calculated as the difference between an asset's carrying amount and recoverable amount. Losses are recognised in profit or loss and reflected in an allowance account. When the Company considers that there are no realistic prospects of recovery of the asset, the relevant amounts are written off. If the amount of impairment loss subsequently decreases and the decrease can be related objectively to an event occurring after the impairment was recognised, then the previously recognised impairment loss is reversed through profit or loss.

The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the "cash-generating unit").

ix. Employee benefits

a) Gratuity & Provident Fund:

The Company's liability towards retirement benefits in the form of gratuity is provided in accordance with the payment of Gratuity Act, 1972 to all the employees other than the whole time Directors which is made on the basis of actuarial valuation.

b) The Company's contribution to the provident fund is remitted to Government based on the percentage of the eligible employees' salary as per Provident Fund act.

c) Accrued Leave Salary:

Liability towards Accrued Leave Salary, as at the end of the year is recognized on the basis of valuation made on basic salary. The balance PL's earned by every employee in the previous year, a maximum of 8 days will be paid out during the month of January. These 8 days will be paid as per the last drawn basic salary and taxes will be applicable as per law

x. Provisions

All the provision are recognized as per Ind AS 37. Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognized as an asset, if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

Twenty First Annual Report 2018-2019

Provisions for onerous contracts are recognized when the expected benefits to be derived by the Company from a contract are lower than the unavoidable costs of meeting the future obligations under the contract. Provisions for onerous contracts are measured at the present value of lower of the expected net cost of fulfilling the contract and the expected cost of terminating the contract.

xi. Revenue recognition:

Ind AS 115 recognises revenue on transfer of the control of goods or services, either over a period of time or at a point in time, at an amount that the entity expects to be entitled in exchange for those goods or services. In order to align with Ind AS 115, the Accounting policy on revenue recognition was reviewed and revised.

The said revision has nil impact on the financials of the company as the company was recognising and accounting revenue in line with the Ind AS 115.

xii. Finance income and expense

Finance income consists of interest income on funds invested, dividend income and gains on the disposal of Fair value through profit and loss account financial assets. Interest income is recognized as it accrues in the statement of profit and loss, using the effective interest method.

Dividend income is recognized in the statement of profit and loss on the date that the Company's right to receive payment is established.

Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the statement of profit and loss using the effective interest method.

Foreign currency gains and losses are reported on a net basis. This includes changes in the fair value of foreign exchange derivative instruments, which are accounted at fair value through profit or loss.

xiii. Income tax

Income tax comprises current and deferred tax. Income tax expense is recognized in the statement of profit and loss except to the extent it relates to items directly recognized in equity or in other comprehensive income.

a) Current income tax

Current income tax for the current and prior periods are measured at the amount expected to be recovered from or paid to the taxation authorities based on the taxable income for the period. The tax rates and tax laws used to compute the current tax amount are those that are enacted or substantively enacted by the reporting date and applicable for the period. The Company offsets current tax assets and current tax liabilities, where it has a legally enforceable right to set off the recognized amounts and where it intends either to settle on a net basis or to realize the asset and liability simultaneously.

b) MAT credit

Minimum Alternate Tax (MAT) credit is recognized as an asset only when and to the extent there is convincing evidence that the Company will pay normal income tax during the specified period. In the year in which the MAT credit becomes eligible to

Jeevan Scientific Technology Limited

be recognized as an asset, in accordance with the provisions contained in the Guidance Note on Accounting for Credit Available under Minimum Alternative Tax, issued by the ICAI, the said asset is created by way of a credit to the Profit and Loss account and shown as "MAT Credit Entitlement". The Company reviews the same at each Balance Sheet date and writes down the carrying amount of MAT Credit Entitlement to the extent there is no longer convincing evidence to the effect that the Company will pay normal income tax during the specified period.

c) Deferred income tax

Deferred income tax is recognized using the balance sheet approach. Deferred income tax assets and liabilities are recognized for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount in financial statements, except when the deferred income tax arises from the initial recognition of goodwill or an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profits or loss at the time of the transaction. Deferred income tax asset are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized. Deferred income tax liabilities are recognized for all taxable temporary differences. The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply in the period when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

xiv. Foreign currency transaction

i. Initial recognition

Foreign currency transactions are recorded in the reporting currency, by applying to the foreign currency amount the exchange rate between the reporting currency and the foreign currency at the date of the transaction.

ii. Conversion

Foreign currency monetary items denominated in foreign currencies at the yearend are restated at year end rates. In case of monetary items which are covered by foreign exchange contracts, the difference between the original entry dates to forward contract date is recognized as an exchange difference.

iii. Exchange differences

Exchange differences arising on the settlement of monetary items, or on reporting such monetary items of company at rates different from those at which they were initially recorded during the year, or reported in previous financial statements, are recognized as income or as expenses in the year in which they arise.

iv. Foreign currency Transactions.

Twenty First Annual Report 2018-2019

(in lakhs)

Particulars	Current Year	Previous Year
Earnings in Foreign exchange	766.94	566.53
Expenditure in Foreign exchange	NIL	NIL

xv. Earnings per share

Basic earnings per share is computed using the weighted average number of equity shares outstanding during the year.

Diluted EPS is computed by dividing the net profit after tax by the weighted average number of equity shares considered for deriving basic EPS and also weighted average number of equity shares that could have been issued upon conversion of all dilutive potential equity shares. Dilutive potential equity shares are deemed converted as of the beginning of the year, unless issued at a later date. Dilutive potential equity shares are determined independently for each year presented. The number of equity shares and potentially dilutive equity shares are adjusted for bonus shares, as appropriate.

xvi. Borrowing costs

Borrowings costs directly attributable to acquisition or construction of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized as part of the cost of the asset. All other borrowing costs are expensed in the period in which it occurs. Borrowing costs consist of interest and other costs that the entity incurs in connection with the borrowing of funds.

xvii. Ind AS issued and not yet effective:

Ind AS 116 Leases :

Ministry of Corporate Affairs has notified 'The Companies (Indian Accounting Standards) Amendment Rules, 2019 dated March 30, 2019 which inter alia includes the new standard on Leases Ind AS 116 replacing the existing standard Ind AS 17, to be effective from the 1st April 2019. The impact of the same is yet to be assessed. The Company is proposing to use the Modified Retrospective Approach for transitioning to Ind AS 116.

xviii. Contingent liabilities

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence of non-occurrence of one or more uncertain future events beyond the control of the company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The company does not recognize a contingent liability but discloses its existence in the financial statements.

The contingent liability is Rs. 4.13 Lakhs during the financial year.

Jeevan Scientific Technology Limited

2. Property, Plant and Equipment I. Tangible Assets

(in Rupees)

S. No.	Description	GROSS BLOCK					DEPRECIATION					NET BLOCK				
		As at 01.04.2017	Additions	Deletions	As at 31.03.2018	As at 31.03.2019	As at 01.04.2017	Up to 31.03.2018	Deletions For the year 31.03.2018	For the year 31.03.2019	Up to 31.03.2019	As at 31.03.2019	As at 31.03.2018	As at 31.03.2017		
1	LEASE HOLD BUILDINGS	8,165,864	0	0	8,165,864	0	8,165,864	0	806,948	0	8,165,864	0	0	806,948		
2	PLANT & MACHINERY	17,868,587	121,757	0	17,990,344	155,534	2,643,877	0	1,619,085	4,262,962	5,889,021	12,256,857	13,727,382	15,224,710		
	a. Electrical Installations	1,194,942	0	0	1,194,942	867,082	0	56,760	923,842	0	890,602	214,340	271,100	327,860		
	b. Airconditioners	1,048,582	0	0	1,048,582	832,610	0	49,808	882,418	0	932,226	116,356	166,164	215,972		
	c. U.P.S. Systems	275,203	0	0	275,203	175,626	0	13,072	188,698	0	201,770	73,433	86,505	99,577		
	d. Inverter	20,387,314	121,757	0	20,509,071	155,534	0	1,738,725	6,257,920	0	8,003,619	12,640,986	14,251,151	15,868,119		
3	COMPUTERS	17,503,439	2,082,678	0	19,586,117	1,793,699	9,851,923	0	2,744,658	12,596,581	3,051,888	5,731,347	6,989,536	7,651,516		
	a. Computers	17,503,439	2,082,678	0	19,586,117	1,793,699	9,851,923	0	2,744,658	12,596,581	3,051,888	5,731,347	6,989,536	7,651,516		
4	VEHICLES	6,571,475	4,202,964	0	10,774,439	5,574,019	2,380,080	0	843,903	3,223,983	1,390,651	11,733,824	7,550,456	4,191,395		
	a. Motor Car	131,086	0	49,170	81,916	143,994	105,638	36,175	12,453	81,916	8,526	90,442	135,468	25,448		
	b. Scooter	6,702,561	4,202,964	49,170	10,856,355	5,718,013	2,485,718	36,175	856,356	3,305,899	1,399,177	11,869,292	7,550,456	4,276,843		
5	FURNITURE & FIXTURES	28,547,276	1,037,682	0	29,584,958	72,376	7,499,042	0	2,576,984	10,076,026	2,420,606	17,160,702	19,508,932	21,048,234		
	a. Furniture	988,151	0	0	988,151	0	988,151	0	0	988,151	0	0	0	0		
	b. Fixtures	29,535,427	1,037,682	0	30,573,109	72,376	8,487,193	0	2,576,984	11,064,177	2,420,606	17,160,702	19,508,932	21,048,234		
6	OFFICE & LABORATORY EQUIPMENT	1,315,859	366,360	0	1,682,219	380,470	418,483	0	206,112	624,595	237,450	1,200,644	1,057,624	897,376		
	a. Office Equipments	63,413,019	85,879,213	0	149,292,232	31,494,979	7,843,319	0	10,431,520	18,274,839	15,498,088	33,772,927	147,014,284	131,017,393		
	b. Laboratory Equipments	460,323	0	0	460,323	296,659	0	21,865	318,524	0	21,865	340,389	119,934	163,664		
	c. E.P.A.B.X & Telephones	15,100	0	0	15,100	0	12,752	0	717	13,469	717	14,186	914	2,348		
	d. Fax Machine	366,841	0	0	366,841	0	366,841	0	0	366,841	0	366,841	0	0		
	e. Projector with LCD Panel	65,571,142	86,245,573	0	151,816,715	31,875,449	8,938,054	0	10,640,214	19,598,268	15,758,120	35,356,388	148,335,776	132,218,447		
	f. LIBRARY:	89,983	0	0	89,983	0	82,060	0	4,274	86,334	3,649	89,983	0	7,923		
	a. Books	89,983	0	0	89,983	0	82,060	0	4,274	86,334	3,649	89,983	0	7,923		
	Total:	147,955,730	93,690,654	49,170,241,597,214	39,615,071	281,212,285	41,723,059	36,175	19,388,159	61,075,043	24,379,139	85,454,182	180,522,171	106,232,671		

II. Intangible Assets

		GROSS BLOCK						DEPRECIATION						NET BLOCK				
		As at 01.04.2017	Additions	Deletions	As at 31.03.2018	Additions	Deletions	As at 31.03.2019	Up to 01.04.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	Deletions 31.03.2019	For the year 31.03.2019	Up to 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2017
S. No.	Description																	
1	COMPUTERS Software	7,344,803	3,911,184	0	11,255,987	2,655,856	0	13,911,843	2,310,111	0	1,800,167	4,110,278	0	2,192,261	6,302,539	7,145,709	5,034,692	
2	COPYRIGHTS	1,204,000	0	0	1,204,000	0	0	1,172,550	1,172,550	0	31,450	1,204,000	0	0	1,204,000	0	31,450	
	Total:	8,548,803	3,911,184	0	12,459,987	2,655,856	0	15,115,843	3,482,661	0	1,831,617	5,314,278	0	2,192,261	7,506,539	7,609,304	5,066,142	

III. Intangible Assets Process

		GROSS BLOCK						DEPRECIATION						NET BLOCK				
		As at 01.04.2017	Additions	Deletions	As at 31.03.2018	Additions	Deletions	As at 31.03.2019	Up to 01.04.2017	Deletions 31.03.2018	For the year 31.03.2018	Up to 31.03.2018	Deletions 31.03.2019	For the year 31.03.2019	Up to 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2017
S. No.	Description																	
1	Process Knowhow	52,202,550	45,882,165	0	98,084,715	36,438,772	0	134,523,487	0	0	4,058,837	4,058,837	0	7,894,676	11,953,513	94,025,878	52,202,550	
	Total:	52,202,550	45,882,165	0	98,084,715	36,438,772	0	134,523,487	0	0	4,058,837	4,058,837	0	7,894,676	11,953,513	122,569,974	52,202,550	

Notes: An amount of Rs. 40,63,661/- has been transferred from depreciation to Process Knowhow since the assets are used to create process

Jeevan Scientific Technology Limited

Consolidated Notes to financial statements for the year ended 31st March, 2019

3. Non Current Investments

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Enhops Solutions Inc.	-	-
Enhops Solutions Pvt Ltd	-	-
Total	-	-

4. Long Term Loans

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
i) Loans to Subsidiaries	-	-
Total	-	-

5. Advances

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
i) Capital Advances	32,500,000	-
ii) Security Deposit	5,670,869	5,034,310
iii) Other Advances	103,599	103,599
Total	38,274,468	5,137,909

6. Deferred Tax (Net)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Deferred Tax Asset Opening	-1,393,060	1,170,872
Add/Less: Deferred Tax liability	-2,568,466	-2,563,932
Total	-3,961,526	-1,393,060

7. Inventories

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Work in progress point of sale boxes	210,240	210,240
Consumables - R & D	2,093,799	779,346
Total	2,304,039	989,586

Twenty First Annual Report 2018-2019

8. Trade receivables (Unsecured)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Debtors outstanding for - more than Six months Considered good	78,582,393	79,644,969
Doubtful debts	889,815	1,164,207
Other debts for less than six months Considered good	68,353,793	83,373,069
	147,826,001	164,182,245
Less: Bad Debts Written off	889,815	1,164,207
Total	146,936,186	163,018,038

9. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Cash and cash equivalents Balances with Banks in current accounts	232,861	833,206
cash on hand	35,905,034	6,375,040
Total	36,137,895	7,208,246

10. Cash and Cash Equivalents

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Bank balances other than in fixed deposits more than 12 months	563,173	524,806
in fixed deposits Less than 12 months	0	6,492,015
Total	563,173	7,016,821

11. Loans and Advances (Current)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Advances Given	4,118,092	4,236,158
Total	4,118,092	4,236,158

Jeevan Scientific Technology Limited

12. Other Financial Assets

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Interest Receivable	8,411,442	2,702,750
Rent Receivable	2,592,000	-
Total	11,003,442	2,702,750

13. Current Tax Assets (Net)

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Tax deducted at source	34,104,031	13,223,279
MAT Credit	10,263,564	6,928,976
Total	44,367,595	20,152,255

14. Other Current Assets

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Prepaid Expenses	2,606,015	1,373,014
Hero Finance corporation	467,523	234,904
GST Input Credit	295,487	5,679
Total	3,369,025	1,613,597

Twenty First Annual Report 2018-2019

STATEMENT OF CHANGES IN EQUITY

Jeevan Scientific Technology Limited

Statement of changes in Equity for the Period ended 31st March 2019

(in Rupees)

A. Equity Share Capital	As at 31.03.2019	As at 31.03.2018
Authorised 2,10,00,000 equity Shares of Rs.10/- each	210,000,000	210,000,000
Issued, subscribed and paid- up 1,53,01,465 (31st March 2019:1,53,01,465) equity Shares of Rs. 10/- each fully paid-up	153,014,650	114,594,650

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Issued, subscribed and paid- up		
Opening Balance	114,594,650	92,794,650
Add : issue of shares during the year	38,420,000	21,800,000
Total	153,014,650	114,594,650

The details of shares in the company held by each shareholder holding more than 5% shares :

Name of the Share Holder	As at 31.03.2019		As at 31.03.2018	
	No. of Shares	% of Share Holding	No. of Shares	% of Share Holding
Sri K. Krishna Kishore	2,201,391	14.39%	1,774,391	15.48%
Smt. K. Vanaja	1,573,800	10.29%	1,257,800	10.98%
Dr. Desaiah Durisala	830,000	5.42%	830,000	7.24%
Sri M. Rajendra Prasad	896,250	5.86%	-	-

Jeevan Scientific Technology Limited

B. Other Equity

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Other reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e., 1st April, 2017	-	-	65,566,766	-	(37,194,052)	-	-	-	-	-	-	47,604,502	75,977,216	
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	
Restated balance at the beginning of the reporting period	-	-	65,566,766	-	(37,194,052)	-	-	-	-	-	-	47,604,502	75,977,216	
Total comprehensive Income for the year	-	-	-	-	1,701,402	-	-	-	-	-	-	-	1,701,402	
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	
Issued during the Year	-	-	44,145,000	-	-	-	-	-	-	-	-	(16,277,796)	27,867,204	
Balance at the end of the reporting period i.e., 31st March, 2018	-	-	109,711,766	-	(35,492,650)	-	-	-	-	-	-	31,326,706	105,545,822	

Particulars	Share application money on pending allotment	Equity component of compound financial instruments	Reserves and Surplus				Debt instruments through other comprehensive income	Equity instruments through other comprehensive income	Effective portion of cash flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of foreign operations	Other items of other comprehensive income	Money received against share warrants	Total
			Capital Reserve	Securities premium reserve	Shares forfeited reserves	Retained Earnings								
Balance at the beginning of the reporting period i.e., 1st April, 2018	-	-	109,711,766	-	(35,492,650)	-	-	-	-	-	-	31,326,706	105,545,822	
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	
Restated balance at the beginning of the reporting period	-	-	109,711,766	-	(35,492,650)	-	-	-	-	-	-	31,326,706	105,545,822	
Total comprehensive Income for the year	-	-	-	-	11,279,703	-	-	-	-	-	-	-	11,279,703	
Dividends	-	-	-	-	-	-	-	-	-	-	-	-	-	
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	
Issued during the Year	-	-	77,800,500	2,016,541	-	-	-	-	-	-	-	(31,325,456)	48,491,585	
Balance at the end of the reporting period i.e., 31st March, 2019	-	-	187,512,266	2,016,541	(24,212,947)	-	-	-	-	-	-	1,250	165,317,110	

Twenty First Annual Report 2018-2019

15. Long Term Borrowings

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018	As at 31.03.2019	As at 31.03.2018
Term Loan- secured				
A) From Banks				
i) Car Loans- Hypothecation against the Cars	3,909,516	2,748,553	3,394,554	1,497,467
ii) Machinery loans	70,245,474	71,699,117	30,860,016	17,568,540
B) Intercorporate Loans	-	9,000,000	0	-
C) Loans and advances from related parties	500,000	14,925,165	0	-
Total	74,654,990	98,372,835	34,254,570	19,066,007

16. Long Term Provisions

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Gratuity Payable	1,809,705	968,587
Total	1,809,705	968,587

17. Short Term Borrowings

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Loan repayable on Demand		
i) Loan From Banks (Guaranteed by Director)	72,576,400	70,414,014
Total	72,576,400	70,414,014

18. Trade Payables

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Trade payables (for services received)	24,366,173	20,562,838
Total	24,366,173	20,562,838

Jeevan Scientific Technology Limited

19. Other Financial Liabilities

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Current maturities of Long term borrowings	34,254,570	19,066,007
Interest Payable	11,839,322	5,308,711
Rent Payable	4,738,058	4,167,798
Total	50,831,950	28,542,516

20. Other Financial Creditors

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Creditors for Capital Assets	19,394,295	25,545,192
Total	19,394,295	25,545,192

21. Other Current Liabilities

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
TDS Payable	3,015,897	6,500,137
Professional tax payable	23,850	19,150
GST Payable	24,923,072	9,017,963
Provident Fund payable	425,574	311,706
ESI payable	115,655	101,434
Salaries payable	6,313,924	5,118,757
Directors Remuneration Payable	1,349,827	1,324,994
Provision for expenses	410,386	1,391,275
Advance received from Customers	5,373,227	3,731,250
Other Payables	203,113	87,441
Total	42,154,525	27,604,107

22. Short Term Provisions

(in Rupees)

Particulars	As at 31.03.2019	As at 31.03.2018
Leave Encashment Payable	98,261	93,318
Bonus Payable	1,466,951	116,975
Gratuity Payable	30,172	15,205
Provision for tax	3,334,588	-
Total	4,929,972	225,498

Twenty First Annual Report 2018-2019

23. Revenue from operations

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
IT Consultancy Service Charges - Export	5,577,813	6,945,312
IT Consultancy Service Charges - Domestic	1,382,835	4,396,035
Clinical Research Services- Domestic	183,200,242	123,017,832
Clinical Research Services- Export	71,116,082	49,707,896
Data Management service charges	-	19,917,661
Total	261,276,972	203,984,736

24. Other non operating income

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Interest on Income Tax Refund	109,317	166,222
Interest Received from Others	6,342,991	5,010,019
Interest Received from Banks	158,452	63,188
Miscellaneous Income	994,821	225,844
Exchange Variance Profit	34,398	154,970
Rent Received	2,400,000	3,600,000
Total	10,039,979	9,220,243

25. Cost of Material Consumed

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Hardware		
Opening Stock	210,240	210,240
Purchases: Components & Software	-	-
	210,240	210,240
Less: Closing Stock	210,240	210,240
Total (A)	-	-
Consumables - R & D		
Opening Stock	779,346	4,531,437
Purchases: Consumables	20,885,167	13,473,286
	21,664,513	18,004,723
Less: Closing Stock	2,093,799	779,346
Less: Transfer to Process Knowhow	3,152,775	4,237,945
Total (B)	16,417,939	12,987,432
Total (A+B)	16,417,939	12,987,432

Jeevan Scientific Technology Limited

26. Employees benefit Expenses

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Salaries & Allowances	66,417,953	45,172,941
Contribution to Provident Fund&Others	2,994,105	2,415,218
Welfare Expenses	2,457,692	2,097,037
Gratuity	716,382	559,746
Bonus	1,151,965	116,975
Leave encashment	259,290	93,318
Director's Remuneration	9,558,000	6,346,080
Total	83,555,387	56,801,315

27. Finance Cost

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Bank charges	419,645	231,933
Loan Processing Charges	254,880	1,120,090
FLC Charges	-	84,840
Interest expense		
on Vehicle Loans	442,238	166,041
on Bank Overdraft	5,749,177	3,588,051
on Term loan from Bank	10,071,815	7,312,323
on Customduty	-	40,124
on Others	100,873	
on Unsecured Loans	2,643,697	6,013,507
Total	19,682,325	18,556,909

28. Other Expenses

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Rent	11,346,487	10,034,312
Electricity	6,927,335	4,691,596
Repairs & Maintenance	2,911,529	2,038,088
Insurance	1,674,855	1,035,550
Licenses & Renewals	1,457,819	1,563,854
Communication Charges	1,411,611	2,466,949
Travelling,Conveyance	2,671,829	1,841,128
Printing & Stationery	2,339,374	1,455,720

Twenty First Annual Report 2018-2019

(in Rupees)

Particulars	For the year 2018-2019	For the year 2017-2018
Advertisement ,Publicity & Business Promotion	937,065	722,611
Professional Charges	5,336,919	12,658,593
Technical Services	5,570,786	-
Audit Fee: As Auditors	100,000	97,000
: For Certification	40,000	68,607
General Expenses	2,419,449	2,782,988
Office Maintenance	2,976,170	5,450,111
Director's Sitting fees	340,000	337,000
Registrar's expenses	144,091	169,992
Web Designing Charges	63,192	8,626
Garden Maintenance	76,360	73,385
Conference Fee	-	17,250
BSE Listing Fee	250,000	287,500
ROC Filing Fee	67,600	37,200
Interest on delay Payments for Statutory dues	3,891,937	104,069
Service Tax Paid	-	144,794
TDS interest & late filing fee	-	240,000
Volunteer Expenses	15,865,232	9,824,582
Volunteer Study Payments	36,248,167	21,762,754
Bad debts Written off	889,815	1,164,207
Deposits Written Off	-	8,400
VAT Input Credit Written Off	-	49,637
Foreign Exchange Variance Loss	612,308	270,207
Water Bill Paid	120,444	152,192
Loss on Sale of Assets	-	3,995
Data Management Service Charges	-	18,461,300
Total	106,690,374	100,024,197

Jeevan Scientific Technology Limited

Note-29: OTHER DISCLOSURES:

i. Gratuity:

The Company has conducted Actuarial valuation of its Gratuity as on 31st Mar 2019.

Accounting Disclosures Statement	GRATUITY	
Period of accounting	1-Apr-18 to 31-Mar-19	
Valuation Result as at	<i>(all figures in Indian Rupees)</i>	
	31-Mar-18	31-Mar-19
I Changes in present value of obligations		
PVO at beginning of period	746,915	983,792
Interest cost	49,969	75,208
Current Service Cost	509,777	641,174
Past Service Cost- (non vested benefits)	-	-
Past Service Cost -(vested benefits)	-	-
Benefits Paid	-	(24,231)
Contributions by plan participants	-	-
Business Combinations	-	-
Curtailments	-	-
Settlements	-	-
Actuarial (Gain)/Loss on obligation	(322,869)	163,934
PVO at end of period	983,792	1,839,877
II Interest Expenses		
Interest cost	49,969	75,208
III Fair Value of Plan Assets		
Fair Value of Plan Assets at the beginning	-	-
Interest Income	-	-
IV Net Liability		
PVO at beginning of period	746,915	983,792
Fair Value of the Assets at beginning report	-	-
Net Liability	746,915	983,792
V Net Interest		
Interest Expenses	49,969	75,208
Interest Income	-	-
Net Interest	49,969	75,208
VI Actual return on plan assets		
Less Interest income included above	-	-

Twenty First Annual Report 2018-2019

	Return on plan assets excluding interest income	-	-
VII	Actuarial (Gain)/loss on obligation		
	Due to Demographic Assumption*	-	-
	Due to Financial Assumption	(144,417)	18,382
	Due to Experience	(178,452)	145,552
	Total Actuarial (Gain)/Loss	(322,869)	163,934

*This figure does not reflect interrelationship between demographic assumption and financial assumption when a limit is applied on the benefit, the effect will be shown as an experience

VIII	Fair Value of Plan Assets		
	Opening Fair Value of Plan Asset	-	-
	Adjustment to Opening Fair Value of Plan Asset	-	-
	Return on Plan Assets excl. interest income	-	-
	Interest Income	-	-
	Contributions by Employer	-	24,231
	Contributions by Employee	-	-
	Benefits Paid	-	(24,231)
	Fair Value of Plan Assets at end	-	-

IX	Past Service Cost Recognised		
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Average remaining future service till vesting of the benefit	-	-
	Recognised Past service Cost- non vested benefits	-	-
	Recognised Past service Cost- vested benefits	-	-
	Unrecognised Past Service Cost- non vested benefits	-	-

X	Amounts to be recognized in the balance sheet and statement of profit & loss account		
	PVO at end of period	983,792	1,839,877
	Fair Value of Plan Assets at end of period	-	-
	Funded Status	(983,792)	(1,839,877)
	Net Asset/(Liability) recognized in the balance sheet	(983,792)	(1,839,877)

XI	Expense recognized in the statement of P & L A/C		
	Current Service Cost	509,777	641,174
	Net Interest	49,969	75,208
	Past Service Cost- (non vested benefits)	-	-
	Past Service Cost -(vested benefits)	-	-
	Curtailment Effect	-	-

Jeevan Scientific Technology Limited

Settlement Effect	-	-
Unrecognized Past Service Cost- non vested benefits	-	-
Expense recognized in the statement of P & LA/C	559,746	716,382
XII Other Comprehensive Income (OCI)		
Actuarial (Gain)/Loss recognized for the period	(322,869)	163,934
Asset limit effect	-	-
Return on Plan Assets excluding net interest	-	-
Unrecognized Actuarial (Gain)/Loss from previous period	-	-
Total Actuarial (Gain)/Loss recognized in (OCI)	(322,869)	163,934
XIII Movements in the Liability recognized in Balance Sheet		
Opening Net Liability	746,915	983,792
Adjustment to opening balance	-	-
Expenses as above	559,746	716,382
Contribution paid	-	(24,231)
Other Comprehensive Income(OCI)	(322,869)	163,934
Closing Net Liability	983,792	1,839,877
XIV Schedule III of The Companies Act 2013		
Current Liability	15,205	30,172
Non-Current Liability	968,587	1,809,705
XV Projected Service Cost 31 Mar 2020		912,281
Unrecognised Past Service Cost- non vested benefits		
Average remaining future service till vesting of the benefit		
XVI Asset Information	Total Amount	Target Allocation %
Cash and Cash Equivalents		
Gratuity Fund ()	-	0%
Debt Security - Government Bond		
Equity Securities - Corporate debt securities		
Other Insurance contracts		
Property		
Total Itemized Assets	-	0%
		Annexure 'A'
XVII Assumptions as at	31-Mar-18	31-Mar-19
Mortality	IALM (2006-08) Ult.	IALM (2006-08) Ult.
Interest / Discount Rate	7.74%	7.66%
Rate of increase in compensation	4.00%	4.00%
Annual increase in healthcare costs	-	-
Future Changes in maximum state healthcare benefits	-	-
Expected average remaining service	16.77	16.94
Employee Attrition Rate(Past Service (PS))	PS: 0 to 40 : 3%	PS: 0 to 40 : 3%

Twenty First Annual Report 2018-2019

Note-30: Segment Reporting as per Ind-AS-108

A. Basis for segmentation

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Board of Directors to make decisions about resources to be allocated to the segments and assess their performance.

The Company has three reportable segments, as described below, which are the company's strategic business units. These business units offer different services, and are managed separately because they require different technology and marketing strategies. For each of the business units, the company's Board reviews internal management reports on a periodic basis.

The following summary describes the operations in each of the Company's reportable segments:

B. Information about reportable segments

Information regarding the results of each reportable segment is included below. Performance is measured based on segment profit (before tax), segment revenue and segment capital employed as included in the internal management reports that are reviewed by the board of directors. Segment profit is used to measure performance as management believes that such information is the most relevant in evaluating the results of certain segments relative to other entities that operate within these industries.

Reportable Segments

Segment Reporting as on 31-03-2019

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	2640.13	-	73.04	-	2713.17
Segment Result	161.98	-	(25.43)	-	136.55
Assets	6081.70	-	48.41	-	6130.11
Liabilities	6081.70	-	48.41	-	6130.11
Depreciation and Amortization	307.45	-	5.71	-	313.16
Capital Expenditure during the year	620.42	-	166.68	-	787.10

Jeevan Scientific Technology Limited

Segment Reporting as on 31-03-2018

Rs. In Lakhs

Particulars	Clinical Research Services	Data Management Services	Information Technology Services	Unallocated	Total
Revenue from External Customers	1727.25	199.18	115.13	90.48	2132.04
Segment Result	104.93	5.66	-12.29	-62.10	36.20
Assets	4105.22	555.87	209.07	67.53	4937.69
Liabilities	2588.95	-	77.22	2271.52	4937.69
Depreciation and Amortization	182.05	-	5.68	24.42	212.15
Capital Expenditure during the year	1243.54	-	191.30	-	1434.84

Note-31: Related parties

a. Key management personnel

Name of the personnel	Nature of relationship
K Krishna Kishore	Vice chairman & Managing Director
M Rajendra Prasad	Executive Director & CEO
K Vanaja	Non-Executive Director
S S R Koteswara Rao	Independent Director- Chairman
T Ravi Babu	Non-Executive Director
G Bhanu Prakash	Independent Director
K R K Prasad	Independent Director
Chandra Sekhar Tumula	Company secretary

b. Name of the related party

Name of the entity	Nature of relationship
Jeevana Mitra Finance Corporation	Enterprise owned by Key managerial person
Enhops Solutions Pvt Ltd	Wholly owned subsidiary
EnhopsInc, USA	Wholly owned subsidiary

Twenty First Annual Report 2018-2019

c. Particulars of transactions with related party

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
Rent Paid		
a) Jeevana Mitra Finance corporation	8,40,000	8,40,000
b) K Krishna Kishore	4,80,000	4,80,000
c) K Vanaja	4,80,000	4,80,000
Long term Borrowings		
a) K Krishna Kishore	5,08,00,000	10,79,08,000
b) K Vanaja	85,25,000	1,80,76,000
c) M Rajendra Prasad	1,27,61,000	4,70,000
d) K R K Prasad	-	45,37,500
Interest paid on short term borrowings		
a) K Krishna Kishore	6,64,116	32,96,330
b) K Vanaja	67,704	3,41,198
c) M Rajendra Prasad	-	7,315
Remuneration Paid		
a) K Krishna Kishore	54,00,000	36,00,000
b) M Rajendra Prasad	54,00,000	30,99,996

d. The Company has the following amounts due from / to related parties:

(i) Due to related parties.

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
Long term Borrowings		
a) K Krishna Kishore	-	1,34,74,165
b) K Vanaja	5,00,000	14,51,000

Note No. 32: Earnings per share (IND AS-33): The details are as under:

(Amount in Rs.)

Particulars	As at March 31, 2019	As at March 31, 2018
1. Profit after Tax (Rs)	1,12,79,703	17,01,402
2. No of Equity shares	1,53,01,465	1,14,59,465
3. Nominal value per Equity share (Rs.)	10	10
4. Basic Earnings per share (Rs.)	0.74	0.15
5. Weighted Average No of Equity Shares	1,45,41,509	94,34,753
6. Diluted Earnings per share (Rs.)	0.78	0.18

Note No. 33 Accounting for Deferred Taxes on income (INDAS-12): Necessary details have been disclosed in note no: 6.

Note No. 34 General:

- i. Expenses are accounted under prepaid expenses only where the amounts relating to unexpired period are material.

Jeevan Scientific Technology Limited

- ii. Some of the balances appearing under Trade receivables, Trade payables, advances, Security deposits and other payables are subject to confirmations.
- iii. Figures for the previous year have been regrouped/rearranged wherever considered necessary so as to confirm to the classification of the current year.

34.1 Disclosures – Revenue (Ind AS 115)

a) Disaggregated revenue information

Set out below is the disaggregation of the Company's revenue from contract with customers

	Rupees in Lakhs	
Segment	Current Year March 31, 2019	Previous Year March 31, 2018
Types of goods or service		
Sale of Service		
Clinical Research Services	2,640.13	1,727.25
Information Technology Services	73.04	115.13
Data Management Services	-	199.18
Others		
Other Operating Revenue	-	90.48

	Rupees in Lakhs	
Segment	Current Year March 31, 2019	Previous Year March 31, 2018
Total revenue from contracts with customers		
India	1,946.23	1,565.51
Outside India	766.94	566.53
Types revenue from contracts with customers	2,713.17	2,132.04
Timing of revenue recognition		
Services transferred over time	2,713.17	2,132.04
Total revenue from contracts with customers	2,713.17	2,132.04

Per our report of even Date
for **PAVULURI & Co.**
Chartered Accountants
Firm Regn No: 012194S

for and on behalf of the Board of Directors
Jeevan Scientific Technology Limited

Sd/-
CA N. Rajesh
Partner
Membership No:224434

Sd/-
K.Krishna Kishore
Vice Chairman & Managing Director
DIN: 00876539

Sd/-
M. Rajendra Prasad
Executive Director & CEO
DIN: 06781058

Sd/-
T. Chandra Sekhar
Company Secretary
M.No. 48005

Place : Hyderabad
Date : 30.05.2019

Twenty First Annual Report 2018-2019

Form No. MGT-11

Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: L72200TG1999PLC031016

Name of the Company: **Jeevan Scientific Technology Limited**

Registered office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills, Golconda Post, Hyderabad – 500 008

Name of the member(s):

Registered Address:

E-mail Id:

Folio No./Client Id:

DP ID:

I/We, being the member (s) of shares of the above named company, hereby appoint

1. Name :
Address :
E-mail Id :
Signature:, or failing him
2. Name :
Address:
E-mail Id :
Signature:, or failing him
3. Name :
Address:
E-mail Id:
Signature:

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 21st Annual General Meeting of the Company, to be held on Saturday, 28th day of September, 2019 at 9.30 A.M. at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad – 500001 and at any adjournment thereof in respect of such resolutions as are indicated below:

Jeevan Scientific Technology Limited


Resolution No.

1. To consider and adopt the Audited Stand alone and consolidated Balance Sheet as at 31st March 2019, Statement of Profit & Loss for the year ended 31st March 2019 , statement of Cash Flows for the year ended 31st March 2019 and together with the Report of the Board of directors and the Auditors Report thereon.
2. To appoint a director in place of Mr. T. Ravi Babu (DIN: 01274099) who retires by rotation and being eligible, offers himself for re-appointment.

Signed this day of..... 2019

Signature of shareholder

Signature of Proxy holder(s)



Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Jeevan Scientific Technology Limited

Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir, Near Lanco Hills,
Golconda Post, Hyderabad – 500 008

ATTENDANCE SLIP

(Please present this slip at the Meeting venue)

I hereby record my presence at the 21st Annual General Meeting of the members of the company to be held on Saturday, 28th day of September, 2019 at 9.30 A.M. at 3rd floor, North Block, Raghava Ratna Towers, Chirag Ali Lane, Abids, Hyderabad – 500001 and at any adjourned meeting thereof.

Shareholders/Proxy's Signature_____

Shareholders/Proxy's full name_____

(In block letters)

Folio No./ Client ID_____

No. of shares held_____

Note: Shareholders attending the meeting in person or by proxy are required to complete the attendance slip and hand it over at the entrance of the meeting hall.

Twenty First Annual Report 2018-2019

Form No. MGT-12 Polling Paper

*[Pursuant to section 109(5) of the Companies Act, 2013 and rule 21(1)(c) of
the Companies (Management and Administration) Rules, 2014]*

Name of the Company: **M/s. Jeevan Scientific Technology Limited**

Registered office: Plot No. 1 & 2, Sai Krupa Enclave, Manikonda Jagir,
Near Lanco Hills, Golconda Post, Hyderabad – 500 008

BALLOT PAPER

Sl.No.	Particulars	Details
1.	Name of the First Named Shareholder (In block letters)	
2.	Postal address	
3.	Registered folio No. / *Client IDNo. (*Applicable to investors holding shares in dematerialized form)	
4.	Class of Share	Equity

Jeevan Scientific Technology Limited

I hereby exercise my vote in respect of Ordinary/ Special resolution enumerated below by recording my assent or dissent to the said resolution in the following manner:

Resol- ution No.	Description	No. of Shares held by me	I assent to the resolution	I dissent from the resolution
1.	To consider and adopt the Audited Stand alone and consolidated Balance Sheet as at 31 st March 2019, Statement of Profit & Loss for the year ended 31 st March 2019 , statement of Cash Flows for the year ended 31 st March 2019 and together with the Report of the Board of directors and the Auditors Report thereon.			
2.	To appoint a director in place of Mr. T. Ravi Babu (DIN: 01274099) who retires by rotation and being eligible, offers himself for re-appointment.			

Place:

Date:

(Signature of the shareholder)

Route Map





Enhops Solutions Pvt. Ltd., India and Enhops, Inc., USA are fully owned “subsidiary” companies of **Jeevan Scientific Technology Limited.**

Services Overview



Test Advisory
Services



Test
Automation



Performance
Testing



Security
Testing



Mobile
Testing



TCoE



DevOps



Functional
Manual Testing



Process Framework
Establishment

**Clinical Pharmacology Unit
Balanagar, Hyderabad**



js JEEVAN SCIENTIFIC
TECHNOLOGY LIMITED

If undelivered, please return to :



Jeevan Scientific Technology Limited

Registered Office: Plot No. 1&2, Sai Krupa Enclave,
Manikonda Jagir, Near Lanco Hills,
Golconda (PO) Hyderabad - 500 008.

Ph : +91-40-67364700, Fax : +91-40-67364707

Email: info@jeevanscientific.com, Web : www.jeevanscientific.com